Genetic and metabolic alterations in maternal and paternal one carbon metabolism and development of pregnancy complications of placental origin by Haro Barceló, Júlia
 
 
 
 
 
 
 
 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND 
PATERNAL ONE CARBON METABOLISM AND DEVELOPMENT OF 
PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
 
Júlia Haro Barceló 
 
 
 
ADVERTIMENT. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els 
drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o 
materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de 
Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa 
de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma 
clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva 
reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació 
pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una 
finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com 
als seus resums i índexs. 
 
 
ADVERTENCIA. El acceso a los contenidos de esta tesis doctoral y su utilización debe respetar los 
derechos de la persona autora. Puede ser utilizada para consulta o estudio personal, así como en 
actividades o materiales de investigación y docencia en los términos establecidos en el art. 32 del Texto 
Refundido de la Ley de Propiedad Intelectual (RDL 1/1996). Para otros usos se requiere la autorización 
previa y expresa de la persona autora. En cualquier caso, en la utilización de sus contenidos se deberá 
indicar de forma clara el nombre y apellidos de la persona autora y el título de la tesis doctoral. No se 
autoriza su reproducción u otras formas de explotación efectuadas con fines lucrativos ni su 
comunicación pública desde un sitio ajeno al servicio TDR. Tampoco se autoriza la presentación de su 
contenido en una ventana o marco ajeno a TDR (framing). Esta reserva de derechos afecta tanto al 
contenido de la tesis como a sus resúmenes e índices. 
 
 
WARNING. Access to the contents of this doctoral thesis and its use must respect the rights of the 
author. It can be used for reference or private study, as well as research and learning activities or 
materials in the terms established by the 32nd article of the Spanish Consolidated Copyright Act (RDL 
1/1996). Express and previous authorization of the author is required for any other uses. In any case, 
when using its content, full name of the author and title of the thesis must be clearly indicated. 
Reproduction or other forms of for profit use or public communication from outside TDX service is not 
allowed. Presentation of its content in a window or frame external to TDX (framing) is not authorized 
either. These rights affect both the content of the thesis and its abstracts and indexes. 
 
 
 
 
 
 
 
 
Genetic and metabolic alterations in maternal and paternal one 
carbon metabolism and development of pregnancy 
complications of placental origin 
 
 
Júlia Haro Barceló 
 
 
 
 
 
 
 
 
DOCTORAL THESIS 
2020 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
 
Júlia Haro Barceló 
 
 
 Genetic and metabolic alterations in maternal and 
paternal one carbon metabolism and development of 
pregnancy complications of placental origin 
 
 
Doctoral thesis  
 
 
Thesis supervised by Dr. Michelle Murphy 
 
 
 
Department of Basic Medical Sciences 
 
 
 
 
 
 
 
 
 
 
Reus 
2020 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
 
 
 
 
 
FAIG CONSTAR que aquest treball, titulat “Genetic and metabolic alterations 
in maternal and paternal one carbon metabolism and development of 
pregnancy complications of placental origin”, que presenta Júlia Haro Barceló 
per a l’obtenció del títol de Doctor, ha estat realitzat sota la meva direcció al 
Departament Ciències Mèdiques Bàsiques d’aquesta universitat. 
 
 
HAGO CONSTAR que el presente trabajo, titulado Genetic and metabolic 
alterations in maternal and paternal one carbon metabolism and development 
of pregnancy complications of placental origin”, que presenta Júlia Haro 
Barceló para la obtención del título de Doctor, ha sido realizado bajo mi 
dirección en el Departamento Ciencias Médicas Básicas de esta universidad. 
 
 
I STATE that the present study, entitled “Genetic and metabolic alterations in 
maternal and paternal one carbon metabolism and development of pregnancy 
complications of placental origin”, presented by Júlia Haro Barceló for the 
award of the degree of Doctor, has been carried out under my supervision at 
the Department Ciències Mèdiques Bàsiques of this university. 
 
 
 
 
 
 
Reus, 31 de juliol del 2020 
 
 
 
 
   
 
Dra. Michelle Murphy     
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
 
 
 
 
 
 
 
 
 
 
There is no magic to achievement. 
It’s really about hard work, choices and persistence. 
Michelle Obama 
 
 
 
 
 
 
  
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
9 
 
Acknowledgements 
 
Aquests agraïments no poden començar d’una altra manera que agraïnt a la 
Michelle l’oportunitat que m’ha donat, tant a nivell professional com personal, 
de formar part de l’equip de Medicina Preventiva. Valoro molt la seva 
dedicació, l’esforç i tot el que m’ha ensenyat durant aquests quatre anys. Com 
tampoc podria ser d’una altra manera, agraeixo infinitament la paciència i les 
hores que ha dedicat el Joan ajudant-me amb l’estadística. Gràcies de tot cor 
als dos per acompanyar-me en el món de la investigació. 
Agraeixo també tota la feina dels membres del Servei d’Obstetrícia i 
Ginecologia dels hospitals universitaris Sant Joan de Reus i Joan XXIII de 
Tarragona, sense els quals aquest estudi no es podria haver dut a terme. 
Sobretot el suport rebut pel Dr. Pere Cavallé Busquets i la Montserrat Inglès. 
A les noies del biobanc de Reus – Institut d’Investigació Sanitària Pere Virgili i  
al personal d’extraccions de l’Hospital Sant Joan de Reus, moltes gràcies 
també per tota la feina feta, que no és poca. 
Aquest estudi tampoc hagués estat possible sense la participació voluntària i 
altruista de totes les mares i els pares, a les quals vull agrair el seu esforç i la 
seva petita contribució al a ciència. La participació dels pares, especialment, ja 
que té un valor immens en aquesta tesis.  
Al finançament de: 
- Beca predoctoral Martí-Franquès. 
- Beca de projecte Institut d’Investigació Sanitària Pere i Virgili. 
- PI 16/00506, Alteraciones genéticas y metabólicas en el metabolismo 
monocarbonado paterno y desarrollo de complicaciones del 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
10 
 
embarazo de origen placentario – Instituto de Salud Carlos III (ISCIII), 
FIS. 
Agraeixo també el tracte rebut per tots els membres de la Facultat de 
Medicina de Reus durant aquests anys, especialment a la Sílvia i al Jordi que 
ens faciliten el treball del dia a dia.  
Com no pot ser d’una altra manera, també vull donar les gràcies als 
companys/es d’equip les quals han contribuït exactament a això, a formar un 
gran equip tant a dins com a fora del laboratori. M’han alegrat el dia a dia, 
m’han ajudat a superar els entrebancs i han fet més senzill aquest camí. 
Agraeixo també el recolzament de les meves companyes de pis, de la 
MariAngeles i de la Gemma, que són sense dubte el millor que m’emporto de 
Reus i una amistat que espero duri per sempre. 
Per acabar, i no menys important, agraeixo a la meva família, als amics de 
sempre i al Kevin el seu suport i ànims tant necessaris per arribar fins aquí. 
Espero tenir-vos sempre. 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
13 
 
Abstract 
Pregnancy complications of placental origin such as gestational hypertension, 
intrauterine growth retardation (IUGR) and preeclampsia are major causes of 
perinatal morbidity and mortality affecting maternal and foetal health. 
Maternal characteristics including previous pregnancy complications, 
underlying illness, maternal age, genetics and lifestyle are the principal risk 
factors considered in prenatal care and research. It is well known that 
maternal status in folate and other one carbon (1C) metabolites can 
contribute to adverse pregnancy outcomes. The genetic polymorphisms 
methylene tetrahydrofolate reductase (MTHFR) 677 C>T and SLC19A1 80 G>A, 
(affecting the reduced folate carrier) affect folate metabolism and transport 
into the cell, respectively, and intervene in folate and 1C metabolic status. In 
many cases pregnancy complications cannot be explained by maternal factors. 
Those that stem from poor trophoblast invasion and impaired placentation, 
could also be caused by paternal factors. Nevertheless, paternal risk factors 
have been scarcely studied and in most cases (both in clinical practice and in 
research) are not considered. 
In this thesis, we investigated whether maternal and paternal 1C metabolic 
status and the MTHFR 677 C>T and SLC19A1 80 G>A genotypes are associated 
with impaired placentation, intrauterine growth retardation and gestational 
hypertension.  
Eight hundred and fifty six mothers receiving prenatal care in the University 
Hospitals Sant Joan, Reus and Joan XXIII, Tarragona were recruited before 12 
GW. Their partners were also invited to participate and 66.1% agreed. A total 
of 748 mother-neonate dyads and 414 mother-father-neonate triads have 
been followed up to date from the Reus- Tarragona Birth Cohort study. 
Extensive lifestyle and obstetrical data was recorded from the first trimester 
throughout pregnancy and from separate interviews programmed for the 
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fathers. Fasting blood samples were collected during each trimester and from 
the father, and non-fasting samples at labour and from the cord. Plasma and 
red blood cell folate, plasma total homocysteine (tHcy) and plasma cobalamin 
were determined from maternal and paternal blood samples. MTHFR 677C>T 
and SLC19A1 80G>A genotypes were determined in the mother, the father 
and the cord. Associations between genetic and metabolic alterations in 
maternal and paternal 1C metabolism and development of impaired 
placentation, intrauterine growth retardation and gestational hypertension 
were investigated using multiple lineal and logistic regression analysis. 
Paternal MTHFR variant 677 C>T genotypes were associated with greater 
probability of impaired placentation compared to the CC genotype [OR (95% 
CI)], assessed by Doppler analysis of uterine artery resistance and wave forms: 
CT vs CC [4.0 (1.3, 12.6)] and TT vs CC [7.1 (1.6, 32.8)]. However, no association 
between maternal MTHFR 677 C>T genotypes and placentation was observed. 
Risk of impaired placentation [OR (95% CI)] was also increased when paternal 
tHcy was ≥P90 (14.1 µmol/L) compared to <P90, [2.7 (1.2, 6.0)]. Paternal 
smoking was significantly associated with uterine artery pulsatility index (β 
coefficient: 0.167, p<0.05). There was an interaction between mother’s 
MTHFR genotype and maternal smoking in their relationship with birth weight 
(P=0.024). Therefore, the analysis was stratified by smoking habit during 
pregnancy. Maternal MTHFR 677 TT genotype was positively associated with 
birthweight only in smokers (β coefficient: 0.186, p<0.05), and late pregnancy 
tHcy was positively associated with birthweight in non smokers (β coefficient: 
0.193, p<0.001). Neither paternal or maternal MTHFR 677 C>T genotypes 
were associated with IUGR risk. Paternal tHcy ≥P90 vs <P90 was associated 
with nearly five times greater probability of an IUGR-affected pregnancy [4.5 
(1.7, 12.8)]. Mothers with the MTHFR 677 TT genotype were three times more 
likely to develop gestational hypertension compared with those with the CC 
genotype [2.9 (1.0, 8.4)]. Neither maternal or paternal tHcy concentrations, or 
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paternal MTHFR 677C>T genotype, were associated with risk of gestational 
hypertension. Neither maternal or paternal SLC19A1 80 G>A genotypes were 
associated with risk of any of the three outcomes studied. 
In conclusion, the probability of impaired placentation was higher in 
pregnancies from fathers with the MTHFR 677 C>T variant (versus 
homozygote normal) genotypes and with elevated tHcy (versus <P90). This 
was also true for probability of IUGR, in the case of elevated paternal tHcy. 
Mothers with the TT genotype were at increased risk of developing gestational 
hypertension compared with the CC genotype. Paternal factors were not 
associated with gestational hypertension.  
 
Keywords: homocysteine – MTHFR C677T polymorphism – father – pregnancy 
complications – intrauterine growth retardation – uterine artery doppler – 
uterine artery pulsatility index – gestational hypertension 
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Abbreviation Definition 
RBCF Red blood cell folate 
RDA Recommended Dietary Allowance 
RFC Reduced folate carrier 
RNA Ribonucleic acid 
RTBC Reus-Tarragona Birth Cohort 
SAM S-adenosylmethionine 
SGA Small for gestational age 
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WHO World Health Organization 
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 Enzyme and genetic polymorphism nomenclature 
 
Abbreviation International 
nomenclature 
Definition 
DHFR EC 1.5.1.3 Dihydrofolate reductase 
DNMT1 EC 2.1.1.37 DNA methyltransferase 
MTHFD1 EC 1.5.1.5 Methylenetetrahydrofolate 
dehydrogenase 
MTHFR EC 1.5.1.20 Methylenetetrahydrofolate 
reductase 
MTR EC 2.1.1.13 Methionine synthase 
SHMT EC 2.1.2.1 Serine hydroxymethyltransferase 
TET2 EC 1.14.11 Ten-eleven translocation 
TYMS EC 2.1.1.45 Thymidylate synthetase 
 
 
 
Abbreviation Reference SNP Definition 
MTHFR 677 C>T rs1801133 Methylenetetrahydrofolate reductase 677C>T 
SLC19A1 80 G>A rs1051266  Reduced folate carrier 80G>A 
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UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
28 
 
Table 12. Predictors (Beta coefficients) of pulsatility index of uterine arteries 
according to paternal MTHFR 677 C>T genotype. 
Table 13. Associations between paternal MTHFR 677C>T genotype and 
pathological Doppler measurement of the uterine arteries at 20 GW. 
Table 14. Associations between paternal tHcy levels and pathological Doppler 
measurement of the uterine arteries at 20 GW. 
Table 15. Association between maternal genotype and birthweight, according 
to smoking habit during pregnancy (Beta coefficients). 
Table 16. Maternal red blood cell folate and cord plasma folate status 
according to smoking habit and MTHFR 677 C>T genotype. 
Table 17. Predictors including paternal factors of birth weight according to 
maternal smoking habit. 
Table 18. The associations between maternal and paternal tHcy and birth 
weight, according to maternal smoking habit. 
Table 19. Associations between elevated maternal plasma homocysteine and 
intrauterine growth retardation. 
Table 20. Associations between elevated (≥P90 versus <P90) maternal and 
paternal tHcy and intrauterine growth retardation. 
Table 21. Associations between maternal MTHFR 677C>T genotype and 
gestational hypertension. 
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1. Introduction 
 
Scientific evidence supports numerous roles for folate in maintaining health 
from early life to old age. Dietary folate is metabolised and participates in one-
carbon (1C) metabolism. This metabolic network acts as a potential donor of 
methyl groups that are essential for Deoxyribonucleic acid (DNA) and 
Ribonucleic acid (RNA) biosynthesis and repair, basic in all stages of life, and 
involves amino acid metabolic pathways. Other vitamins, mainly B vitamins, 
also participate in this network and interact together. A complex regulation is 
required to prevent an imbalance in these vitamins, that can cause chronic 
disease in middle and old ages (1). Optimum maternal status in folate is 
especially required around the time of conception, to prevent neural tube 
defects (NTDs). Mandatory fortification of cereal grains with folic acid was first 
introduced in the USA and Canada in 1998, in order to decrease the recurrence 
of NTD-affected pregnancies. The measure was based on evidence from two 
clinical trials in which participants taking preconception folic acid 
supplementation had a reduced risk of NTDs up to 70% (2,3). Since the 
introduction of mandatory folic acid fortification, pregnancies affected by 
NTDs complications in the USA and Canada, have been reduced by 
approximately 50% (4,5). In Europe, many countries have not implemented 
this policy of mandatory fortification, but voluntary fortification provides folic 
acid from foods such as breakfast cereals and dairy foods, depending on 
cultural differences in dietary habits in each country. The recommendations 
for folic acid supplement use vary, but generally are aimed at the 
periconception period (6). Successful adherence to these recommendations 
requires that women are aware of these and planning a pregnancy. There are 
no recommendations for potential fathers. Our research group recently 
reported that 18.8% of adult, nonusers of B vitamin supplements, 
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representative of the population of our geographical region of Spain, had 
folate deficiency (≤ 7 nmol/L (7)) and this was also true in 24.2% of women of 
fertile age (8).  
Folate participates in the remethylation of homocysteine to methionine (9). 
Homocysteine is a good indicator of 1C nutrient imbalance or deficiencies 
because it is sensitive to those changes and increases in these situations (10). 
One of the factors causing folate imbalance is the reduced activity of 
methylentetrahydrofolate reductase (MTHFR) observed in people with the 
MTHFR 677 C>T polymorphism (rs1801133). This enzyme catalyses the 
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, 
the main form of circulatory folate and carbon donor for the remethylation of 
homocysteine into methionine (11). This polymorphism is associated with a 
thermolabile enzyme in the presence of the variant T allele, reducing enzyme 
activity up to 50-60% approximately in the homozygote (TT) genotype (12). 
The MTHFR 677 C>T polymorphism has been commonly studied in pregnancy 
complications and identified as a definite risk factor for the development of 
NTDs, as reported by van der Put N et al (1995) in the Netherlands in a case 
control study where participants with the homozygote variant have a 
threefold increased risk of spina bifida (13). Meta-analyses indicate that this 
genotype is associated with increased risk of other adverse health outcomes 
such as cardiovascular disease (CVD), elevated DNA damage and higher 
probability of a high resistance to flow in the uterine arteries, when folate 
status is low (1). This polymorphism may be a risk factor for developing 
pregnancy complications of placental origin. In a previous study, our research 
group observed that 18% of the adult population from our geographical region 
had the homozygote variant form of the polymorphism (8), similar to the 
general population in Spain and in other areas in Europe as Italy, France, and 
Hungary (14). However, the prevalence appeared to be lower (4%-6%) in the 
north of Europe, for example in a Helsinki study (14). 
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Previous studies have demonstrated that paternal factors may contribute to 
some pregnancy complications such as gestational hypertension, 
preeclampsia and intrauterine growth retardation (IUGR). Advanced paternal 
age (15), being  born from a pregnancy complicated by preeclampsia (16), 
ethnicity (17) and genetic factors as a possible precipitating cause of an 
inadequate trophoblast invasion (18), are some of the paternal non-
modifiable risk factors proposed so far. In addition, modifiable factors related 
with lifestyle and habits such as smoking (19), alcohol consumption (20) or 
poor nutritional status (21) have been related with impaired placentation 
leading to low birth weight or preterm babies. In a review, Dekker et al (2011) 
have described the “dangerous father” concept referring to fathers with some 
of the potential risk factors for preeclampsia including age over 45, unhealthy 
habits (tobacco, alcohol, drugs, etc.) and metabolic diseases (obesity, CVD, 
etc.) (22). However, the mechanism by which the father affects placentation 
is still not clear and there are discrepancies between authors in the results. 
 
For all those reasons, this thesis sets out to study genetic and metabolic 
alterations in paternal one carbon metabolism affecting the development of 
pregnancy complications of placental origin. In order to develop primary 
prevention strategies, more information is needed regarding the effects of 
early life exposures on subsequent prenatal health and pregnancy outcome. 
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1.1. One Carbon metabolism: general insights 
 
One-carbon metabolism encompasses a complex network of enzymatic 
reactions containing the folate and methionine cycles, among other metabolic 
cycles and pathways. Numerous amino acids and other essential nutrients, 
such as B-vitamins, are used as co-factors and co-substrates in the cycle, 
working in the connected metabolic pathways with both inter-dependent and 
disparate functions. For this reason, precise regulation of these is needed to 
maintain optimal functioning of the system to meet its roles as methyl group 
donor and in transmethylation and trans-sulphuration reactions among others 
necessary for purine synthesis, cell division, DNA repair, epigenetic processes, 
etc. Deficient status in the vitamins involved in the network can lead to 
impairment in its functioning and subsequently other complications in related 
biological processes (9).  
 
The folate cycle, an integral part of the 1C metabolic network, is involved in 
the formation and transfer of carbon units to metabolic reactions and methyl 
groups to methylation reactions. Dietary folate is converted into intracellular 
metabolically active forms by physiological and metabolic processes including 
interconversion of polyglutamate and monoglutamate forms of folate, 
intestinal uptake, transport across cell membranes and metabolic reactions 
catalysed by specific enzymes (23). In parallel, 1C pathways exist in the cytosol 
and in the mitochondria and are connected by small metabolites that can 
readily cross the mitochondria. In the mitochondria, the catabolism of the 
amino acid serine, glycine, sarcosine, and dimethylglycine generate formate, 
the primary source of one-carbons for nuclear and cytoplasmic pathways (9). 
In the cytoplasm, 1C metabolism uses mitochondrial derived formate for the 
remethylation of homocysteine to methionine  and also for the synthesis of 
purine nucleotides and thymidylate (dTMP) (9). Methionine is an essential 
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amino acid involved in the methionine cycle, an important methyl group donor 
in the body, involved in various biological processes such as DNA methylation, 
protein biosynthesis and is a precursor for the synthesis of S-
adenosylmethionine (SAM) and homocysteine. SAM is an important cofactor 
and methyl group donor in numerous methylation reactions, including the 
methylation of DNA, RNA phospholipids, and proteins including histones (24). 
Homocysteine is a sulfur-containing amino acid, a demethylated derivative of 
methionine. Elevated fasting plasma homocysteine concentrations are 
influenced by genetic and environmental factors such as nutritional status, 
smoking habit, age, etc and are linked with some important health problems 
including vascular disease (25).  
Dietary folate enters the cells via folate receptors, such as the reduced folate 
carrier (RFC), where is converted into dihydrofolate (DHF). DHF is 
subsequently converted to tetrahydrofolate (THF) the biologically active form 
of folate by dihydrofolate reductase (DHFR). Once in the cycle, THF is 
metabolized to produce methionine, purine and dTMP principally. THF is 
converted to 5,10-methyleneTHF in an NADPH-dependent reaction, and 
MTHFR catalyses the reaction where 5,10-methyleneTHF passes to 5-
methylTHF (26). The one-carbon donor 5-methylTHF can be recycled by 
methionine synthase (MTR) to THF and methionine, in the remethylation of 
homocysteine to methionine in cobalamin dependent reaction (27). 
Alternatively, 5-methylTHF can be used to synthesize purine, which donates 
carbon units to the purine reactions (28).  
 
Folate can also be metabolised to synthetize de novo dTMP by the 
participation of the methylation of deoxyuridylate (dUMP), DHFR, two serine 
hydoxymethyltransferase isozymes (SHMT1 and SHMT2α), and the 
trifunctional enzyme methyleneTHF dehydrogenase (MTHFD1). 5,10-
MethyleneTHF is the required one-carbon donor for the TYMS-catalyzed 
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conversion of dUMP to dTMP and DHF; in this reaction 5,10-methyleneTHF 
serves as both a one-carbon donor and source of reducing equivalents (29).  
Moreover, as 1C metabolism is an important donor of methyl groups for post-
translation modifications that can affect physiological functions and 
contributes to DNA stability and cellular biosynthesis, this metabolic network 
is crucial to other metabolic systems. Taking into account also that both the 
folate and methionine cycles are present in every human cell, derangements 
in 1C metabolism can have profound effects on cell function, metabolism, 
growth and proliferation (30). 
 
 
Figure 1. Folate One-Carbon Metabolism scheme. From article “Folate and One-
Carbon Metabolism and Its Impact on Aberrant DNA Methylation in Cancer” Liu J et 
Ward RL (31). 
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In the literature it has been demonstrated that irregularities in one-carbon 
metabolism are associated with numerous diseases including anaemia (32), 
cancer (31), hypertension and cardiovascular disease (25), as well as 
pregnancy complications such as preeclampsia (33) or low birth weight (35, 
36). Additionally, it is well established that folate deficiency during the 
periconception period is associated with increased risk of neural tube defects 
(36). 
 
It has been proven that genetic polymorphisms, mainly affecting enzyme 
functions, in turn affect the 1C metabolic pathways affecting the complex 
regulation of the cycle. The genetic polymorphism with the most important 
effect on folate status (from the point of view of prevalence and effect) in the 
general population is the common 677 C>T variant in the gene encoding the 
methylenetetrahydrofolate reductase enzyme, MTHFR (1). This enzyme plays 
an important role in folate metabolism by catalyzing the reduction of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, which acts as a 
methyl group donor for the remethylation of homocysteine to methionine 
(37). This enzyme is also important in the reactions maintaining the balance 
between thymidylate (for DNA synthesis) and methionine synthesis 
(methylation reactions) (38). Homozygous individuals (TT genotype) have 
reduced enzyme activity and a predisposition to mild hyperhomocysteinemia 
particularly when folate status is low (39). Several studies have reported that 
this genetic variant increases the risk for vascular disease and for neural tube 
defects (40).  
Furthermore, the network is sensitive to status and availability of various 
amino acids (cysteine, serine and methionine) and B vitamins (folate, 
cobalamin, vitamin B2, vitamin B6) and lifestyle factors such as smoking or 
alcohol consumption. Arve Ulvik et al (2010) observed in a clinical trial 
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conducted in Norway that smoking significantly lowered circulating 
concentrations of folate and riboflavin (41). Modifiable factors such as 
nutrition, physical activity and toxic habits are the most important to take into 
account to prevent complications arising from impaired 1C metabolism. 
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1.2. Folates 
 
Food folates and folic acid: sources, bioavailability and requirements  
 
Folate is a water-soluble B vitamin, found naturally in foods. Different forms 
of folate occur due to the mixture of reduced forms of the vitamin (9). Folate 
cannot be stored in our body and we should eat folate-rich foods every day to 
maintain the required levels of this vitamin, if we are not supplementing our 
diet. The main food sources of folates are dark green vegetables including 
broccoli, spinach or lettuce, dried legumes such as chickpeas, beans or lentils, 
and some fruits like avocado or oranges. In the Spanish population, the most 
important sources of dietary folate are vegetables and cereals, legumes and 
fruits, contributing 20, 12.6 and 12% of total daily intake respectively (42). 
Folic acid refers to the synthetic form, a monoglutamate, found in the human 
diet only in fortified foods and supplements, but readily converted to the 
natural co-factor forms after ingestion (1). This folate form is commonly used 
in vitamin supplements due to its stability and actively reaching the intestine 
after its reduction. Folic acid is fully oxidized, but natural food folates are 
inherently less stable and not completely bioavailable (1). Low intake of folate-
rich foods as well as low bioavailability of the naturally occurring folates in 
such foods (43), led some countries like the USA and Canada to implement the 
mandatory fortification of cereal grain products (bread, rice and pasta)  with 
folic acid  to improve intake of this vitamin in the population (45, 46). The 
proposal for mandatory fortification was made by the Food and Drug 
Administration and other public health services and was based on the 
established risk of NTDs associated with impaired folate status and  NTDs (46).  
Multiple studies have assessed food folate bioavailability in humans, including 
studies measuring plasma, red blood cell (RBC) and urinary folate 
concentrations. The focus on folate bioavailability was needed to inform 
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dietary folate recommendations to provide optimal status as a priority for 
public health (47). The bioavailability of food folates is estimated to be ≤ 50% 
(48) and other evidence shows that folic acid ingested with food has about 
85% of the bioavailability of free folic acid , 1.7 times more than natural folates 
(49). Many factors affect food folate bioavailability, for example, intestinal 
deconjugation of polyglutamyl folates, an obligatory step in folate absorption 
because only monoglutamyl forms can cross cell membranes. Small intestine 
absorption is also a limiting step because it is affected by optimal acidic pH in 
the jejunum, intestinal diseases, age, mutations in the transporter protein 
genes, etc. The food matrix can also influence folate bioavailability by trapping 
folate in the matrix, the instability of certain labile folates during digestion, 
and the presence of certain dietary constituents that may enhance folate 
stability during digestion (10, 51).  
Estimates of folate requirements have been based on intake, associated with 
the maintenance of normal folate concentrations in plasma and erythrocytes 
(51). As said before, folic acid has different bioavailability to natural folate in 
food which is important to consider in dietary intake assessment. Dietary 
folate equivalents are used to express folate recommendations and are 
calculated as the μg natural food folate + 1.7 times the quantity of folic acid in 
the diet. This information is used by the National Academy of Sciences 
Institute of Medicine and other public health organizations for the 
Recommended Dietary Allowance (RDA) determination in some countries 
(52). In most European countries, however, this conversion factor is not 
applied and dietary folate intake is expressed simply as total folate in μg/d (1). 
The Spanish recommendations for daily folate intake are shown in Table  (53). 
Pregnant women have different recommendations, with higher doses of folate 
intake, than other healthy adults in the population. Folate requirements are 
increased during pregnancy to ensure correct development of the foetus. As 
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it might be difficult to achieve the necessary increase in folate intake through 
food intake, they must resort to supplementation.  
Some studies have demonstrated that women supplemented with folic acid in 
the preconception period reduce by 72% the risk of recurrent NTDs (2). 
Nevertheless, the recommendations can differ between countries. The 
majority recommend a healthy diet plus a folic acid supplement of 400 µg/d 
from preconception until the end of the first trimester of pregnancy, in line 
with the World Health Organization (WHO) recommendations (54).  
 
Table 1. Spanish folate (µg/ day) recommendations in adult population. 
 Women Men 
10-13 years 250 250 
14-69 years 300 300 
>70 years 300 300 
Preconception  400¹ - 
Pregnancy 500 - 
Lactation 400 - 
¹ From folic acid supplements. 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
42 
 
Absorption, transport and metabolism  
 
Folates are involved in a complex metabolic process that involves numerous 
reactions occurring in separate compartments. First, they must be 
transformed in order to be absorbed because food folates, mainly 
polyglutamates must be hydrolyzed to monoglutamate forms. Gamma-
glutamylhydrolase located in the brush border membrane of the jejunal 
mucosa is responsible for this hydrolysis (55). When they have changed the 
form, folate monoglutamates can be absorbed across the intestinal mucosa 
by a saturable and energy dependent active transport mechanism. Several 
transmembrane carriers are involved but two of them, the reduced folate 
carrier and the proton coupled folate transporter (PCFT), are the major folate 
transporters into cells. Both transmembrane transporters are expressed on 
the apical membranes of the intestine, and their mRNAs are up-regulated in 
situations of folate depletion (56). The RFC is stimulated by high levels of 
intracellular organic anions and has a reduced affinity for folic acid. On the 
other hand, the PCFT functions at acidic pH and has similar affinity for reduced 
folates and folic acid (9). In situations of high folate concentrations, 
monoglutamates can also cross the membrane by passive diffusion (57).  
Folate can also be taken up by the cell via three receptors in the apical 
membrane, α, β and ɣ. These folate receptors are expressed mostly in placenta 
and foetal tissues. They are found also in adult tissues and in some tumours 
(58). Transport via these receptors is a relatively slow process compared with 
the transmembrane carriers (59). Their well established role is in folate 
reabsorption by the kidney, and FR- α plays a role in embryo development and 
preventing neural tube defects (60).   
The degree of metabolism in the intestinal mucosa depends on the dose of 
folate or folic acid consumed. If it is high, such as during supplementation, 
most of the transported vitamin appears unchanged in the portal circulation 
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(61). Folates are methylated in the mucous membrane cells before entering 
the portal circulation as 5-methyl-tetrahydrofolate. Under normal conditions, 
this metabolite is the primary circulating form of folate in plasma, binding to 
proteins, mainly albumin, which accounts for about 50% of bound folate. After 
folate absorption into the portal circulation, between 13-28 mg is retained in 
the liver and the rest is distributed to other tissues (9). Total body stores of 
folate in humans have been estimated to range from 10 to 100 mg (62). The 
half life of folates after entering into the enterohepatic circulation is 
approximately 100 days (47). This cycle of folate involves release of hepatic 5-
methyl-thf into bile via methionine synthase reductase 2 (MTRR2) and then is 
reabsorbed in the small intestine for distribution to other tissues and liver, 
completing the enterohepatic cycle (63). Some studies clarify that the major 
role of this cycle is the maintenance of folate homeostasis (64). Little or no 
folate is lost in the urine at normal folate intakes.  
 
When folate reaches the tissues, it is distributed among the different folate 
pools in the cells. Up to 50% enters the mitochondria, normally the glutamates 
with longer chain length. The 5-methyl-THF folate form is found in the cytosol 
pool (65). The nucleus also contains a folate pool that may be in equilibrium 
with this latter pool. In cells, folate is metabolized in the one carbon metabolic 
network. 5-methyl-THF, the predominant form, is used by MTR to remethylate 
homocysteine to methionine. This reaction also produces THF, which can be 
methylated by glycine and can also form 5,10-methyleneTHF or be catalyzed 
to generate formate and enter the purine synthesis pathway.  
Concentrations of plasma folate are much lower than in red blood cells and 
almost all red blood cell folates (RBCF) are 5-methylTHF polyglutamates. The 
measurement of total folate provides information on the folate status of the 
individual. Folate plasma levels may be influenced by recent dietary intake (9). 
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For this reason, plasma folate has been used to predict short-term plasma 
status, while RBC folate is an indicator of folate long-term status or 
reservations. In addition, fasting plasma total homocysteine concentration is 
used as a non-specific functional biomarker for folate status (66).  
 
Figure 2. Folate absorption and distribution scheme. From article  “Folate and One-
Carbon Metabolism and Its Impact on Aberrant DNA Methylation in Cancer” Liu J et 
Ward RL (31). 
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Maternal folate status and its determinants to preconception and 
pregnancy outcomes  
 
As mentioned before, optimal folate status is required to prevent adverse 
health outcomes associated with folate deficiency, a potential public health 
problem that could affect many millions of people throughout the world. The 
prevalence of folate deficiency is not general around the world and is not 
associated with the level of development or the geographical location (67). 
However, in some countries like France (68) and Spain (8), where there is no 
mandatory fortification of food with folic acid, it is quite prevalent. People of 
any age can develop folate deficiency. Especially, in situations of increased 
requirements such as pregnancy, neoplastic diseases or in situations of 
malabsorption, the deficiency can appear (69). In addition, behavioural factors 
such as smoking,  alcohol consumption, or oral contraceptive use are common 
causes of low folate status (70), because they are negatively associated with 
folate intake or absorption (69). Inadequate folate intake leads to decreased 
plasma and RBC folate concentrations and is associated with increased tHcy, 
a sensitive biomarker of impaired folate status. Cobalamin (B12) deficiency 
also leads to elevated tHcy so, elevated urinary or serum methylmalonic acid 
(MMA) concentration, affected by a pathway not shared by folate and 
cobalamin, is a specific  indicator of impaired cobalamin status (69). Cobalamin 
is another vitamin involved in 1C metabolism, acting as a cofactor for key 
enzyme reactions in this cycle including the generation of methionine and 
tetrahydrofolate. Importantly, cobalamin and folate play inter-dependent 
roles in this specific pathway. The main and exclusive source of cobalamin is 
from foods of animal origin. Pregnant women are more likely to be B12 
deficient than non-pregnant women (71). 
The study of folates as a key nutrient for human health, and their importance 
before and during pregnancy (52), started in 1931 when Lucy Wills tested 
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marmite, which is a yeast extract rich in folate, as a cure for macrocytic 
anaemia in pregnant women (72). The increase in knowledge of the 
importance in avoiding folate deficiency over decades, motivated some 
countries to opt for folic acid fortification of cereal products (54). The impact 
of mandatory fortification is now reflecting a significant decline in the 
prevalence of NTDs in some countries. In the USA and Canada, the cases of 
some NTDs have decreased by 28% (73) and 46% (74), respectively. Nowadays, 
fortification with folic acid is mandatory in eighty one countries from global 
regions (75).  
The National Health and Nutrition Examination Survey (US NHANES III) in line 
with the Institute of Medicine and in accordance with the WHO (76), has 
established the blood cut off concentrations for defining folate and B12 
deficiencies. Values of serum folate <10 nmol/L and <340 nmol/L for RBC 
folate, as well as <150 pmol/L for plasma vitamin B12 are considered deficient 
(77). These data are based on the plasma vitamin concentrations below which 
plasma metabolites become elevated (total homocysteine concentration for 
folate and MMA for vitamin B12). However, until recently <7 nmol/L was 
widely used as the cut off for plasma folate deficiency (7). This cut off was 
based on the concentrations at which macrocytic anaemia was more likely to 
appear and was later revised due to its low precision. 
As human’s intake of folate and B12 depends on dietary sources, in some cases 
the ingestion of dietary supplements is needed to supply the required levels. 
Vegetarians, who don’t eat animal products, are one of the examples of 
people who need to take supplementary vitamin B12. The periconceptional 
period is another of the recommended moments to supplement with folic acid 
and vitamin B12, to reduce associated pregnancy complications (71, 72). 
Nevertheless, according to NHANES I data, approximately 90% of the women 
of fertile age in the USA consume <400mg folate/day and only <10% meet the 
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RDA for pregnancy (78). Periconceptional maternal nutritional status is 
considered to be very important, due to its involvement in the development 
of the embryo and the fetus (79). Women with low dietary folate and 
cobalamin intake before and during pregnancy, resulting in vitamin 
deficiencies and an imbalance of the 1C metabolism, can develop pregnancy 
complications such as impaired placentation, intrauterine growth retardation 
and gestational hypertension. These are the main outcomes studied in this 
thesis and described in detail in subsequent sections of the introduction.   
 
The focus of research into the relationship between 1C metabolism and 
pregnancy complications has been largely centred on the importance of folate 
in nucleic acid synthesis, required for the cell division stage of embryonic and 
fetal development. Marginal folate status during pregnancy can impair cellular 
growth and replication in the fetus or placenta (70). In 1975, Bryan Hibbard 
was one of the first authors to describe the importance of optimum folate 
status during pregnancy, especially in the early weeks when placentation and 
organogenesis occur. The author explained that fetal complications such as 
low birthweight, abortion and fetal malformation, occurred in women with 
disturbances in folate metabolism (80). Later, several authors continued 
researching the relationship between folate status and pregnancy 
complications. As is well established, Scott JM explained in a review that 
deficient folate status increased the risk of delivering a child with NTDs and 
argues that periconceptionally folic acid supplement use normalizes this risk 
(81). Poor folate status has also been associated with preterm delivery. In 
1996, T O Scholl et al observed that women with a low mean daily folate 
intake (≤ 240 µ/d) had an approximately twofold greater risk of preterm 
delivery (82). Low folate status has also been associated with gestational 
hypertension and preeclampsia (83). De Ocampo M et al reported an 
attenuated risk with early and late folic acid supplement use and observed 
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also a decreased risk to develop those complications when the duration of this 
supplementation increased (83). In a review from 1987, Kramer MS described 
folic acid as one of the nutritional factors predicting indirectly intrauterine 
growth retardation, among other determinants such as genetic, demographic 
and obstetric factors (84). 
Folate deficiency leads to elevated tHcy, which has also been reported to be a 
risk factor for pregnancy complications (70) in several studies. Cotter A et al 
(2003) observed in matched case-control studies, that elevated tHcy plasma 
levels (>10 µmol/L)  in early pregnancy increase the risk of non-severe (85) and 
severe (86) preeclampsia compared with the control population (mean 
homocysteine of 7.07 ± 1.5 µmol/L). Rajkovic A et al found similar results in an 
observational study, showing significantly elevated homocysteine plasma 
concentrations in the preeclamptic group compared to control group (8.66 ± 
3.05 versus 4.99 ± 1.11 µmol/L) (87). Increased maternal plasma 
homocysteine concentrations are also associated with increased risk of 
habitual spontaneous abortion. W L Nelen et al observed that women in the 
highest homocysteine concentration percentile (over the 95th, concentrations 
greater than 18.3µmol/L) tended toward 3.6 times increased risk (88). In a 
recent report from the Reus Tarragona Birth Cohort we also confirmed that 
elevated early pregnancy tHcy (≥ P90 (7.1 µmol/L)) is associated with 
increased risk of miscarriage (89). Increased plasma homocysteine levels are 
also related with low birth weight as well as intrauterine growth restriction. 
Murphy MM et al (2004) reported that mothers in the highest tHcy tertile at 
8 weeks of pregnancy were three times, and at labour were four times, more 
likely to give birth to a neonate in the lowest birth weight tertile (34). In 
addition, Denise Furness et al in a prospective cohort study shown that the 
combination of both low folate concentrations and high homocysteine are 
associated with the subsequent development of IUGR (90). However, in a 
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multivariate regression analysis the authors revealed that RBC folate was a 
strong predictor of this pregnancy complication. 
On the other hand, it has been shown that cobalamin status is closely related 
with folate levels (91). Even when folate levels are high, if the status of 
cobalamin is poor, metabolic signs of cobalamin deficiency can appear 
involving high MMA and tHcy plasma levels, combined with low 
holotranscobalamin (holoTC) levels, one of the plasma B12 bound proteins 
(92). This suggests that an imbalance in the folate-cobalamin pool adversely 
affects cobalamin metabolism, potentially leading to adverse perinatal health 
when cobalamin status is low in pregnancy (93). Low cobalamin status has 
been related with adverse pregnancy outcomes such as small for gestational 
age (SGA) (94), preterm birth and low birth weight (95). In a prospective 
observational cohort study in south Indian women, low vitamin B12 intake 
(<1.2 µg/day) was independently associated with a higher risk of SGA. 
However, in a subgroup of folic acid supplement users, those with the lowest 
B12: folate ratio (low intake of vitamin B12 in the presence of a high intake of 
folate) had a higher risk of SGA compared to those with the highest ratio. This 
suggests that in addition to vitamin B12 and folate deficiencies alone, there 
may be adverse birth outcomes associated with imbalanced vitamin B12 and 
folate intakes or status during pregnancy (94). On the other hand, Yurdanur G 
et al described no association between maternal B12 status and risk of 
preeclampsia. They only found an association with other B12 related 
biomarkers such as plasma homocysteine or folate (96).  
Compromised cobalamin status during pregnancy may also affect the lactation 
period, leading to deficient status, and impaired development of the baby 
(97). Finally, the combination of both elevated folate and low cobalamin status 
have been linked with increased risk of gestational diabetes (98), increased 
insulin resistance (99), and small-for-gestational-age status (94) in the 
offspring.  
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All these evidences suggest a relationship between impaired 1C metabolism 
and adverse pregnancy outcomes. Even though the biological mechanisms are 
still unclear, a possible mechanism by which folate status and other B vitamins 
acting in the cycle can influence disease predisposition is by epigenetic 
processes, such as methylation, that can modify gene expression. These 
biological reactions will be discussed later. Another possible mechanism 
proposed is by DNA damage associated with elevated maternal homocysteine 
concentrations (90). Or endothelial dysfunction due to elevated homocysteine 
levels (negatively correlated with nitric oxide (NO)) that contributes to 
vasodilatation that occurs during normal pregnancy (100).   
 
During pregnancy, as folate requirements are higher, vitamin supplement use 
is useful to achieve optimal folate status, as well as other minerals and 
vitamins. Our research group have recently shown that folic acid 
supplementation is associated positively with plasma and RBC folate 
concentrations and lower tHcy throughout pregnancy. In addition, when 
supplementation continues throughout pregnancy plasma folate status 
decrease between 15 and 24–27 GW and remain stable thereafter, whereas 
in the absence of continued supplementation plasma folate decreased 
throughout the remainder of pregnancy. Contrarily, when the 
supplementation stops plasma folate concentration decline throughout 
pregnancy (93). If women have poor folate status at the beginning of 
pregnancy, plasma and RBC folate levels will decrease further throughout.  
In 2002 our research group, Murphy MM et al reported that tHcy levels 
decreased as a physiologic response to pregnancy, even further in mothers 
who use folic acid supplements (101). These results were complemented with 
further information in 2004, regarding the increase in tHcy during the third 
trimester, and further by labour. In women that were taking folic acid 
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supplements, tHcy concentrations by labour were similar to those at 
preconception point (34).  
On the other hand, Murphy MM et al as well as other authors, have 
demonstrated that during pregnancy cobalamin blood levels drop (100, 101). 
In a longitudinal study, our research group also observed that the decrease in 
plasma cobalamin by 32GW is not merely due to a physiological effect of 
pregnancy but also due to possible mobilisation of maternal cobalamin stores. 
This is reflected by the rise in methylmalonic acid during the second half of 
pregnancy in the face of continuing haemodilution and increased glomerular 
filtration rate that occur during pregnancy. The levels of plasma 
Methylmalonic Acid (MMA) are higher by 32GW and labour than at 
preconception (Figure 3). This rise is higher in women with suboptimal early 
pregnancy cobalamin status than in those who are replete (102). Cobalamin is 
also negatively associated with tHcy, and as it happens with MMA the 
association became stronger as pregnancy progressed (93). This suggests that 
maternal cobalamin stores, even in non-vegetarian women, can be strained 
during pregnancy. 
 
Figure 3. Cobalamin (blue line) and MMA (red line) concentrations during 
preconception, three points of pregnancy (8, 20 and 32 GW) and at labour are 
shown(102). 
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In a recent publication, our research group found that folate could modify the 
relation between cobalamin and MMA status during pregnancy. We observed 
that women with elevated plasma folate in the 1st trimester have higher MMA 
concentrations than the group of women with low folate status, if they have 
suboptimal B12 status. In women with normal cobalamin status, the plasma 
MMA concentrations are not affected by folate status (Figure 4) (93).  
 
 
 
Figure 4. Estimated marginal means (95% CIs) for plasma MMA and tHcy throughout 
pregnancy according to first-trimester plasma cobalamin and folate status. Linear 
mixed models were used. MMA, methylmalonic acid; MTHFR, 
methylenetetrahydrofolate reductase; tHcy, plasma total homocysteine. Figure from 
article “Early pregnancy folate-cobalamin interactions and their effects on cobalamin 
status and hematologic variables throughout” Pol Solé-Navais et al. 2018 (93). 
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There are other modifiable factors related with maternal lifestyle that can 
negatively affect pregnancy outcomes. Some of them are inadequate 
gestational gain, inadequate prenatal care, smoking, alcohol and drug use 
(104). However, other non-modifiable factors may also influence pregnancy 
complications. This is the case of history of spontaneous abortion, preterm 
delivery, low birth weight or intrauterine growth restriction in previous 
pregnancies that can affect the current pregnancy (105). Genetics is also a 
non-modifiable factor that may influence pregnancy complications and folate 
status. There is potential evidence that polymorphisms, affecting genes coding 
for proteins or enzymes involved in folate uptake or metabolism, can modify 
plasma or body folate levels leading to health and pregnancy problems 
commented before (69). MTHFR C677T is a common polymorphism that leads 
to instability of methylenetetrahydrofolate reductase (106). As explained 
before, this enzyme is known to catalyse the reactions involved in  transferring 
the methyl groups to the principal methyl donor (methionine), that are 
necessary for DNA synthesis, methylation, cell division and tissue growth 
(107), and is essential for placenta and foetal development. The homozygote 
variant genotype (TT) is associated with elevated tHcy plasma levels, as well 
as decreased levels of DNA methylation compared with those with the CC 
genotype (homozygote normal) (66). The effect of the polymorphism on tHcy 
is intensified under low folate and cobalamin conditions, and it has been 
related with increased risk of NTDs and other adverse pregnancy outcomes 
(108). The effect of this polymorphism on pregnancy and other complications 
is discussed further below.   
Apart from the effect of maternal factors on pregnancy outcome, some 
literature supports the implication of paternal factors as one of the causes of 
pregnancy complications of placental origin. Examples are impaired 
placentation, IUGR and gestational hypertension. Paternal lifestyle as well as 
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nutrition and poor folate status, are some of the modifiable factors that can 
lead to potential paternal precursors of pregnancy complications (109). 
Likewise, non-modifiable genetic factors affecting 1C metabolism and folate 
status in the father, may lead to  pregnancy complications (110). The paternal 
involvement in the development of adverse pregnancy outcomes, as a main 
objective of this thesis, will be commented in the next chapters.  
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1.3. MTHFR C677T polymorphism  
 
The MTHFR C677T polymorphism and pregnancy complications 
 
Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and adverse 
pregnancy outcomes such as IUGR, preterm delivery, preeclampsia, pregnancy 
loss and others has been the focus of interest by various authors for many 
years (111). The MTHFR gene catalyzes the conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, the main form of 
circulatory folate, which is the co-enzyme of methionine synthase together 
with vitamin B12 and plays a key role in the remethylation of homocysteine 
into methionine (11).  
A cytosine to thymine substitution at position 677 (MTHFR C677T) is a quite 
common polymorphism in this gene, leading to the substitution of valine for 
alanine in the corresponding protein resulting in a reduction of the enzyme 
activity (112). Consequently, the conversion of homocysteine to methionine is 
impaired, leading to elevated tHcy (113), which is a risk factor for 
cardiovascular disease (114), and reduced DNA methylation due to less 
available free methyl groups (66). The polymorphism is relatively common in 
the Spanish adult population (18.1 %) (8) and has been suggested to be 
involved in thrombotic events or impaired methylation during pregnancy 
(115).  
Elevated maternal plasma tHcy levels, due to the reduced enzyme activity may 
contribute to placenta-mediated pregnancy complications (114). Increased 
tHcy may lead to endothelial dysfunction (116), inflammatory processes (117), 
oxidative stress (11), arteriolar constriction (11) and placental thrombosis 
(113). These conditions might be associated with impaired blood flow and 
prothrombotic changes in the uterine artery wall, inadequate trophoblast 
invasion into the uterine vasculature, and placental hypo perfusion that 
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subsequently leads to pregnancy complications (11). Furthermore, these 
complications may also result from the increased requirements for DNA 
methylation and protein synthesis involved in the growth of the baby and the 
placenta, taking into account that methyl groups are decreased in the TT 
genotype of the MTHFR polymorphism (118).  
Chaudhry et al (2019) reported that a 5 μmol/L increase in tHcy (4 standard 
deviations of tHcy approximately) was associated with elevated probability of 
IUGR and preeclampsia but not with placental abruption or pregnancy loss, in 
a Canadian cohort after adjusting for gestational age at the time of blood draw 
and explanatory maternal characteristics (114). Mishra et al (2018) studied the 
MTHFR gene methylation patterns of placental tissue in preeclamptic Indian 
women, and observed lower MTHFR gene methylation on the foetal side of 
preeclamptic placenta compared to gestation-matched controls (115). 
Hypomethylation of genes involved in placentation is reported to be 
associated with impaired trophoblastic invasion (119), leading to unsuccessful 
placentation. In the same study, preeclampsia cases with the CT genotype had  
higher levels of global DNA methylation compared to controls with the CT 
genotype (115). This suggests that heterozygote women with hyper global 
DNA methylation are more prone to preeclampsia (115). In addition, a meta-
analysis performed by Han Wu et al (2017) aimed at clarifying the association 
between maternal MTHFR C677T genotype and susceptibility to preterm birth 
and low birth weight. The maternal MTHFR C677T polymorphism increased 
the risk of preterm birth and low birthweight in homozygote TT versus CT or 
CC genotypes. Therefore, they concluded that identification of the maternal 
MTHFR C677T mutation might be useful in identifying women needing primary 
prevention of these pregnancy complications (11).    
Other studies have investigated the relationship between the MTHFR C677T 
polymorphism and pregnancy loss. Mehandjiev et al (2019) studied the 
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association between the MTHFR C677T polymorphism and intervillous and 
decidua pathology in patients with pregnancy loss, and they reported that the 
T allele and MTHFR TT genotype are associated with severe intervillous and 
decidua pathologies such as fibrin deposits and thrombosis in those patients 
(118). Turgal et al (2018) also studied the effect of the MTHFR C677T 
polymorphism on pregnancy loss, and reported that the MTHFR C677T 
polymorphism increases early pregnancy loss, with the  highest rates occurring 
in the MTHFR homozygote variant genotype (120). They proposed an impaired 
homocysteine/methionine metabolism disorder due to the polymorphism as 
a potential risk factor for this complication. Yajuan Xu et al (2018) observed in 
a case-control study significantly higher frequencies of the T allele of the 
MTHFR C677T polymorphism in the unexplained recurrent pregnancy loss 
group compared to the control group (121). On the other hand, the presence 
of CC and CT genotypes was significantly reduced in the unexplained recurrent 
pregnancy loss compared to the control group. Finally, our research group 
recently reported from the Reus-Tarragona Birth Cohort study that mothers 
with first trimester tHcy ≥ P90 (7.1 µmol/L) have increased risk of miscarriage 
(OR 95% CI, 2.5 [1.1, 5.7]). The prevalence of the MTHFR 677 TT genotype was 
higher in this group compared with mothers with tHcy < P90 (89).  
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The MTHFR C677T polymorphism and cardiovascular diseases 
 
Apart from its reported involvement in some pregnancy complications, 
numerous studies have also reported an association between the MTHFR 
C677T polymorphism and cardiovascular diseases such as coronary artery 
disease, stroke or hypertension (122). The homozygous mutant genotype is 
associated with a 40% greater risk of cardiovascular disease compared to the 
homozygous normal genotype (123). Most of studies have focused on 
homocysteine metabolism disorders as the putative risk factor associated with 
this polymorphism (124). In homozygotes, with the MTHFR 677 TT genotype,  
impaired folate metabolism and higher homocysteine concentrations has 
been reported (125). Homocysteine produces reactive oxygen species during 
the thiol oxidation process. This species are toxic to the endothelium and may 
cause endothelial injury in various organs (126). Many studies have been 
performed in the general population showing that mildly elevated tHcy is 
associated with increased risks of atherosclerosis and venous thrombosis, 
such that hyperhomocysteinemia is considered an independent risk factor for 
cardiovascular diseases (127). Endothelial cell dysfunction has been identified 
as a key mechanism by which vascular risk factors may mediate their effect on 
vascular disease risk (128).  
 
Shiran et al (2015) observed higher tHcy in the presence of endothelial 
dysfunction detected by flow-mediated dilatation, in individuals with B12 
deficiency (B12 <150 pmol/L) with the MTHFR 677 TT compared to the CC 
genotype. They also confirmed the interaction between B12 deficiency and 
the MTHFR C677T mutation and observed that among individuals with B12 
deficiency, TT homozygosity was associated with higher tHcy compared to the 
CC or CT genotypes. In addition, endothelial function was more affected in B12 
deficiency patients with the TT genotype, compared to those with normal 
levels of B12 due to the role of hyperhomocysteinemia in oxidative stress and 
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reduced endothelial cell proliferation (129). Tang et al (2014) studied a cohort 
of coronary slow flow phenomenon patients and found higher frequencies of 
the MTHFR 677 TT and CT genotypes and MTHFR 677 T allele in the patients 
compared to controls (130).  They also verified that tHcy plasma levels were 
higher in the patients with the homozygote genotype compared to CT and CC 
genotypes. Other studies have investigated the relationship between the 
MTHFR C677T polymorphism and deep vein thrombosis (DVT), caused by an 
imbalance between vascular relaxing factor and vascular contraction. It was 
shown in two populations, Iranian and Chinese, that the frequencies of the TT 
genotype and T alleles of the polymorphism were higher in the DVT group 
compared with those in the control group (130, 131). These results suggest 
that the MTHFR C677T polymorphism may be a risk factor for DVT. In another 
study with 160 ischemic stroke patients divided into two groups with or 
without hypertension, Ariana et al (2019) observed that the TT genotype was 
more prevalent in ischaemic stroke patients with hypertension (16 patients; 
69.5%) compared with the group without hypertension. All patients with 
ischaemic stroke in the group with hypertension have the MTHFR 677 TT 
genotype (5 patients; 100%)(133). As this paper shows, many other studies 
have proposed this genetic variant as an independent risk factor for 
hypertension, with an increased risk of between 24 and 87% in homozygotes 
for the MTHFR C677T polymorphism compared to the MTHFR 677 CC and CT 
genotypes (123). Lynch et al (2019) reported in 75  cardiovascular disease 
patients that those with the TT genotype had higher systolic and diastolic 
blood pressure at baseline compared to those with the CC genotype (134). In 
a study conducted in Southwest Cameroon, Ghogomu et al (2016) also 
reported that the frequency of the T allele of the MTHFR C677T polymorphism 
was higher in the hypertensive group than in the normotensive group. On the 
other hand, the C allele was higher in the normotensive than in the 
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hypertensive subjects (135). These results are comparable to those obtained 
in populations from Spain (136), Australia (137) and Turkey (138).  
Our research group also investigated the relationship between the MTHFR 
C677T polymorphism and moderately elevated tHcy and hypertension in an 
adult population study (139). There was no association between either of the 
variant MTHFR C677T genotypes and diagnosed hypertension in the overall 
representative sample (randomly selected from population records) of the 
adult population, that was unexposed to mandatory fortification with folic 
acid. However, the TT genotype was associated with greater probability of 
having hypertension than the CC genotype in participants ≤50 years. On the 
other hand, moderately elevated tHcy was associated with hypertension in the 
overall population and specifically in people over 50 years of age. Therefore, 
both moderately elevated tHcy and the MTHFR C677T polymorphism are 
associated with risk of hypertension, and these associations differ in 
subgroups of the population (139). However, our data do not directly support 
that the mechanism linking the MTHFR genotype to hypertension is via 
elevated tHcy as other studies do. Several studies show that homocysteine is 
a predictor of secondary, but not primary events (140), suggesting that is a 
product rather than a cause of vascular disease. The inconsistent results may 
be due to the methodology used for each study as the matching of correct 
controls with the cases, inadequate measurements or adjustments for the risk 
factors, sample storage and determinations at baseline, etc (128). Moreover, 
intervention studies performed to lower tHcy have shown little or no 
corresponding blood pressure response. This could be due to the fact that 
there is no mechanistic association between homocysteine and blood 
pressure (123), or could be because intervention is ineffective once the 
disease is established. Few or no studies have investigated the effects of 
lowering tHcy as a primary preventive strategy. Thus, MTHFR polymorphism 
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may be related to blood pressure via a mechanism independent of 
homocysteine.  
 
The effect of nutritional status on the MTHFR C677T polymorphism 
 
It is well established that TT homozygotes for the MTHFR C677T polymorphism 
have elevated homocysteine concentrations and lower folate status 
compared to the common genotype, indicating a gene-nutrient interaction 
(128). The prejudicial effect of the homozygous variant genotype is significant 
only when folate status is low, such as in countries with no mandatory food 
fortification, like in Spain. In regions with folic acid fortification policies the 
apparent effect of the MTHFR genotype has been proposed to be null (141). 
Therefore, dietary folate can influence the phenotype and thus disease risk 
(pregnancy complications, cardiovascular diseases, etc.) (123). It is proven that 
folic acid supplementation is an effective method to lower plasma 
homocysteine levels (123).  
 
Recently, riboflavin (vitamin B2) is taking more attention due to its important 
role in one-carbon metabolism because it acts in the form of flavin adenine 
dinucleotide (FAD) as a cofactor for the MTHFR enzyme (123). Low riboflavin 
status, more frequent in individuals with the homozygous mutant TT genotype 
(125), is associated with elevated tHcy and low folate concentrations (123).  
Molecular studies have shown that MTHFR activity is reduced in the presence 
of the MTHFR 677 TT genotype  due to its reduced affinity for the FAD cofactor 
(142). In addition, in human studies, riboflavin supplementation of individuals 
with the TT genotype can reduce homocysteine levels (143). This suggests that 
optimal riboflavin status can stabilize the variant enzyme and restore  MTHFR 
activity (123).  
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Recent evidence suggests that riboflavin may be an important modulating 
factor via a novel effect on blood pressure (123). Lynch et al (2019) confirmed 
the involvement of riboflavin in ensuring optimum MTHFR activity, suggesting 
that this vitamin may interact with the MTHFR gene to influence blood 
pressure. They observed that riboflavin supplementation, at dietary level (1.6 
mg/day), can decrease blood pressure in TT hypertensive adults compared 
with controls (134). They did not find a significant reduction in the CC 
genotype group. In addition, people with the TT genotype and poor riboflavin 
status, can reduce plasma tHcy levels with riboflavin supplementation (143). 
In a randomized trial, Wilson et al (2013) demonstrated in hypertensive 
individuals with the MTHFR 677 TT genotype treated with antihypertensive 
drugs, that those supplemented with riboflavin decrease blood pressure more 
effectively than those in the placebo group (treatment with current 
antihypertensive drugs alone)(144).  
Increasing the activity of the MTHFR enzyme by riboflavin supplementation is 
only observed in those individuals with the homozygous MTHFR 677 TT 
genotype, with no response evident in CC or CT genotype groups (143). This 
effect might lead to improved endothelial function through increased 
bioavailability of nitric oxide via increases in 5-methyltetrahydrofolate (123). 
 
This emerging evidence of riboflavin supplementation in lowering tHcy and 
blood pressure, suggests that nutritional and pharmacological interventions 
based on folic acid and other B vitamin supplementation can provide useful 
targeted therapy to reduce pregnancy complications and cardiovascular 
diseases in genetically at risk people. However, large-scale clinical intervention 
studies are needed to confirm the effects and correct doses to prevent 
negative effects. 
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1.4. Placentation and pregnancy complications of placental origin  
 
Trophoblast invasion and placentation  
 
The origin of a successful pregnancy and fetal development stems from 
fertilisation. The resulting zygote cell goes through several stages of division 
and proliferation resulting in different cellular stages. During the first steps 
after conception, cellular division leads to the 32 cells considered the morula 
(145) as it passes  through the fallopian tube. Two days after fertilization, the 
cells reach the uterine cavity in the next cell stage, the blastocyst. The 
blastocyst is a vesicle composed of between 107-256 cells that make up the 
early embryo, composed by two types of cells; the inner layer cell mass called 
the embryoblast that will develop into fetal and embryonic tissues  (146) and 
the outer layer of cells called the trophoblast that is the forerunner of the 
placenta and the cord (147). From the cluster of the embryonic disc (inner cell 
mass) grows another cell layer to line the cavity of the yolk sac, an 
extraembryonic membrane that plays an important role in the early nutrition 
of the embryo, and is the source of early hematopoiesis (148). On the other 
hand, the placenta is the principal organ required for embryonic development, 
because is an autonomous and transitory organ that allows nutritional and gas 
exchanges between the fetus and the mother, provides an immunological 
barrier between both, and produces and secretes a number of hormones, 
cytokines and sing molecules (149).  
During the blastocyst stage, by day 6-7 after fertilization, this group of cells 
adheres to the maternal endometrium and the embryo develops a fluid-filled 
central cavity. On the 10th day, the single layer of the trophoblast proliferates 
and it differentiates into two types of cells; the inner layer called 
cytotrophoblast and the outer layer syncytiotrophoblast (145). The 
cytotrophoblast is composed of individual, well defined and rapidly 
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proliferating cells (150). Contrarily, the syncytiotrophoblast comprises 
multinucleated cells with indistinct cell borders (145). The cytotrophoblast 
cells proliferate and create cell columns with invasive properties into the 
maternal tissues. The blood vessels surrounding the blastocyst are broken, 
and trophoblast invasion occurs so that the vessels required to initiate 
circulation between the uterus and the placenta are formed (151). 
Trophoblast invasion is the main process of placentation, starting in early 
pregnancy and lasting until the 20th GW, so that contact with the maternal 
blood is established (152) and allowing the physiological transformation of the 
structure of the intrauterine arteries, required for a successful pregnancy 
(149). The trophoblast will also contribute to placental hormonal production 
(149). After the first phase of implantation into the maternal uterus, the 
trophoblast differentiates along two main pathways; the villous or the extra 
villous (153). The first one covers the chorionic villi, the site of maternal-fetal 
gas and nutrient exchange, and the extra villous trophoblasts invade the 
uterus wall to anchor the placenta in the uterus (145). To guarantee an 
adequate blood flow to the foetus, the blood vessels in the outer 
endometrium (the outer epithelial part of the uterus) have to change their 
form into large flaccid tubes (154), and transform the normal musculoelastic 
structure of the arterial wall to amorphous fibrinoid material in which 
trophoblast cells are embedded (155). This physiological transformation of the 
spiral arteries requires trophoblast cell invasion and the activation of 
macrophages and maternal Natural Killer (NK) cells that secrete growth factors 
and produce apoptosis in the endothelial cells. They strip off the muscular wall 
of the spiral arteries and substitute the endothelial cells that line these vessels 
(154). The arteries are converted into dilated conduits to maximize the 
delivery of oxygen and nutrients from maternal blood to the intervillous space, 
to ensure optimal foetal development (156). During this process, maternal–
fetal interaction creates a state of mild systemic inflammation (157), in part 
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due to the HLA antigens such as HLA-G expressed by the trophoblast 
extravillous cells, that may influence maternal rejection of the fetus (158). 
Apart from the NK cells and the trophoblast cells, many molecules interact 
together to regulate trophoblast growth, migration and invasion to maintain 
a healthy utero-placenta equilibrium. These molecules include growth factors, 
inflammatory cytokines, growth factor binding proteins and leukocytes (159). 
For this reason, a complex network of soluble autocrine and paracrine factors, 
signalling pathways and regulatory transcription factors are needed to 
regulate it (160). 
 
Figure 5. Uterine arteries in three different times are represented. On the left, uterine 
arteries with spiral form in non-pregnant women. In the middle, unsuccesful 
remodelation during pregnancy leading to preeclampsia. On the right, remodelled 
uterine arteries in a normal pregnancy. Figure from article “NK Cells and Trophoblasts” 
Parham P (154).   
 
Briefly, placentation is a complex process and one of the most important 
determinants of pregnancy outcome. Trophoblast invasion, as the main 
process of placentation, is the key to avoiding pregnancy complications 
related with inadequate transformation of the spiral arteries that are 
important to ensure adequate fetal oxygen and nutrient supply. Extended 
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literature shows that successful placentation will prevent adverse pregnancy 
outcomes such as severe forms of intrauterine growth restriction and 
gestational hypertension (156). Both complications are explained below, as 
they are the main outcomes studied in this thesis. 
 
Pregnancy complications of placental origin: impaired placentation, 
intrauterine growth retardation and gestational hypertension 
 
Impaired placentation is a common complication in severe pregnancy 
outcomes, and in part is caused by  impaired physiological transformation of 
the spiral arteries in the placenta, leading to high resistance to blood flow in 
the uterine arteries (161). The Doppler ultrasound measurement of the 
intrauterine arteries is a physiological test to measure the blood flow in these 
arteries. This technique is used to assess the resistance of the blood flow 
between the mother and the fetus, determined by placental volume, the 
number of spiral arteries and their transformation (162). It was introduced in 
the 80’s by Campbell et al (163) and still used due to its efficiency as a non-
invasive measurement of fetal pathologies as well as feto-placental and utero-
placental circulation (164). Currently, Doppler sonography of the uterine 
arteries is an established screening method during the second trimester and 
has been advanced to the first trimester, in many clinical settings, as an early 
detection strategy of impaired uterine artery flow.  
In the first trimester of pregnancy, the waveforms of the uterine arteries 
present high resistance and a pronounced decrease of the blood flow velocity 
at the beginning of the diastole, known as a notch (165). In normal pregnancy,  
uterine artery pulsatility index decreases gradually as pregnancy progresses, 
the notch tends to disappear (166) and blood flow to the placenta increases. 
Pathological conditions are diagnosed as bilateral uterine artery notches 
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(confirmed by image) and/ or mean pulsatility index of the left and right 
uterine arteries above the 95th percentile (P95th >= 1.5250) (167).  
These conditions are the result of high resistance to blood flowing into the 
placenta such as occurs in the non-pregnant uterus, because blood vessels in 
the placenta are not enlarging or dilating as they should. Patients with bilateral 
notches in the Doppler wave from of the uterine arteries and high resistance 
index at 12 and 20 GW, have higher risk of developing adverse pregnancy 
outcomes but the condition can still normalise and the risk can decrease (168). 
However, when the abnormal Doppler waveforms persists into the third 
trimester of pregnancy, it shows a high risk of high impedance to flow and the 
resulting placental complications (161). Preeclampsia and intrauterine growth 
retardation are two of the main adverse outcomes reported in the literature 
to be associated with failed trophoblast invasion and spiral artery 
transformation (155, 159).  
 
The definitions of IUGR and small for gestational age (SGA) are similar in most 
of the literature, when the estimated fetal weight is <10th percentile of 
population curves for the given gestational week and sex (169). IUGR refers to 
a growth restriction in utero due to maternal, fetal or placental pathology and 
stems from placental insufficiency that causes failure to achieve growth in line 
with the genetically programmed trajectory (170). IUGR-affected pregnancies 
will result in a low birth weight baby with adverse perinatal outcomes (171). 
Using an ultrasound scan, biometric measurements can be calculated to 
estimate the fetal weight in the third trimester. Therefore, IUGR can be 
diagnosed during pregnancy, with antenatal measurements of head 
circumference, femur length, abdominal circumference, and bi-parietal 
diameter, taking into account the real gestational age (172). In case of low 
fetal weight (below the 10th percentile) the clinician will do the growth follow-
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up (173). In Spain, it is estimated to affect nearly 10% of pregnancies, and it is 
associated with 30% of all perinatal mortality and severe morbidity (170).   
IUGR occurs in up to 30% of pregnancies that are affected by preeclampsia, 
and being small at birth has also been associated with an increased risk for 
developing cardiovascular disease and hypertension in adulthood (174). 
Babies with IUGR can be classified into two categories: asymmetric IUGR when 
the babies tend to have normal heads sizes and small bodies, or symmetric 
IUGR when the whole baby is small (175). The first one is caused by maternal 
or placental risk factors, whereas the second one is due to fetal factors. 
Maternal risk factors are those affecting the fetus development like maternal 
history of previous IUGR, maternal age (<16 or >35 years old), maternal 
insufficient weight gain, maternal hypoxia, malnutrition or toxic substance 
abuse (176). Some of these factors are modifiable; consequently, maternal 
habits during pregnancy have an important impact. In addition, placental risk 
factors affect the placental capacity to provide oxygen and nutrients to the 
fetus required for its development. Abnormal placental vasculature, placental 
infection, placental abruption and dysfunction or molar pregnancy are some 
of the known factors (18). Normally, these factors cannot be changed during 
pregnancy. Finally, there are risk factors of foetal origin leading to symmetric 
IUGR, for example, multiple gestation, chromosomal abnormalities, genetic 
syndromes, congenital abnormalities or congenital heart defects, infections 
and metabolic disorders (177).  
Urgent induction of delivery may be the principal treatment for IUGR babies. 
Although the maintenance of the fetus as long as possible in the uterus is the 
current preference, due to the risk associated with premature births, in IUGR 
cases the risk posed for the fetus may be higher in utero. Due to their small 
size and potential prematurity, these babies have four times more risk of 
having severe fetal complications (178) including perinatal asphyxia during 
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delivery, hypothermia, metabolic and hematologic alterations, cerebral palsy 
and higher risk of cardio pathologies (179).  
 
Gestational hypertension described as the first appearance of systolic blood 
pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg after 20 
gestational weeks in women that had normal blood pressure up until 20 GW 
or  a difference in first trimester blood pressure and that after 17GW of 
>=30mmHg for systolic and/or >= 15mmHg for diastolic (180), is the first 
clinical sign of preeclampsia. Severe hypertension is considered for systolic 
blood pressure >=160 mmHg and/or diastolic blood pressure >=110 mmHg 
(96). Preeclampsia is a serious maternal disorder causing new onset 
hypertension and proteinuria (>300mg/24 hours) only during pregnancy, after 
20 GW, and in some cases lasts up to 6 weeks after delivery (182). This 
syndrome of placental origin is associated with significant maternal and 
neonatal morbidity (159). Risk factors that may increase the risk of developing 
preeclampsia include first pregnancy,  more than one foetus, poor trophoblast 
invasion, unsuccessful placentation and family history of preeclampsia (183). 
Other factors such as elevated maternal age (>35 years old), history of 
previous hypertension, diabetes and obesity, genetics, environmental factors 
or nutrition, especially low folate status and high homocysteine 
concentrations, may also predispose to development of the disease (96). The 
prevalence of this disease is relatively low in Spain, between 1-2%, compared 
with other developed countries where it is double (182).  
The exact causes are unclear, but the origin might come from abnormal 
placenta development. As explained before, in a normal pregnancy the spiral 
arteries dilate to 10 times their normal size. However, in preeclampsia the 
uterine arteries become fibrous and thus narrower, causing less blood flow to 
the placenta (184). In such conditions, pro-inflammatory proteins are released 
into the maternal circulation and predispose the endothelial cells to become 
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dysfunctional, causing vasoconstriction and more salt retention by the kidney 
(185), which can result in hypertension. Vasoconstriction may also affect other 
local areas leading to decreased blood flow in certain parts of the body. In the 
kidney, less blood flow causes oliguria and proteinuria. In the retina, it causes 
blurred vision, flashing lights and the development of scotoma. In the liver, 
poor blood flow may cause injury, swelling and elevation of liver enzymes 
(186). Endothelial injury increases vascular permeability, allowing the water 
to leak from the vessels between endothelial cells and to enter the tissues. 
Because there is also less protein in the blood, due to the proteinuria, even 
more fluid from the blood vessels enters the tissue and causes generalized 
edema in the legs, face and hands (186). If there is a pulmonary edema, other 
complications including cough and shortness of breath can appear. If the 
edema is in the brain, the symptoms may be headaches, confusion and 
seizures. We talk about eclampsia when the seizures appear (182). In addition, 
the poorly perfused placenta can also lead to intrauterine growth retardation 
and even placental abruption, haemorrhagic stroke and fetal death in severe 
cases (186). However, in some cases the symptomatology of preeclampsia can 
be mild. The delivery of the fetus and the placenta is the main treatment for 
preeclampsia. It will depend on gestational age of the fetus as well as the 
severity of disease (how it affects both, maternal and fetal health) (187). If the 
preeclampsia is mild, it is recommendable to finish the gestation on time and 
control regularly the mother to prevent severe complications. If it is severe,  
blood pressure should be controlled using medication to prevent a worst 
scenario like eclampsia and other serious signs, and control the fetal health to 
decide the optimal moment for delivery (182). 
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1.5. Paternal factors affecting placentation and pregnancy 
complications 
 
Pregnancy complications described earlier, such as impaired placentation, 
intrauterine growth retardation and gestational hypertension may influence 
short and long term maternal and fetal health. A variety of genetic and 
environmental factors interact to produce adverse pregnancy outcomes. 
Established maternal risk factors associated with pregnancy complications are 
age (>35 years), multiparity, gestational diabetes, obesity and others. These 
factors are usually studied in the context of the materno-fetal-placenta unit, 
without taking into account paternal factors (18). However, maternal risk 
factors alone may not explain many preeclampsia cases and other pregnancy 
complications. For example, poor trophoblast invasion and deficient 
placentation are important risk factors for these complications, and the causes 
in many cases are unknown or may not be explained by maternal factors (188). 
If we consider that the placenta comes from the trophoblast cells, of 
embryonic origin, we can assume that paternal and maternal factors interact 
in the placentation process. In fact, paternal genetic factors predict good 
trophoblast development, and has a potential bearing on the process of 
placentation failure (189), a key process in fetal development. For this reason, 
the physiopathological process that leads to pregnancy complications may 
involve the paternal-maternal-fetal unit (190). In addition, paternal 
transmission of diseases may result in the exposure of male germ cells to 
environmental factors such as under and over nutrition. In particular, 
environmental paternal exposures can affect the epigenome, including DNA 
methylation, and lead to heritable alterations in fetal gene expression (191). 
The epigenetics process, as a possible mechanism linking 1C metabolism to 
pregnancy complications is explained in detail in the next section.  
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Regarding the risk of developing preeclampsia during pregnancy, recent 
studies have proposed some paternal factors that may be involved. These 
include the length of the relationship with the same father, the compatibility 
of the mother to paternal antigens, primipaternity, etc. There is also a paternal 
phenomenon related with the development of preeclampsia, described as 
“the dangerous father”, commented before (22). In addition, paternal family 
history of preeclampsia may affect pregnancy complications, as shown in a 
study where fathers born from preeclampsia- affected pregnancies have an 
increased probability of fathering a pregnancy affected by this complication 
(16). It was also observed that the risk of developing preeclampsia in 
subsequent pregnancies was reduced when mothers with a previous history 
of preeclampsia, became pregnant by a different partner (192). 
There is also evidence for paternal involvement in other pregnancy 
complications such as IUGR. Some articles have shown a relationship between 
advanced paternal age (>45 years) and IUGR (178), suggesting paternal 
genetics as a possible mechanism inducing the complications because of the 
increasing number of mutations with age (191). However, there are 
controversial results due to the poor association between age and IUGR in 
other studies (193)(191). In the case of Hurley et al (2017), they found no 
association probably because of the small sample size compared to other 
studies that found a relationship between paternal age and IUGR, and due to 
the inaccuracy of paternal age or missing data recorded from the assisted 
reproductive technology pregnancies (194). Furthermore, paternal low birth 
weight, IUGR or SGA, have been reported to be potential factors enhancing 
the probability of fathering an IUGR baby (20, 193). Some studies have also 
investigated the effect of mixed paternal and maternal ethnicity on the risk of 
IUGR and report increased likelihood in these circumstances. Possible 
mechanisms proposed include maternal chronic stress associated with 
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everyday interpersonal and institutional racism (17) and differential prenatal 
and maternity care (196).  
There is a clear paternal implication in successful placentation that can 
prevent pregnancy complications and guarantee optimal health in both the 
mother and the baby. The main paternal factors studied, so far, can be 
classified as modifiable or non-modifiable. Modifiable paternal factors are 
related with lifestyle such as smoking, alcohol consumption, poor nutrition 
status, stress, socioeconomic status, and the non-modifiable ones are age, 
ethnicity and genetics, etc. 
 
Modifiable paternal factors affecting placentation and pregnancy 
complications  
 
Many modifiable factors, stemming from paternal habits and lifestyle, may 
influence the development of pregnancy complications. It’s well known that 
paternal, as well as maternal toxic habits including smoking (19), alcohol 
consumption or drug use (20), are related with impaired placentation leading 
to low birth weight or preterm babies. Other paternal behaviour factors  such 
as sedentary lifestyle, stress or depression, have been reported to increase the 
risk of developing preterm birth (197). Family socioeconomic status (198) or 
paternal educational level (199) have been also studied as possible risk factors 
of pregnancy complications, due to their close relationship with nutritional 
status. Nutritional deficiencies are an important detonator of pregnancy 
complications because of the increased nutrition requirements for fetal 
development. Evidence from animal studies suggests that paternal folate and 
1C metabolism status, before conception, are possible modifiable factors 
involved in adverse pregnancy outcome and long term offspring health (191). 
Maloney  et al (2011) in a study with rats fed with folic acid and methionine 
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deficient diet (methyl-deficient diet) during the periods of oocyte and embryo 
development, observed life-long changes in proteins involved in the processes 
of energy metabolism in the adult offspring (200). Cherif et al (2019) 
investigated also rats fed with a methyl donor deficiency diet during gestation 
and lactation and reported an association between this diet and the 
development and function of energy balance circuits, affecting the expression 
of neuropeptides and related receptors in the hypothalamus, resulting in 
growth and weight deficits (201).  
In human studies, paternal deficiencies or excess of macronutrient during pre 
and post conception periods have also been proposed as potential factors 
affecting pregnancy related complications (202). In a Chinese population, 
Chen et al (2017) reported that a high quality protein paternal diet, with eggs 
and meat, was associated with lower incidence of preterm SGA (21). In a case 
control study with men from infertile couples, Eslamian G et al (2012) showed 
that those fed with a western-type diet with processed meat, sweets, refined 
grains and snacks were associated with reduced sperm motility (203).  
The importance of the paternal 1C metabolic network and nutrition on 
successful placentation and optimum fetal development have recently come 
to light. As men contribute to half of the embryo’s genetic material, paternal 
1C metabolism is also important for pregnancy opportunities and outcomes 
(204). This network has an important role in biological processes such as 
cellular division, synthesis and DNA repair and is an important source of 
methyl groups for epigenetic programming of the paternal seminal fluid and 
subsequently the embryonic genome. Some nutrients such as folate, 
cobalamin and methionine are involved in this network acting as substrates or 
cofactors for the enzymes that participate in the cycle. The deficiency of one 
or more of these nutrients can alter the general network working, therefore, 
paternal folate status is crucial for optimal paternal 1C metabolism (109). 
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Some studies have investigated the relationship between impaired paternal 
1C metabolism and complications related with pregnancy. Studies in humans 
have largely focused on the influence of paternal folate status on semen 
parameters and they have confirmed that plasma and seminal optimal folate 
concentrations positively affect semen quality (205). Boonyarangkul et al 
(2015) showed that after 3-months of treatment with 5 mg of folic acid per 
day the percentage of motile semen increased from 11.4% to 20.4% (206). 
Other studies focused on homocysteine semen concentrations have reported 
higher homocysteine concentrations in infertile men’s sperm compared with 
fertile men. They also reported poor embryo quality in the group of high 
homocysteine sperm concentrations (207). In a study of 280 couples, 
Govindaiah et al reported 7 times more risk of spontaneous abortion in those 
couples with paternal hyperhomocysteinemia (values higher than P.95th, 
≥19.6 μmol/L, measured after the pregnancy) compared to those with normal 
tHcy (110). In a study of mice, epigenetic alterations in DNA methylation in 
two types of folic acid diets were reported. One was a folic acid deficient diet 
and the other one highly supplemented, and both affected sperm DNA 
methylation, sperm counts and the offspring’s abnormal development and 
death (191). Similarly, Lambrot et al (2013) reported that low paternal folate 
status may alter the sperm epigenome and result in adverse pregnancy 
outcomes in mice (208). In addition, in a human study, it has been published 
recently that both low and high long term paternal folate status, assessed by 
RBC folate levels from a blood sample taken between 7 and 9 GW, are 
associated with reduced embryonic growth (109).  
Adverse pregnancy outcomes originating from nutritional deficiencies, such as 
folate deficiency, are interrelated with both, maternal and paternal deficiency. 
Ratan et al (2008) reported lower folate levels in fathers of children born with 
NTDs, compared to controls (209). One possible explanation is that folate 
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status during spermatogenesis influences the paternal epigenome of the 
embryo, with further consequences for the embryonic development (109). 
Another one may be that the final consequences originate from deficient 
intracellular folate concentration in germ cells (71). Current strategies for 
primary prevention proposed to prevent pregnancy complications and 
malformations such as NTDs are aimed at the mother, following the prenatal 
care protocol in Catalonia (180) and European countries. Maternal nutritional 
interventions with folic acid supplementation is the main strategy used. No 
strategies focused on the father are implemented yet, but there is more 
interest in paternal involvement in pregnancy complications. This problem is 
overcome in countries with mandatory folic acid food fortification, but in 
countries where the fortification is absent and only some food is 
supplemented, such as Spain, people have to be aware of the benefits of 
taking folic acid.  
Moreover, 1C network regulation also depends on nutrient-gene interactions. 
MTHFR 677C>T and SLC19A1 are two important polymorphism determinants 
for folate and homocysteine status, because of their roles in folate metabolism 
and entrance into the cell (8). Therefore, we should consider non-modifiable 
paternal factors such as genetics, due to their important role in guaranteeing 
an optimal nutritional status and in preventing pregnancy complications.  
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Non-modifiable paternal factors affecting placentation and 
pregnancy complications  
 
As previously stated, paternal genetics, age and ethnicity are some of the non-
modifiable factors that have been related with adverse pregnancy outcomes 
such as SGA, preterm birth, IUGR and preeclampsia. In the context of this 
thesis, we are very interested in the genetic factors that may provide links 
between paternal and pregnancy health. Since foetal genes are derived from 
each of a maternal and a paternal copy, the non-imprinted expression in the 
placenta and in the fetus can be affected by the paternal genotype (18). In the 
literature, some articles have proposed genetic factors as a possible 
precipitating cause of inadequate trophoblast invasion, which in turn affects 
pregnancy health (160). Imprinted genes, for example, are important for 
embryo growth and development, with evidence generally showing that 
paternally expressed genes promote fetal growth, while maternally expressed 
genes suppress it (210). 
 
Genetic factors are closely related with nutritional status due to gene-nutrient 
interactions. Some polymorphisms are affected by nutrients and may modify 
the activity of the enzyme, protein or biological molecule they are affecting. 
In our group, we are interested in studying 1C metabolism, the vitamins 
involved in the cycle and the genes involved in the regulation and optimum 
functioning of the pathway. We focus our investigation on two polymorphisms 
affecting folate metabolism (MTHFR 677C>T) and transport (SLC19A1 80G>A). 
Data from a case-control observational study, show that the homozygote 
mutant genotype (TT) of the paternal MTHFR 677C>T polymorphism was 
linked with 2.4 times increased risk of miscarriage, compared with the control 
group (110). However, another study with 151 cases and 157 controls studied 
two months after the last pregnancy did not obtain comparable data (211).   
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On the other hand, the reduced folate carrierencoded by the SLC19A1 gene, 
is the main entrance of folate to the cell and it is strongly associated with the 
final folate status. Fetal folate availability is dependent on maternal folate 
levels and placental folate transport capacity. To date, several studies 
demonstrated that maternal SLC19A1 80AA polymorphism, affecting the RFC 
transport activity, was associated with pregnancy complications such as NTDs 
and fetal malformations,  due to elevated folate requirements during 
pregnancy (211, 212). In addition, this risk was influenced by a gene–
environment interaction between the SLC19A1 80AA genotype and maternal 
periconceptional use of folic acid reducing the occurrence of NTDs (214). In 
2015, Pei L et al observed a significant interaction between maternal GG/GA 
genotype and the risk of developing an NTDs in the offspring (215). The 
SLC19A1 80AA  polymorphism has also been related with an elevated risk of 
other adverse pregnancy outcomes including recurrent pregnancy loss (216), 
IUGR (217) and preeclampsia (218). Protein expression of the RFC was 
decreased in placentas from pregnancies with IUGR and preeclampsia 
compared with placentas of uncomplicated pregnancies (216, 217). However, 
we did not find any evidence in the literature focusing on paternal RFC 
expression or activity and pregnancy complications.  
 
With the current evidences, the hypothesis that paternal factors may 
contribute to pregnancy complications of placental origin seems to be clear. 
However, there is limited and sometimes conflicting evidence in the literature. 
We still have a limited understanding of the influence of paternal factors on 
human offspring. The most frequently proposed biological mechanisms in the 
literature, to explain the role of the father are based on the immunological 
tolerance of the mother and the paternal genes. The invasion of trophoblasts 
into the decidua and myometrium appears to be primarily controlled by 
immune mechanisms, for this reason the mother has to tolerate the paternal 
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antigens to avoid unsuccessful placenta development due to poor vascular 
adaptation. Paternal genes inducing angiogenesis of the placenta, trophoblast 
apoptosis, oxidative stress, etc may increase the predisposition of the mother 
to suffer pregnancy complications. In addition, paternal epigenetic changes 
may also affect genetic expression involved in vascular dysfunction, 
inflammation and other causes of pregnancy diseases (22). Further research is 
needed to validate this hypothesis and establish the paternal biological 
mechanisms involved in the development of pregnancy complications. This 
way, it will be possible, if necessary, to establish primary prevention strategies 
against pregnancy complications focusing on the father. In the present thesis 
project, we want to study this topic focusing our hypothesis and investigation 
on the possible role of paternal one carbon metabolism, considering paternal 
genetics and folate status, in the development of some adverse pregnancy 
outcomes described before.  
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1.6. Epigenetics, a potential link between 1CM and outcomes 
 
A potential mechanism proposed to explain the association between one 
carbon metabolism and the outcomes studied are epigenetic changes, which 
can regulate gene expression. Some nutrients can modulate gene expression 
induced by epigenetic modifications. Epigenetic factors are DNA modifications 
that can affect gene expression without altering the sequence (219). Some of 
them, including DNA methylation, histone acetylation, as well as micro RNA 
modifications can modify chromatin structure making it accessible or not for 
transcription mechanisms. Chromatin is the genetic material packed into 
eukaryotic cells, composed by the association of DNA with histones and other 
proteins. Depending on the chromatin structure, euchromatin as the active 
form or heterochromatin as inactive, the gene will be expressed or not (220).  
DNA can be only modified by methylation, but histones can suffer changes by 
acetylation, methylation, phosphorylation and others.  
The 1C network is an important methyl group donor system that can 
contribute to epigenetic modifications of DNA and histones, especially by 
methylation (220). Methylation is the covalent addition of a methyl group at a 
nitrogenous base, mediated by the enzyme methyl transferase. In the CpG 
islands, in the zone of the eukaryotic genome with regulatory and promoter 
parts of the genes, the cytosine of the dinucleotide CpG is methylated. S-
Adenosyl methionine, synthetized in our body by methionine coming from 
diet, is the methyl group donor. Methylation of DNA sequence at the CpG 
islands is linked to downstream gene silencing by recruiting histone 
deacetylases that contribute to chromatin condensation restricting the access 
of regulatory transcription factors (219). It is a heritable mechanism to 
inactivate genes in a stable way, therefore, an important process to control 
gene expression. On the other hand, histone modifications are post-
translational affecting the N-terminal part of some histones in the 
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nucleosome. These modifications affect the condensed status of chromatin 
(221). Apart from methylation, histones can be acetylated by the acetyl 
transferase in lysine residues. When histones are acetylated, chromatin has a 
non-condensed status and transcription can be activated. They can also be 
deacetylated, catalyzed by histone deacetylase. The elimination of acetyl 
groups blocks the union between transcriptional factors and DNA (219). Both, 
histone deacetylation and DNA methylation decrease gene expression by 
increasing chromatin condensation and lowering the accessibility of 
transcriptional factors to DNA.  
Vitamins and amino acids acting in one carbon metabolism can be responsible 
for the epigenetic changes explained. As commented before, methionine is 
the precursor of the methyl group donor, and is an essential amino acid 
obtained exclusively from the diet because it cannot be synthetized in our 
body (222). Meat, fish, eggs, dairy products and other foods rich in proteins 
are good sources of methionine (223). In addition, the transfer of the methyl 
group from the donor to cytosine also requires the participation of folates and 
cobalamin (222). Niacin (vitamin B3) is also needed for DNA methylation. This 
vitamin is involved in the synthesis of some factors that participate in the 
inhibition of enzymes that regulates DNA methylation. Niacin is also needed 
for NAD+ synthesis, required for DNA reparation (224). Vitamin B3 is found in 
eggs, fish, legumes, lactic products, enriched bread, and cereals (225). We can 
suppose that diets poor in this nutrient, or deficiencies, causing an imbalance 
in one carbon metabolism can reduce DNA methylation and modify gene 
expression. Such alterations can induce health problems, and if they occur 
during prenatal or pregnancy periods they can lead to pregnancy 
complications such as impaired implantation, intrauterine growth retardation 
or gestational hypertension (221). 
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There is evidence in the literature linking epigenetic changes with adverse 
pregnancy outcomes. Related with preeclampsia, epigenetic changes play a 
crucial role in the development and the progression of the disease, particularly 
by methylation process. In a review, Kamrani et al (2019) reported evidence 
of the methylation pattern changes in pregnancies affected by preeclampsia 
compared to healthy pregnancies. In preeclamptic placentas, changed global 
DNA methylation models are related to maternal blood pressure. They review 
DNA methylation of some genes in relation to preeclampsia. For example, the 
TET2 enzyme involved in the regulation of trophoblast cell invasion through 
regulating MMP-9 promoter demethylation is hypermethylated in 
preeclamptic patients. Furthermore, the hypermethylation of the IGF-1 
promoter by DNMT-1 reduces IGF-1 in the hypoxic trophoblast and causes 
preeclampsia (221). Herzog et al (2017) performed a case-control study to 
compare the epigenetic patterns of placental and fetal tissues between 
preeclamptic pregnancies and three control groups (uncomplicated 
pregnancies, normotensive fetal growth restricted and normotensive preterm 
birth pregnancies). They have demonstrated significant differences in 
genome-wide white blood cells and placental DNA methylation between the 
group with preeclampsia and the control preterm birth group, but no 
differences were found with the other control groups. The differences in the 
hypermethylated genes between groups were those closely associated with 
cardiovascular and metabolic developmental pathways (226).  
Regarding IUGR, placental epigenetic dysregulation has been proposed as a 
cause. In a study with monozygotic twins, with the same genotype at 
conception and a shared maternal environment, Roifman et al (2016) studied 
the differences in genome-wide placental DNA methylation patterns between 
severely growth-discordant twins and normal twins to identify novel 
candidate genes. They observed differentially methylated regions in the 
promoters of eight genes related with fatty acid beta-oxidation and 
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transcriptional regulation in the IUGR compared to the control group, 
suggesting that IUGR in monozygotic twins is associated with impaired lipid 
metabolism and transcriptional regulation (227). Other studies also indicate 
epigenetic dysregulation associated with IUGR. Einstein et al (2010) collected 
samples from women who delivered IUGR or infants with appropriate growth 
to detect global patterns of epigenetic changes. They found that changes in 
cytosine methylation occur in response to IUGR of moderate degree and 
involving a restricted number of loci. They also identify specific loci that are 
targeted for dysregulation of DNA methylation, in particular the hepatocyte 
nuclear factor 4a (HNF4A) gene, a well-known diabetes candidate gene and 
other loci encoding HNF4A-interacting proteins (228). 
 
In addition, paternal nutritional imbalance in 1C metabolism can also alter 
genotype expression and induce abnormal phenotypes, following the 
fundamental epigenetic gene-nutrients link commented before (71). The 
father can transmit epigenetic modifications to the oocyte, modulating gene 
expression during fetal development and consequently, affecting postnatal 
and adult health. The epigenetic process can be considered as a 
reprogramming of the DNA methylation patterns in the zygote, and signifies 
an environmental regulation of the expression pattern of some genes that 
persist throughout life (229). Paternal folate status is also involved in the 
epigenetic programming of the seminal and subsequent embryonic genome. 
Steegers-Theunissen et al (2013) reviewed evidence indicating that paternal 
nutrition and other lifestyle factors during the periconception period can 
affect reproductive performance via 1C metabolism pathways (204). 
Restricted dietary provisions of 1C substrates and cofactors around the time 
of conception could lead to genome-wide epigenetic modifications to DNA 
methylation in offspring (204). In a human study with idiopathic infertility in 
men, Arabi et al (2015) revealed that 6 months treatment with high-dose 
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(5mg) folic acid supplements significantly changed the overall seminal DNA 
methylation pattern (230). Interestingly, the most marked loss of DNA 
methylation was found in sperm form patients with the homozygous variant 
genotype of the MTHFR C677T polymorphism. A study in mice also showed 
changes in the seminal epigenome when paternal dietary folate intake was 
low. Lambrot et al (2013) fed male mice either a folate deficient or folate 
sufficient diet throughout life. They found differential methylation in sperm of 
genes implicated in the development of chronic diseases such as cancer, 
diabetes, autism and schizophrenia (208). This study indicates that paternal 
dietary folate is essential for offspring health, because there are environment 
sensitive regions in the sperm epigenome that respond to diet and transfer an 
epigenomic map that influences development. Similarly, Lundi Ly et al (2017) 
designed a mouse study to expose male germ cells to low, high and very high 
folate levels throughout male germ cell development. Female mice were fed, 
before and throughout pregnancy, diets with four different folic acid doses 
(0.3 mg/kg, 2 mg/kg, 20 mg/kg and 40 mg/kg) and F1 males were weaned to 
their respective prenatal diets to allow for diet exposure during all windows 
of germline epigenetic reprogramming. DNA methylation at a global level and 
at the differentially methylated regions of imprinted genes in F1 sperm and 
placenta was assessed. The results indicate that both folic acid deficiency and 
high dose supplementation can be detrimental to germ cell development and 
reproductive fitness, in part by altering DNA methylation in sperm (191).  
All this data provides further support for paternally transmitted 
environmental effects, by epigenetic changes and reprogramming in germ 
cells, associated with pregnancy complications and offspring abnormalities.  
Emerging evidence indicates that derangements in 1C metabolism can lead to 
epigenetic modifications to DNA methylation implicated in long-term 
programming of offspring health. This provides a mechanistic explanation for 
at least some of the associations between reproductive failure, age-related 
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diseases and modifications induced by nutritional factors and lifestyle (204). 
This information opens new avenues of understanding the potential 
mechanisms underlying inter-generational disease transmission and 
preventing developmental defects via paternal routes. 
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2. Hypothesis and Aims 
 
2.1 Hypothesis 
 
  Alterations in maternal or paternal 1C metabolism, caused by MTHFR 
677C>T and SLC19A1 80G>A polymorphisms and/ or deficiencies or 
imbalances in folate or cobalamin status, may be associated with the 
development of pregnancy complications stemming from inadequate 
placental perfusion such as IUGR and gestational hypertension. 
   
2.2 Aims 
 
Main aim 
 
To investigate the association between genetic, nutritional and metabolic 
components of the maternal and paternal 1C metabolic network and the 
probability of impaired placentation, intrauterine growth retardation and 
gestational hypertension. 
Specific aims 
 
- To compare the likelihood of impaired placentation, intrauterine 
growth retardation or gestational hypertension between the maternal 
or paternal MTHFR 677C>T (TT versus CC, CT versus CC) and SLC19A1 
80 G>A (AA versus GG, AG versus GG) genotypes. 
 
- To investigate the association between elevated early pregnancy 
maternal tHcy, elevated paternal tHcy and the probability of impaired 
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placentation diagnosed by pathological Doppler of uterine arteries at 
20 gestational weeks, intrauterine growth retardation or gestational 
hypertension.  
 
- To explore whether the associations between the genotypes and the 
three pathologies is modulated by the status in the 1C metabolism 
nutrients. 
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3. Material and methods 
 
3.1. Design and study population 
 
This thesis is based on The Reus-Tarragona Birth Cohort (RTBC) study. The 
RTBC is an ongoing population based longitudinal cohort study from early 
pregnancy until mid-childhood carried out by the Area of Preventive Medicine 
and Public Health from the “Universitat Rovira i Virgili” in collaboration with 
the Obstetrics and Gynaecology Units of the University Hospitals Sant Joan 
Reus and Joan XXIII Tarragona. The fathers of these pregnancies are also 
invited to participate in the study and investigating their contribution to 
pregnancy outcome is the main objective of this thesis. The study was 
designed to identify early pregnancy nutrition and parental genetic factors 
influencing fetal growth and pregnancy outcomes of placental origin, as well 
as growth, development and mental performance in their offspring at 7.5 
years. The project for this thesis is based on the pregnancy phase and the 
influence of both maternal and paternal 1C metabolism in the establishment 
and functioning of the materno-feto-placental unit.  
The study was carried out according to the Declaration of Helsinki and was 
approved by the Ethical Committees from each of the two participating 
University Hospitals (Sant Joan, Reus and Joan XXIII, Tarragona). Signed 
informed consent was obtained from all study participants. 
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3.2. Mother and baby  
 
Pregnant women attending their first check-up, before 12 GW, with a 
confirmed viable fetus and singleton pregnancy were eligible to participate 
and were recruited by the Areas of Obstetrics and Gynecology from the two 
University Hospitals. Exclusion criteria were multiple pregnancy, chronic 
illness or surgical interventions affecting nutritional status or use of any 
medication that affects folate or vitamin B12 metabolism. 
Following the Spanish Obstetrics and Gynaecology Society guidelines (181) 
pregnant women with low obstetrical risk were recommended to take daily 
supplements containing 400µg of folic acid until the end of the first trimester. 
The recommended prenatal supplement also contained 2µg of 
cyanocobalamin. Women with a history of a previous pregnancy affected by 
NTDs, other congenital defects or complications or with a first-degree relative 
with NTDs were recommended to take 4-5 mg of folic acid per day until the 
end of the first trimester. As a preventive measure against anaemia, low dose 
iron supplements (40 mg/d) were recommended from 12 GW throughout the 
second and third trimesters of pregnancy to all participants. Women that were 
already anaemic were treated with iron supplements containing 80 or 120 
mg/d according to the treatment regime determined by the obstetricians. 
Participant recruitment started in January 2005 and 2006 in the Sant Joan, 
Reus and Joan XXIII, Tarragona University Hospitals respectively. All 
pregnancies completed before March 2020 were included in the thesis. This 
represented 856 pregnancies. Of these, 672 fathers were eligible to invite.  
Fasting blood samples were taken from mothers at <12, 24-27, and 34 GW, 
and non-fasting blood samples on admission to hospital with confirmed labour 
and from the umbilical cord vein. Blood samples were programmed to be 
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collected  at the same time of those routinely collected during prenatal 
monitoring of pregnancy according to the regional health authorities protocol 
(181). 
 
Medical and obstetrical history and lifestyle data collection 
 
Maternal age and BMI were recorded at the first antenatal check-up. Detailed 
information regarding supplement use and lifestyle data before and during 
pregnancy were collected by questionnaire at 20 and 32 GW (coinciding with 
programmed ultrasound scans) and covers the six months preconception and 
each trimester of pregnancy. 
The questionnaires specifically targeted folic acid, cobalamin and iron use and 
were designed to obtain detailed information regarding supplement brand, 
composition, timing of initiation, frequency and duration of use. Other 
multivitamin/ mineral supplement use was also recorded with the same detail. 
We used this information to estimate the daily intake of folic acid, cobalamin 
and iron from supplements during the first trimester and between the 4th and 
7th months of pregnancy. 
Smoking habit during the 5 years prior to pregnancy and throughout the 
pregnancy itself was assessed by interviews at 20 and 32 GW (number of 
cigarettes/d), medical history and plasma cotinine concentrations (>10 ng/mL 
confirmed active smokers) from blood samples at <12, 24-27 GW and from 
cord blood. Similarly, alcohol consumption (duration, drinks/w, timing of 
cessation before or during pregnancy) and illegal drug use in the previous 5 
years (type and frequency of use in the 12 months prior to conception and at 
the time of the interview) was also recorded.  
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Information on participant’s education, occupation and salary were recoded 
to classify them according to socioeconomic status in three different 
categories (low, mid and high) based on guidelines for the socioeconomic 
measurement (231).  
Information on parity, previous adverse obstetrical outcomes, gestational age 
at labour and offspring’s sex and birthweight were obtained from the 
obstetrical records. Gestational hypertension was also registered and was 
defined as systolic blood pressure >140 mmHg and/or a diastolic blood 
pressure >90 mmHg occurring for the first time after the 20th GW in at least in 
two check-ups (6 hours apart) (181).  
Preeclampsia was defined as high blood pressure and proteinuria (>300mg/24 
hours) occurring after 20 GW (182).  
Gestational diabetes was diagnosed according to a two-step approach 
stipulated in the pregnancy monitoring protocol established in both Hospitals 
(181). The first screening was performed with a 50 g oral glucose challenge 
test (GCT) at 24-27 GW in low risk pregnancies. If positive (glucose 
concentration >7.8 mmol/L), a 100 g Oral Glucose Tolerance Test was 
performed (232). Blood samples for glucose determination were taken at 
baseline (fasting) and at 1, 2 and 3 hours after glucose administration. 
Gestational diabetes was diagnosed if at least two glucose determinations 
were above 5.8, 10.6, 9.2 or 8.1 mmol/L at the respective sample collections. 
In pregnancies with previous gestational diabetes, a glucose challenge test 
was performed at the first obstetrical visit and, if negative, at 24-27 GW and 
again at 30 GW. In the case of a positive glucose challenge test, the same 
protocol described before used for the diagnosis in low risk pregnancies was 
then applied in those patients.  
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Preterm birth was defined according to WHO criteria (birth at less than 37 GW) 
(233). Intrauterine growth restriction was defined as birth weight below the 
10th percentile according to sex and gestational age standardized  birth weight 
curves from the Spanish Obstetrics and Gynaecology Society (234).  
Placentation was assessed using Doppler evaluation of the intrauterine artery 
waveforms and pulsatility index. Pathological Doppler was defined as a mean 
of pulsatility index of right and left uterine arteries ≥P95 and/or the presence 
of a bilateral notch in the waveforms (167). The notch is the result of elevated 
resistance to blood flowing into the placenta (as occurs in the non-pregnant 
uterus).  
 
Blood sample collection   
 
Fasting blood samples were collected at <12, 24-27 and 34 GW and non-
fasting at labour into ethylenediaminetetraacetic acid (EDTA)-K2 treated 
vacutainers (10 ml), a dry vacutainer for serum (10 ml) and small (EDTA)-K2 
treated vacutainers (5 ml). In the case of cord samples, blood was collected 
from the umbilical vein into 2 X 10 ml EDTA vacutainers and 2 X 10 ml dry 
vacutainers before the placenta was expulsed.  
All samples were processed at the “Institut d’Investigació Sanitària Pere Virgili 
Biobank”, in the laboratories of “Facultat de Medicina de l’Universitat Rovira i 
Virgili”, and in the Joan XXIII University Hospital research laboratory and the 
central hospital laboratories of both hospitals (cord and labour samples) 
according to a strict standardized protocol. This ensured that samples were 
kept at 4ºC until processed within less than an hour of collection to separate 
whole blood, plasma, serum, washed red cells and leukocyte fractions for 
storage in the biobank at -80º C. Times of sample collection and separation of 
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plasma were recorded as a quality control measure to ensure that this 
protocol was complied with. 
Whole blood from EDTA tubes was prepared for posterior red blood cell folate 
analysis by diluting it 1:10 with 1% freshly prepared ascorbic acid solution. The 
mixture was kept at room temperature for 30 minutes in order to allow the 
ascorbic acid erythrocyte lysates to release the serum conjugase, which 
converts the folate polyglutamates to assayable monoglutamate forms. Two 
aliquots of 250 µl were prepared and stored at -80º C. 
Plasma was separated from the EDTA vacutainer at 1800 g for 15 minutes at 
4ºC and stored in aliquots of 1 ml at -80º C. Serum was separated after 
coagulation of blood at room temperature (approximately 30 minutes after its 
collection) and aliquoted and stored at -80º C. 
In order to isolate leukocytes, phosphate buffered solution was added to the 
remaining buffy coat and erythrocytes in the EDTA tube and was thoroughly 
mixed by inversion. The mixture was transferred to a Falcon tube containing 
30 ml of hemolysis solution. It was mixed by inversion and then kept at room 
temperature for 20 minutes to lyse the remaining erythrocytes. The Falcon 
tube was centrifuged for 5 minutes at 2200 g at room temperature and the 
supernatant discarded. The pellet was re-suspended in 20 ml of hemolysis 
solution. The tube was centrifuged as described above and as a result, the 
leukocytes were isolated from the other cell types. The supernatant was 
discarded again and 450 µl of PBS and 10 ml of Cell Lysis Solution (Qiagen 
GmbH, Hilden, Germany) were added to the leukocyte aliquot and preserved 
at -80º C. This tube was kept at room temperature and protected from light 
for at least 1 month and a maximum of 6 months. 
Leukocyte DNA was extracted and quantified in preparation for maternal and 
cord genetic polymorphism determinations. Auto pure Protein Precipitation 
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Solution (3.33 mL) was added and mixed with vortex to obtain a homogenous 
mix before incubation in iced water for 15 minutes. The mixture was 
centrifuged at 2200 g at 4º C for 12 minutes. The supernatant containing the 
suspended DNA was removed and added to a 50 ml Falcon tube with 10 ml of 
cold 100% isopropanol. The tube was gently mixed by inversion until the 
precipitated DNA was visible. After centrifuging at 2200 g at 4º C for 5 minutes, 
the supernatant was discarded (pellet contained the DNA). The tube was dried 
for 30-40 minutes on absorbent paper, and 1200 µl of DNA Hydration Solution 
were added to the Falcon tube, mixed and further incubated at room 
temperature for 3-4 days in a mixer incubator. DNA quantification was 
performed using a spectrophotometer Nanodrop 1000 at 260 nm wavelength 
using 2µl of hydrated DNA.  
 
Biochemical and genetic determinations 
 
Plasma aliquots of 0.5 ml from each pregnancy sample and the cord and 120 
ng of lyophilized DNA from mother and cord were shipped on dry ice to BeVital 
A/S (Bergen, Norway) and analyzed, ensuring that all samples from the same 
pregnancy were analyzed in the same batch, within <18 months after sample 
collection.  
Red blood cell and plasma folate 
Folate concentrations in plasma and whole blood were determined by an 
automated gold standard microbiological assay using a microtiter plate and a 
chloramphenicol-resistant strain of Lactobacillus casei (235).  Performances 
for inter- and intra-assay coefficient of variation were 4 and 5% respectively 
and the lower detection limit was 2nmol/L. 
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RBC folate values were calculated using the following formula (236):  
Whole blood folate – [Plasma folate*(1-hematocrit/100)] / (Haematocrit/100) 
Whole blood folate was corrected for dilution prior to this.  
Plasma cobalamin 
Total cobalamin concentrations were determined by an automated 
microbiological assay using a microtiter plate and a colistin sulphate-resistant 
strain of Lactobacillus leichmannii (237). The lower detection limit was 30 
pmol/L, and inter- and intra-assay coefficients of variation 4 and 5% 
respectively. 
Plasma total homocysteine and cotinine 
Plasma total homocysteine, methylmalonic acid and cotinine were 
determined by liquid chromatography–tandem mass spectrometry (238). 
Cotinine, an oxidized metabolite of nicotine, is a marker of recent tobacco 
exposure. Participants with plasma cotinine concentration >10 ng/mL were 
considered smokers, and ≤10 ng/mL non-smokers. The lower limits of 
detection were 0.1 and 0.03µmol/L and 1nmol/L, inter-assay coefficient of 
variation 2, 3-8 and 6% and intra-assay coefficient 1-2, 1-4 and 2-3% 
respectively for total homocysteine, methylmalonic acid and cotinine 
determinations.  
Plasma creatinine 
Creatinine concentrations were determined by Jaffé reaction (Química Clínica 
Aplicada, SA, Amposta, Spain) and were used as an estimation of renal 
function (239). Inter- and intra-assay coefficients of variation were 2.1 and 
1.7% respectively.  
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Genetic polymorphisms 
DNA isolated from both mother and cord blood leukocytes were used to 
determine genetic polymorphisms affecting folate metabolism and cobalamin 
metabolism and transport. Matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry was used to analyze the 
methylenetretrahydrofolate reductase 677C>T, and the solute carrier family 
19 member 1 80G>A genotypes, by Bevital (Norway).  
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3.3. Recruitment and follow-up of fathers 
 
Eligible fathers were invited to participate in the study. In the first instance, 
we informed the mothers of our interest in investigating the association of 
paternal genetic and metabolic factors with pregnancy outcome. We asked 
them if they agreed to provide us the contact details for the father. When the 
mothers agreed, the fathers were contacted by phone, following a 
recruitment protocol. The aims of the study, their contribution and what 
participation would entail was explained to them and they were asked 
whether they were interested in participating. The time of contact with the 
father and the time of participation depended on when we spoke to the 
mother (preferably coinciding with a prenatal visit where possible), how long 
it took to secure contact with the father and when it suited the father to give 
a fasting blood sample.  
Those that accepted, came to the “Hospital Universitari Sant Joan de Reus” to 
provide informed signed consent, a fasting blood sample and complete a 
lifestyle questionnaire.  
Ideally, we invited them to participate as near as possible to conception. To 
evaluate the association of biochemical results at that moment with possible 
paternal origin complications during placentation, it would be better for the 
study to have the fasting blood sample just before the conception. To reduce 
the effect of this limitation, we asked all fathers if they had changed their 
nutritional habits or lifestyle from the six months before pregnancy until the 
moment of participation. On the other hand, the results of the genetic analysis 
will have been unaffected with lifestyle changes, if any, over a relatively short 
period of time. 
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Medical history and lifestyle data collection 
 
On the day of their blood sample, a member of our team administered a 
questionnaire (exemplar in appendices) to fathers regarding basic elements of 
their medical history as well as supplement use, lifestyle and toxic habits. The 
questionnaire was specifically designed to cover the time around pre-
conception and conception. Any change six months before pregnancy and 
during pregnancy in paternal diet, supplement use, or habits was recorded to 
take into account if considered to have a relevant effect on nutritional status.  
Concrete vitamin or mineral supplementation use, timing of initiation, 
duration, doses, and brand was recorded. We used this information to 
estimate the real intake of folic acid or other vitamins and minerals apart from 
diet. As with the mothers, smoking habit data covered the 5 years before 
pregnancy and during pregnancy, was assessed by questionnaire (number of 
cigarettes/d), and whether the habit was maintained, reduced or given up 
during pregnancy. Plasma cotinine concentrations (>10 ng/mL confirmed 
active smokers) from blood was checked to corroborate their answers. 
Similarly, alcohol consumption (duration, drinks /w, timing of cessation before 
or during pregnancy) and illegal drug use in the previous 5 years (type and 
frequency of use in the 12 months prior to conception and at the time of the 
interview) was recorded.  
 
Paternal age and BMI were calculated from the information collected during 
the visit (birth data, weight and height). BMI calculated as Kg/m², was 
classified as normal weight, overweight or obesity. 
Medical history and blood group was obtained by the self-reported 
information.  
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Before carrying out the analysis to study the objectives proposed for this 
thesis, parental verification was performed to prevent introducing errors into 
the analysis. A battery of 19 polymorphisms was used. If the cord genotype 
did not match with parental genotypes for more than three polymorphisms, 
the mismatched mother-cord or father-cord sets would have been excluded 
from the analysis.  
 
Blood sample collection 
 
The blood sample was programmed as near as possible to conception 
(determined by ability to contact the father and compatibility of his work 
schedule). Protocol for collection and processing of samples for biochemical 
and genetic determinations were the same as for the pregnancy phase and 
the same laboratories were used.  
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3.4. Statistical analysis 
 
All statistical analysis were performed using SPSS (SPSS Inc, Chicago, IL, USA) 
for Windows, version 25.0.   
The normality of continuous variables was checked with the Kolmogorov-
Smirnov test. Variables not normally distributed were natural log transformed 
when necessary, to meet the necessary criteria for the application of 
parametric statistical tests. Descriptive characteristics comprising geometric 
means (95% CI) or median (P10-P90) and relative frequencies (95% CI), where 
applicable, are reported for all the participants. Genotype and allele 
frequencies (95% CI) of the studied genetic variants are also reported. 
Confidence intervals of categorical variables expressed in % are calculated 
using the “CIA” programme (Southampton, UK). The McNemar test was used 
to compare the prevalence of plasma and red blood cell folate deficiency 
between different time points of pregnancy (<12, 15, 24-27, 34 GW, labour). 
Post-hoc Bonferroni correction for multiple comparisons of the P values was 
applied. ANOVA for repeated measures was performed to compare means 
between different pregnancy time points (<12, 15, 24-27, 34 GW, labour) and 
post-hoc Bonferroni correction for multiple comparisons of the P values was 
applied. Maternal, paternal and cord 1C metabolism status (plasma folate, 
erythrocyte folate, total plasma homocysteine and plasma cobalamin) were 
compared between the different genotypes for MTHFR 677C>T and SLC19A1 
80 G>A, as well as the combination of both. Statistical significance was 
accepted from p. values <0.05. Percentages (95% CI) of the outcomes included 
in the study and according to genotypes are also reported.  
BMI was calculated as weight (kg) divided by height squared (m²). Smoking 
pattern was categorized by women who smoke throughout pregnancy versus 
never or women who smoke in the first trimester versus never. Previous 
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pregnancy was categorized as confirmed previous live newborn or none. 
Socioeconomic status was categorized as low versus mid-high status 
considering maternal and paternal status together. Variables of the 
polymorphisms were used comparing the homozygote normal versus the 
heterozygote or the homozygote genotypes: CC vs CT or TT for MTHFR 677 
C>T and GG vs GA or AA for SLC19A1 80G>A. The variable used as control for 
the three clinical outcomes was created with participants without any 
pregnancy complication such as gestational hypertension, gestational 
diabetes, IUGR, etc.  
The 3 main outcomes studied were: pathological doppler of uterine arteries 
at 20GW, intrauterine growth restriction and pregnancy induced 
hypertension. Multiple linear and logistic regressions were used to examine 
the associations between maternal and paternal genetic, nutritional and 
metabolic components of 1C metabolism and continuous and categorical 
variables associated with the development of pregnancy outcomes and 
complications respectively. 
Interaction terms were calculated to assess possible interactions between 
independent variables, in their relationship with the dependent variable of 
interest. The product of the independent variables being tested was calculated 
and included in the linear or logistic regression analysis. When the interaction 
term was significant, we proceeded to perform the regression analysis on 
stratified sets of data to account for the interaction.  
Multiple linear regression analysis was performed to identify maternal and 
paternal predictors of pulsatility index of uterine arteries (dependent variable, 
natural log transformed). The models will be described in detail in the results 
section. Generally, for each analysis we designed 2 models. The first model 
explored the association of the 1CM variables of interest and pulsatility index. 
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For the genotype models, this included the MTHFR C677T and SLC19A1 G80A 
genotypes as well as first trimester plasma cobalamin and red blood cell folate 
status (low tertile versus the others). Subsequently maternal clinical and 
lifestyle factors (smoking during pregnancy versus never, socioeconomic 
status, age, BMI, late pregnancy anaemia (3rd trimester haemoglobin <11 
g/dL), previous pregnancies longer than 20 GW versus none, gestational age 
(weeks at birth and sex of the baby) were added to form the complete model. 
In the tHcy models, only tHcy (representing overall 1CM status) at the 
corresponding time of pregnancy was included in the first model. 
Subsequently, the next model was adjusted for the same maternal clinical and 
lifestyle factors described for the complete 1CM model above.  
To study the involvement of paternal factors, we added the paternal variables 
to the complete maternal models described above. Therefore, paternal 
MTHFR 677C>T genotype, cobalamin and red blood cell folate status and 
paternal tHcy ≥P90 were included in the corresponding models. 
Multiple logistic regression analysis was used to identify maternal and 
paternal factors associated with Pathological doppler of uterine arteries at 20 
GW (dependent variable). The models to examine the association between 
genotypes and impaired placentation included MTHFR 677C>T and SLC19A1 
80G>A genotype, red blood cell folate and plasma cobalamin concentrations 
at <12 and 15 GW. In the models focused on the association between tHcy and 
impaired placentation, the categorical tHcy variable (≥P90 tHcy in early 
pregnancy versus other percentiles) replaced the genotypes and red blood cell 
folate and plasma cobalamin variables in each model, at <12 and 15 GW. The 
models were adjusted for smoking habit, socioeconomic status, 1st trimester 
BMI, age, parity and gestational age at doppler measurement. Adjusting for 
study centre did not change the results in any of the models so it was not 
included. 
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We checked for outliers and influential cases (Cook’s distance >4/n) and 
excluded them from the models when identified. 
Paternal factors were also studied in the logistic regressions. Paternal MTHFR 
677C>T genotype, smoking habit, age, red blood cell folate concentrations and 
elevated paternal tHcy levels (≥P90) were included in the same models used 
for the mothers.  
Multiple linear regression analysis was performed to identify maternal and 
paternal predictors of birthweight (dependent variable) with a similar strategy 
to those described for uterine artery pulsatility index above. In all multiple 
linear regression analyses, participants with gestational diabetes were 
excluded due to its potential effect on birth weight.  
Multiple logistic regression analysis was used to identify maternal and 
paternal factors associated with IUGR (dependent variable) applying a similar 
strategy as described for pathological doppler above.  In this case we did not 
exclude participants with gestational diabetes to avoid loss of statistical 
power.  
Multiple logistic regressions analysis was used to study the association 
between maternal and paternal genetic and 1CM related factors and 
gestational hypertension. We excluded pregnancies affected by gestational 
diabetes or intrauterine growth retardation from the analysis and used similar 
model designs as described above for pathological Doppler and IUGR. 
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4. Results 
 
4.1. Descriptive results 
 
Eight hundred and fifty six women were screened at their first antenatal 
check-up. 16 women were not eligible to participate (twin pregnancies, drug 
abuse, donated oocytes and GA >20 GW). From the 840 mothers invited, 21 
were not interested and 8 refused for language or cultural reasons. 811 
mothers accepted and 748 were identified, as pregnancy progressed, to invite 
the father (the others had miscarried, moved hospital or left the study). From 
those participants, 3 were donor fathers, we could not establish contact with 
60 mothers and 13 had adverse outcomes before establishing contact with 
them (12 pregnancy terminations due to foetal anomalies and 1 fetal death). 
Given the nature of these reasons, paternal contact details could not be 
requested from the mothers due to discontinuation of prenatal follow up and 
loss of contact with the study team. A total of 672 fathers were eligible to 
invite. A further 46 fathers were ineligible for recruitment because 39 mothers 
refused to provide their contact details and we could not establish the contact 
with 7 of them. A total of 626 fathers were invited to participate. Of these, 212 
fathers refused. 414 fathers agreed to participate by December 2019 allowing 
us to complete 414 mother-father-neonate triads (66.1 of those eligible) 
(Figure 6).   
Maternal and paternal demographic and lifestyle descriptive characteristics 
are shown in Table 2. A total of 25.7% of the mothers smoked at some time of 
pregnancy and 36.7% of the fathers were smokers. A total of 36.0% of the 
women reported taking folic acid before pregnancy and 94.2 % during the first 
trimester. 51.8% did not meet the recommended red blood cell folate status 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
112 
 
of 906 nmol/L for NTDs prevention. Only 6.8% of men reported taking 
multivitamin or mineral supplements. 
 
Figure 6. Participant flow chart from recruitment until triads included. 
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Maternal plasma folate, red blood cell folate, total plasma homocysteine and 
cobalamin concentrations throughout pregnancy at <12, 15, 24-27, 34 GW and 
at labour are reported in Table 3. The same determinations were also 
performed in the cord blood. During the first trimester (<12 GW) plasma folate 
status was the highest, with a median of 28.9 nmol/L and similar at 15 GW. By 
 
 
 
 
Table 2. Maternal and paternal characteristics during the first trimester. 
Basic characteristics Mothers  Fathers   
Age (years)1 32.0 (26.0, 39.0) 
[752] 
34.0 (29.0, 41.0) 
[414] 
BMI (kg/m2)1 
23.3 (19.6, 29.8) 
[752] 
25.7 (22.1, 31.2) 
[413] 
Socioeconomic status2,3   
Low 12.2 (10.0, 14.7) 
[93/764] 
 
Middle 45.8 (42.3, 49.4) 
[350/764] 
 
High 42.0 (38.6, 45.5) 
[321/764] 
 
Smoking status2   
Never  74.3 (71.1, 77.3) 
[569/ 766] 
 
1st trimester only 9.4 (7.5, 11.7)  
[72/ 766] 
 
Throughout pregnancy 16.3 (13.9, 19.1) 
[125/766] 
36.7 (32.1, 41.4) 
[151/412] 
Previous Pregnancies2 52.4 (48.9, 55.8) 
[411/785] 
 
Folic acid supplement use2,4   
Preconception 36.0 (32.5, 39.7)  
[249/691] 
 
1st trimester 94.2 (92.2, 95.7) 
[662/703] 
6.8 (4.7, 9.6) 
[28/413] 
RBC folate <906 nmol/L2 51.8 (48.2, 55.3) 
[391/755] 
 
Abbreviations: BMI, Body Mass Index. 1Median (P10, P90). 2Percentages (95% 
confidence interval). 3Combined maternal and paternal. 4Information only available 
from mothers that completed the relevant information in the questionnaires. [n]. 
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24-27 GW, it had fallen to 14.4 nmol/L and continued to decrease until the 
end of pregnancy. Plasma folate concentration in the cord was higher than in 
the mother during labour. Erythrocyte folate concentrations increased from 
<12 to 15 GW but had started to decline by 24-27 GW. Median tHcy decreased 
from 5.3 µmol/L at <12 GW to 4.5 µmol/L by 15 GW. During late pregnancy, it 
increased and reached 6.0 µmol/L by labour. Median cord blood tHcy was 
lower than maternal tHcy at labour. Median plasma cobalamin decreased 
gradually from 364 pmol/L in the first trimester to 233 pmol/L by labour and 
cord cobalamin was higher than the mothers at labour. Folic acid supplement 
use interacts significantly with plasma folate concentrations from 15 GW to 
the end of pregnancy. This interaction was also observed between folic acid 
supplementation and red blood cell folate and tHcy levels at 24-27 and at 34 
GW. No interaction between folic acid supplementation and B12 
concentrations was observed (data not reported in the table).
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Table 3. Maternal 1CM folate, cobalamin and tHcy status during pregnancy and in the cord. 
 <12GW 15GW 24-27GW 34GW Labour Cord 
Plasma folate 
(nmol/L) 
28.9 (10.0, 61.2)¹ 26.6 (9.9, 53.8)¹ 14.4 (5.8, 39.7)¹ 11.0 (5.0, 38.6)¹ 10.0 (4.9, 36.5)¹ 26.3 (12.2, 56.5)¹ 
 
27.0  (25.7, 28.4)²  
[773] 
24.9 (23.4, 26.6)² †† 
[448] 
15.3 (14.4, 16.2)² *** ††† 
[665] 
12.8 (12.0, 13.7)² *** †† 
[633] 
12.1 (11.3, 12.9)² **† 
[611] 
26.0 (24.8, 27.3)² 
[577] 
Erythrocyte 
folate (nmol/L) 
936 (466, 1841)¹ 1266 (665, 2204)¹ 1138 (602, 2119)¹ 949 (464, 2065)¹ - - 
 
942 (906, 980)² 
[753] 
1248 (1191, 1307)² *** 
[446] 
1150 (1105, 1196)²*** 
††† 
[651] 
975 (932, 1021)² ***††† 
[616] 
- - 
Plasma total 
homocysteine 
(µmol/L) 
5.3 (4.0, 7.1)¹ 4.5 (3.5, 5.9)¹ 4.6 (3.5, 6.3)¹ 5.2 (3.8, 7.3)¹ 6.0 (4.3, 8.6)¹ 4.8 (3.4, 6.7)¹ 
 
5.3 (5.2, 5.4) ² 
[774] 
4.5 (4.4, 4.6)² *** 
[449] 
4.6 (4.6, 4.7)² ** ††† 
[666] 
5.2 (5.1, 5.3)² *** † 
[634] 
6.1 (6.0, 6.3)² *** 
[613] 
4.8 (4.7, 4.9)² 
[578] 
Plasma B12 
(pmol/L) 
364 (240, 525) ¹ 332 (213, 467)¹ 277 (178, 424)¹ 252 (160, 388)¹ 233 (143, 369)¹ 336 (115, 635)¹ 
 
360 (351, 369)² 
[773] 
324 (314, 334)²*** 
[448] 
274 (267, 281)²*** 
[665] 
250 (244, 257)²*** 
[633] 
231 (224, 238)²*** 
[606] 
316 (299, 333)² 
[550] 
Abbreviations: GW, gestational week. 1Median (P10, P90). 2Geometric mean (95% confidence interval). [n]. Geometric means between the different time points of pregnancy 
were compared using ANOVA for repeated measures analysis. Post-hoc Bonferroni correction for multiple comparisons was applied. Intrasubject factor: time of pregnancy; 
intersubject factor folic acid supplement use (>400 µg/ d in the first trimester and continued use in the second and third trimesters). Different to previous time point: *P<0.05, 
**p<0.01, ***p<0.001. Intersubject factor folic acid supplement use †P<0.05, ††p<0.01, †††p<0.001.  
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The following graphs illustrate the percentage of participants deficient in 
plasma and red blood cell folate during pregnancy, at <12, 15, 24-27, 34 
GW and labour. Deficiency was defined as plasma folate concentrations ≤ 
7 nmol/L (7), and red blood cell folate concentrations ≤ 340 nmol/L. The 
prevalence of plasma folate deficiency increased as pregnancy progressed, 
mainly after 15 GW. In the case of red blood cell folate deficiency, the 
prevalence was the lowest at 15 and 24-27 GW but it had increased by 34 
GW.  
 
 
Figure 7. Prevalence of plasma folate deficiency (≤ 7nmol/L) in participants 
during pregnancy and at labour are represented. [n]. Means (dots) and 95% 
Confidence Interval (bars) are illustrated. Prevalences of deficiency with the 
preceding time point were compared using Chi-square (McNemar) and 
post-hoc Bonferoni correction of P values for multiple comparisons was 
applied. *P<0.05, ***P<0.001. 
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Paternal 1CM nutrient and metabolite status is reported in Table 4. 
Median plasma folate was relatively low at 8.8 nmol/L. Median 
erythrocyte folate concentration was 456.8 nmol/L, tHcy was 9.6 µmol/L 
and plasma cobalamin 367.2 pmol/L.  
 
 
 
Figure 8. Prevalence of red blood cell folate deficiency (≤ 340 nmol/L) in 
participants during pregnancy are represented. [n]. Means (dots) and 95% 
Confidence Interval (bars) are illustrated. Prevalences of deficiency with the 
preceding time point were compared using Chi-square (McNemar) and post-
hoc Bonferoni correction of P values for multiple comparisons was applied. 
*P<0.05, ***P<0.001. 
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Maternal, paternal and cord genotypes and allele frequencies for the 
MTHFR 677C>T and SLC19A1 80 G>A genetic variants and the combination 
of both are shown in Table 5. All the observed genotype frequencies were 
in Hardy-Weinberg equilibrium (p>0.05). The homozygote variant 
genotype for the MTHFR C677T polymorphism was 17.0, 14.1 and 18.6% 
for the mother, father and cord respectively. For the SLC19A1 G80A 
polymorphism, the homozygote variant genotype frequency was 27.2, 
28.9 and 26.9% for the mother, father and cord respectively. Regarding 
the combined genotypes, the CT-GA combination was the most frequent, 
found in >20% of mothers, fathers and cords.  
  
Table 4. Paternal status in 1CM nutrients and metabolites. 
 Fathers N 
Plasma folate (nmol/L) 8.8 (4.5, 16.8)¹ 405 
 8.7 (8.3, 9.2)²  
Erythrocyte folate (nmol/L) 456.8 (205.4, 802.9)¹ 384 
 425.9 (404.6, 448.4)²  
Plasma total homocysteine 
(µmol/L) 
9.6 (7.5, 14.0)¹ 404 
 9.9 (9.7, 10.2)²  
Plasma B12 (pmol/L) 367.2 (282.5, 570.4)¹ 403 
 380.3 (369.6, 391.4)²  
1 Median (P10, P90). 2 Geometric mean (95% confidence interval). 
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Table 5. Frequencies of maternal, paternal and cord MTHFR 677 C>T and SLC19A1 80 
G>A genotypes.1 
 Mother Father Cord 
MTHFR 677 C>T genotype 
CC 
34 (30.5, 37.3) 
[249] 
36.3 (31.6, 41.2) 
[139] 
35.4 (31.5, 39.6) 
[188] 
CT 
49.3 (45.7, 52.9) 
[363] 
49.6 (44.6, 54.6) 
[192] 
46.0 (41.8, 50.2) 
[244] 
TT 
17.0 (14.4, 19.8) 
[125] 
14.1 (11.0, 17.9) 
[54] 
18.6 (15.6, 22.2) 
[99] 
T allele frequency 
41.6 (39.1, 44.1) 
[613/1474] 
38.9 (35.5, 42.4) 
[298/766] 
41.6 (38.7, 44.6) 
[442/1062] 
SLC19A1 80 G>A genotype 
GG 
27.2 (24.2, 30.6) 
[200] 
27.9 (23.6, 32.6) 
[106] 
25.6 (22.1, 29.5) 
[135] 
GA 
45.5 (41.9, 49.1) 
[334] 
43.2 (38.3, 48.2) 
[164] 
47.4 (43.2, 51.7) 
[250] 
AA 
27.2 (24.2, 30.6) 
[200] 
28.9 (24.6, 33.7) 
[112] 
26.9 (23.3, 30.9) 
[142] 
A allele frequency 
50.0 (47.4, 52.6) 
[734/1468] 
50.5 (47.0, 54.1) 
[384/760] 
50.7 (47.6, 53.7) 
[534/1054] 
MTHFR 677 C>T + SLC19A1 80 G>A genotype 
CC-GG 10.6 (8.6, 13.1) 
[78] 
10.0 (7.4, 13.4) 
[38] 
10.3 (8.0, 13.2) 
[54] 
CC-GA 15.0 (12.6, 17.8) 
[110] 
17.4 (13.9, 21.5) 
[67] 
16.6 (13.6, 20.0) 
[87] 
CC-AA 8.3 (6.5, 10.5) 
[61] 
9.2 (6.7, 12.5) 
[35] 
8.8 (6.6, 11.5) 
[46] 
CT-GG 11.9 (9.7, 14.4) 
[87] 
13.2 (10.1, 16.9) 
[50] 
10.9 (8.5, 13.8) 
[57] 
CT-GA 24.3 (21.3, 27.5) 
[178] 
21.6 (17.7, 26.0) 
[83] 
21.3 (18.0, 25.0) 
[112] 
CT-AA 12.9 (10.7, 15.6) 
[96] 
14.5 (11.3, 18.4) 
[57] 
13.5 (10.9, 16.7) 
[72] 
TT-GG 4.8 (3.4, 6.6) 
[35] 
4.7 (3.0, 7.4) 
[18] 
4.6 (3.1, 6.7) 
[24] 
TT-GA 6.3 (4.7, 8.3) 
[47] 
4.2 (2.6, 6.7) 
[16] 
9.3 (7.1, 12.1) 
[49] 
TT-AA 6.0 (4.5, 8.0) 
[44] 
5.3 (3.4, 8.0) 
[20] 
4.8 (3.2, 6.9) 
[25] 
1 All data shown are percentages (95% confidence interval).  
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; SLC19A1, solute carrier family 
19 member 1. [n]  
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
120 
 
Maternal one carbon metabolism status  (plasma folate, erythrocyte folate 
and total plasma homocysteine) according to MTHFR 677 C>T and 
SLC19A1 80 G>A genotypes and the combination of both at 5 different 
points of pregnancy (<12, 15, 24-27, 34 GW and labour) are reported in 
Figure 9 and tables 6 and 7. A similar pattern to that observed for change 
in plasma folate  (Table 3) was observed for all the MTHFR 677 C>T 
genotypes and plasma folate did not differ between them (Figure 9). In the 
women with available RBC folate measurements at 15 GW, we observed 
that it increased between the first trimester and 15 GW and then gradually 
declined for the rest of pregnancy. In contrast to plasma folate, we did 
observe lower RBC folate status in the MTHFR 677TT compared to CC 
genotype from 24-27 GW and also compared to the CT genotype at 34 GW 
(Figure 9). THcy decreased between the first trimester and 15 GW and 
then gradually increased for the rest of pregnancy, reaching the highest 
concentration at labour. THcy was higher in the MTHFR 677TT compared 
to CC and CT genotypes from 15GW throughout the rest of pregnancy 
(Figure 9). No significant differences were observed in plasma or tHcy 
status between SLC19A1 80 G>A genotypes (Table 6). Regarding the 
combination of both genotypes, only tHcy at <12, 24-27 and 34 GW and at 
labour differed among these (Table 7). People with the combination of 
MTHFR 677 + SLC19A1 TT-GG, TT-GA genotypes had the highest tHcy out 
of all of the combinations. People with the combinations of MTHFR 677 + 
SLC19A1 CC-GA and CC-AA genotypes had the lowest. People with the 
combinations of MTHFR 677 + SLC19A1 CC-GG, CT-GA and CT-AA had 
lower tHcy compared to the TT-GG and TT-GA genotype combinations but 
higher than those with the CC-GA and CC-AA combinations. Plasma 
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cobalamin concentrations and changes during pregnancy did not differ 
between genotypes (data not shown).  
 
 
Figure 9. Maternal one carbon metabolism status according to MTHFR 677 C>T genotype. Geometric 
means (95% confidence interval) are shown. Blue line represents CC genotype; plasma folate and tHcy 
at <12GW n= 248, 15GW n=148, 24-27GW n=217, 34GW n=202 and at labour n=206. RBC folate at 
<12GW n= 241, 15GW n=146, 24-27GW n=212, 34GW n=194. Orange line represents CT genotype; 
plasma folate and tHcy at <12GW n=355, 15GW n=214, 24-27GW n=309, 34GW n=299 and at labour 
n=289. RBC folate at <12GW n= 345, 15GW n=214, 24-27GW n=301, 34GW n=291. Grey line represents 
TT genotype; plasma folate <12GW n= 122, 15GW n=83, 24-27GW n=108, 34GW n=102 and at labour 
n=94. RBC folate at <12GW n= 121, 15GW n=83, 24-27GW n=107, 34GW n=101. THcy at <12GW n= 123, 
15GW n=84, 24-27GW n=109, 34GW n=103 and at labour n=95. ANOVA with post-hoc Bonferroni 
correction for multiple comparisons were used to compare the differences in geometric means between 
the genotypes and to compare plasma concentrations of 1C metabolites between different times of 
pregnancy and labour. *p<0.05 **p<0.01 *** p<0.001 TT compared to CC genotype. ††p<0.01 †††p<0.001 
TT compared to CT genotype. ap <0.001 compared with <12 GW, bp <0.001 compared with 15GW, cp 
<0.001 compared with 24-27GW, dp <0.001 compared with 34GW. GW, gestational week; MTHFR, 
methylenetetrahydrofolate reductase.  
< 
< 
< 
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Table 6. Maternal one carbon metabolism status according to SLC19A1 80 G>A genotype.  
 <12GW 15GW 24-27GW 34GW Labour 
Plasma folate (nmol/L) 
SLC19A1 GG 
genotype 
30.4 (9.2, 61.5)¹       28.2 (10.2, 45.6)¹ 13.5 (5.6, 36.6)¹ 9.7 (4.9, 35.6)¹ 9.0 (4.6, 37.7)¹ 
 27.3 (24.6, 30.4)² 
[198] 
25.9 (23.1, 29.1)² 
[123] 
14.8 (13.3, 16.6)²bbb 
[175] 
11.8 (10.4, 13.3)²ccc 
[169] 
11.3 (9.9, 12.8)² 
[163] 
SLC19A1 GA 
genotype 
27.2 (10.1, 59.7)¹       25.2 (10.1, 55.5)¹ 13.5 (5.7, 39.8)¹ 11.2 (5.0, 40.6)¹ 10.1 (4.9, 34.6)¹ 
 26.7 (24.7, 28.8)² 
[330] 
25.0 (22.7, 27.5)² 
[201] 
14.8 (13.6, 16.2)²bbb 
[292] 
12.8 (11.6, 14.2)²ccc 
[269] 
12.0 (10.9, 13.2)²d 
[273] 
SLC19A1 AA 
genotype 
30.3 (10.5, 58.9)¹       27.0 (9.6, 54.7)¹ 13.1 (5.9, 39.7)¹ 9.9 (5.1, 36.9)¹ 10.0 (4.9, 37.3)¹ 
 26.4 (24.0, 29.1)² 
[194] 
24.5 (21.6, 27.8)² 
[118] 
14.7 (13.0, 16.5)²bbb 
[164] 
12.2 (10.8, 13.7)² ccc 
[162] 
12.2 (10.7, 14.0)² 
[150] 
p value 0.885 0.802 0.986 0.525 0.631 
Erythrocyte folate (nmol/L) 
SLC19A1 GG 
genotype 
1003.5 
 (454.7, 1840.3)¹        
1380.3 
 (789.9, 2245.2)¹ 
1170.6 
 (584.9, 2006.6)¹ 
904.1 
 (462.9, 1691.1)¹ 
- 
 970.7 
 (897.8, 1049.5)² 
[193] 
1330.5  
(1221.9, 1448.7)²aaa 
[122] 
1107.3  
(1019.9, 1202.2)²bbb 
[172] 
869.8  
(801.3, 944.2)² ccc 
[166] 
- 
SLC19A1 GA 
genotype 
941.6  
(466.0, 1778.0)¹  
1237.5  
(622.3, 2196.1)¹ 
1137.1  
(580.9, 2099.7)¹ 
1028.2  
(461.4, 2166.3)¹ 
- 
 937.1  
(884.4, 992.9)² 
[323] 
1228.0  
(1145.5, 1316.6)²aaa 
[201] 
1134.2  
(1068.4, 1204.0)²bbb 
[284] 
1006.3  
(936.2, 1081.6)² ccc 
[264] 
- 
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Table 6. Maternal one carbon metabolism status according to SLC19A1 80 G>A genotype. 
 <12GW 15GW 24-27GW 34GW Labour 
SLC19A1 AA 
genotype 
886.0  
(468.8, 1931.4)¹  
1247.4  
(681.3, 2221.4)¹ 
1092.5  
(599.4, 2083.3)¹ 
815.1  
(432.9, 1958.1)¹ 
- 
 914.7  
(842.0, 993.6)² 
[188] 
1234.4  
(1129.4, 1349.2)²aaa 
[117] 
1113.8  
(1025.7, 1209.6)²bbb 
[161] 
925.9  
(847.2, 1011.9)²ccc 
[153] 
- 
p value 0.564 0.343 0.865 0.199 - 
Plasma total homocysteine (µmol/L) 
SLC19A1 GG 
genotype 
5.3 (4.2, 7.4)¹     4.4 (3.6, 6.0)¹ 
 
4.7 (3.5, 6.5)¹ 
 
5.3 (3.9, 7.9)¹ 
 
6.2 (4.1, 9.2)¹ 
 
 5.4 (5.2, 5.6)² 
[198] 
4.5 (4.3, 4.7)²aaa 
[123] 
4.8 (4.6, 5.0)²bb 
[175] 
5.4 (5.2, 5.6)²ccc 
[169] 
6.3 (6.0, 6.6)²ddd 
[163] 
SLC19A1 GA 
genotype 
5.3 (4.0, 7.2)¹  4.5 (3.5, 5.7)¹ 4.6 (3.5, 6.3)¹ 5.1 (3.8, 7.0)¹ 6.0 (4.3, 8.5)¹ 
 5.3 (5.2, 5.5)² 
[331] 
4.5 (4.4, 4.6)²aaa 
[202] 
4.6 (4.5, 4.7)² bb 
[293] 
5.2 (5.1, 5.4)²ccc 
[270] 
6.1 (5.9, 6.3)²ddd 
[275] 
SLC19A1 AA 
genotype 
5.3 (3.8, 6.9)¹  4.6 (3.3, 5.9)¹ 4.7 (3.4, 6.3)¹ 5.3 (3.6, 7.1)¹ 5.9 (4.4, 8.8)¹ 
 5.3 (5.1, 5.4)² 
[194] 
4.6 (4.4, 4.8)²aaa 
[116] 
4.6 (4.5, 4.8)² 
[132] 
5.1 (4.9, 5.3)²ccc 
[130] 
6.1 (5.9, 6.4)²ddd 
[120] 
p value 0.587 0.605 0.347 0.190 0.598 
Abbreviations: GW, gestational week; SLC19A1, solute carrier family 19 member 1.1 Median (P10, P90). 2Geometric mean (95% confidence interval). 
Geometric means were compared between time points using ANOVA for repeated measures and between genotypes using ANOVA (post hoc Bonferroni 
p value are shown). ap <0.05, aap <0.01, aaap <0.001 compared with <12 GW,  bp<0.05, bbp<0.01, bbbp <0.001 compared with 15GW,  cp <0.05,  ccp <0.01, cccp 
<0.001 compared with 24-27GW,  dp <0.05,  ddp <0.01,  dddp <0.001 compared with 34GW. 
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Table 7. Maternal one carbon metabolism status according to maternal combination of both genotypes.  
 <12GW 15GW 24-27GW 34GW Labour 
Plasma folate (nmol/L) 
MTHFR 677 CC + 
SLC19A1 GG 
genotype 
30.6 (10.2, 59.2)¹ 
27.3 (23.4, 31.7)² 
[78] 
28.0 (12.8, 43.3)¹ 
26.2 (22.3, 30.8)² 
[43] 
15.3 (6.2, 40.0)¹ 
16.1 (13.5, 19.2)²bbb 
[68] 
10.2 (5.0, 34.2)¹ 
11.9 (9.8, 14.4)²c 
[62] 
9.5 (5.1, 38.4)¹ 
12.6 (10.2, 15.5)²d 
[64] 
MTHFR 677 CC + 
SLC19A1 GA 
genotype 
29.3 (10.8, 53.0)¹  
27.3 (24.1, 30.9)²  
[110]      
24.6 (10.9, 70.3)¹ 
26.1 (21.6, 31.4)² 
[67] 
12.9 (5.8, 42.4)¹ 
15.2 (13.1, 17.6)² 
[96] 
12.3 (5.1, 40.8)¹ 
13.3 (11.1, 15.9)²ccc 
[88] 
10.9 (5.1, 33.9)¹ 
12.5 (10.5, 14.8)² 
[90] 
MTHFR 677 CC + 
SLC19A1 AA 
genotype 
31.5 (11.0, 55.3)¹  
27.8 (23.5, 32.9)²  
[60] 
28.8 (9.6, 49.9)¹ 
24.3 (19.7, 29.8)² 
[38] 
12.0 (6.5, 39.8)¹ 
13.5 (11.3, 16.3)²bbb 
[53] 
8.4 (5.2, 37.3)¹ 
11.8 (9.5, 14.6)²cc 
[52] 
8.2 (4.9, 42.6)¹ 
11.4 (9.0, 14.3)²dd 
[52] 
MTHFR 677 CT + 
SLC19A1 GG 
genotype 
28.1 (8.2, 79.4)¹  
26.1 (21.8, 31.3)² 
[85] 
27.4 (6.8, 46.8)¹ 
24.5 (20.0, 29.9)² 
[55] 
11.1 (5.4, 36.8)¹ 
13.9 (11.6, 16.5)²bbb 
[76] 
8.6 (5.1, 39.1)¹ 
11.6 (9.7, 14.0)²cc 
[75] 
8.2 (4.1, 39.8)¹ 
10.4 (8.5, 12.6)²dd 
[70] 
MTHFR 677 CT + 
SLC19A1 GA 
genotype 
26.9 (9.8, 62.2)¹  
25.9 (23.3, 28.9)² 
[175] 
25.2 (9.3, 55.9)¹ 
24.5 (21.5, 27.9)² 
[104] 
13.6 (5.5, 36.5)¹ 
14.6 (12.9, 16.5)²bbb 
[155] 
10.4 (4.9, 44.5)¹ 
12.8 (11.2, 14.7)²cc 
[143] 
9.7 (4.7, 35.3)¹ 
11.7 (10.3, 13.3)²dd 
[148] 
MTHFR 677 CT + 
SLC19A1 AA 
genotype 
28.8 (10.5, 60.0)¹   
26.1 (22.8, 29.9)² 
[92] 
26.5 (9.6, 46.2)¹ 
23.9 (20.2, 28.2)² 
[52] 
16.5 (6.2, 39.7)¹ 
15.7 (13.1, 18.8)²bbb 
[75] 
11.2 (5.0, 35.4)¹ 
12.8 (10.9, 15.0)² 
[78] 
11.6 (5.8, 37.6)¹ 
13.4 (11.2, 16.1)² 
[68] 
MTHFR 677 TT + 
SLC19A1 GG 
genotype 
36.8 (11.8, 57.9)¹  
30.8 (24.7, 38.4)² 
[35]  
29.3 (10.4, 69.7)¹ 
28.8 (22.2, 37.4)² 
[25] 
14.9 (5.7, 34.1)¹ 
14.7 (11.3, 19.1)²bbb 
[31] 
12.3 (3.6, 41.7)¹ 
11.9 (8.7, 16.2)²ccc 
[32] 
10.7 (4.5, 31.3)¹ 
10.8 (8.2, 14.2)² 
[29] 
MTHFR 677 TT + 
SLC19A1 GA 
genotype 
25.8 (9.5, 81.1)¹  
28.1 (22.2, 35.6)² 
[45] 
28.2 (7.8, 49.1)¹ 
24.2 (19.2, 30.6)² 
[30] 
14.3 (5.2, 38.2)¹ 
14.8 (11.7, 18.7)²bbb 
[41] 
11.4 (4.6, 35.5)¹ 
11.9 (9.1, 15.5)² 
[38] 
12.1 (4.9, 32.8)¹ 
11.9 (9.1, 15.7)² 
[35] 
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Table 7. Maternal one carbon metabolism status according to maternal combination of both genotypes.  
 <12GW 15GW 24-27GW 34GW Labour 
MTHFR 677 TT + 
SLC19A1 AA 
genotype 
30.2 (8.9, 60.4)¹   
25.4 (19.7, 32.6)² 
[42] 
25.2 (8.5, 89.0)¹ 
26.2 (18.6, 36.8)² 
[28] 
12.3 (5.4, 47.5)¹ 
14.4 (10.7, 19.3)²bbb 
[36] 
9.5 (4.9, 49.6)¹ 
11.4 (8.5, 15.3)² 
[32] 
8.3 (3.3, 46.3)¹ 
11.2 (7.5, 16.8)² 
[30] 
p value 0.955 0.974 0.946 0.965 0.766 
Erythrocyte folate (nmol/L) 
MTHFR 677 CC + 
SLC19A1 GG 
genotype 
1038.7  
(452.7, 1836.0)¹ 
991.2 
 (871.7, 1126.9)² 
[76] 
1385.6  
(799.9, 2245.2)¹ 
1366.4  
(1189.8, 1569.2)²aaa 
[42] 
1218.7  
(665.3, 2130.1)¹ 
1215.1  
(1089.3, 1355.5)²bb 
[66] 
953.3  
(466.4, 1703.2)¹ 
942.8  
(831.2, 1069.5)²ccc 
[60] 
- 
MTHFR 677 CC + 
SLC19A1 GA 
genotype 
997.0  
(520.2, 1872.2)¹   
1023.9  
(927.9, 1129.8)²  
[107] 
1171.7  
(602.8, 2299.9)¹ 
1246.7  
(1104.2, 1407.5)²aaa 
[67] 
1215.1  
(651.2, 2402.2)¹ 
1217.5  
(1099.5, 1348.2)² 
[93] 
1061.9 (472.2, 
2449.8)¹ 
1094.8  
(960.8, 1247.5)²ccc 
[85] 
- 
MTHFR 677 CC + 
SLC19A1 AA 
genotype 
975.9  
(519.7, 1960.3)¹  
987.1  
(856.7, 1137.4)² 
[58] 
1186.6  
(770.7, 2006.2)¹ 
1258.9 
 (1101.4, 1439.0)²aa 
[37] 
1122.0  
(662.1, 1846.1)¹ 
1160.2 
 (1011.4, 1330.8)² 
[53] 
867.4  
(525.7, 1936.6)¹ 
902.3  
(777.6, 1046.9)²ccc 
[49] 
- 
MTHFR 677 CT + 
SLC19A1 GG 
genotype 
1064.6  
(441.6, 1868.5)¹   
982.7 
 (869.5, 1110.6)² 
[83] 
1391.7  
(775.5, 2167.6)¹ 
1290.0  
(1136.4, 1464.3)²aaa 
[55] 
1118.0  
(527.6, 2019.8)¹ 
1121.8  
(996.7, 1262.6)² 
[76] 
904.6  
(426.4, 1782.2)¹ 
952.3  
(843.8, 1074.8)²ccc 
[74] 
- 
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Table 7. Maternal one carbon metabolism status according to maternal combination of both genotypes.   
 <12GW 15GW 24-27GW 34GW Labour 
MTHFR 677 CT + 
SLC19A1 GA 
genotype 
 
 
939.9  
(457.8, 1711.1)¹  
916.8 
 (847.4, 991.9)² 
[171] 
1342.4  
(756.3, 2155.8)¹ 
1278.8 
 (1161.6, 1407.9)²aaa 
[104] 
1136.4 
 (573.1, 1991.1)¹ 
1126.6 
 (1039.1, 1221.3)²bb 
[150] 
1026.2 
 (521.9, 2067.7)¹ 
1014.2  
(923.5, 1113.8)²ccc 
[141] 
- 
MTHFR 677 CT + 
SLC19A1 AA 
genotype 
910.3  
(443.9, 1895.0)¹  
915.2 
 (814.7, 1028.2)² 
[88] 
1248.1  
(658.6, 2195.3)¹ 
1215.9  
(1062.8, 1391.1)²aaa 
[52] 
1103.9 
 (576.1, 2151.2)¹ 
1135.3 
 (1007.3, 1279.6)²bb 
[72] 
912.6  
(500.0, 2018.2)¹ 
966.8  
(856.0, 1091.8)²cc 
[73] 
- 
MTHFR 677 TT + 
SLC19A1 GG 
genotype 
843.0  
(478.3, 1929.3)¹ 
899.2  
(754.3, 1072.0)² 
[34] 
1339.6  
(648.3, 3080.7)¹ 
1347.4  
(1080.8, 1679.9)²aaa 
[25] 
1116.7  
(452.4, 1987.5)¹ 
1072.7  
(885.9, 1298.8)²b 
[30] 
761.4  
(382.4, 1562.8)¹ 
829.5 
 (681.4, 1009.9)²ccc 
[32] 
- 
MTHFR 677 TT + 
SLC19A1 GA 
genotype 
854.7  
(386.0, 1511.1)¹   
824.8  
(696.1, 977.4)² 
[45] 
992.3  
(510.9, 2026.4)¹ 
1031.8 
 (853.5, 1247.4)²aaa 
[30] 
997.6  
(446.4, 1829.7)¹ 
989.7 
 (827.3, 1183.9)² 
[41] 
838.5  
(357.4, 1690.4)¹ 
809.3 
 (653.0, 1002.9)²ccc 
[38] 
- 
MTHFR 677 TT + 
SLC19A1 AA 
genotype 
716.2  
(345.4, 2027.2)¹  
822.1  
(667.9, 1012.1)² 
[42] 
1252.2  
(601.4, 2693.7)¹ 
1237.0  
(981.5, 1559.0)²aaa 
[28] 
910.5  
(425.9, 2950.5)¹ 
1009.7  
(820.4, 1242.6)²b 
[36] 
797.5  
(393.3, 2033.3)¹ 
871.3  
(676.3, 1122.4)²ccc 
[31] 
- 
p value 0.250 0.518 0.402 0.104 - 
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Table 7. Maternal one carbon metabolism status according to maternal combination of both genotypes. 
 <12GW 15GW 24-27GW 34GW Labour 
Plasma total homocysteine (µmol/L) 
MTHFR 677 CC + 
SLC19A1 GG 
genotype 
5.1 (4.2, 7.0)¹ 
5.4 (5.1, 5.6)²  
[78] 
4.3 (3.7, 5.3)¹ 
4.4 (4.2, 4.6)²aaa 
[43] 
4.7 (3.4, 6.2)¹ 
4.6 (4.4, 4.9)²$# 
[68] 
5.1 (3.8, 7.1)¹ 
5.1 (4.8, 5.5)²$$$# ccc 
[62] 
6.1 (3.8, 8.9)¹ 
6.0 (5.6, 6.5)²$##ddd 
[64] 
MTHFR 677 CC + 
SLC19A1 GA 
genotype 
5.1 (4.0, 7.1)¹   
5.2 (5.0, 5.4)²  
[110] 
4.4 (3.5, 5.5)¹ 
4.4 (4.2, 4.6)²aaa 
[67] 
4.4 (3.6, 6.0)¹ 
4.5 (4.3, 4.7)²  
[96] 
5.0 (3.8, 6.8)¹ 
5.2 (4.9, 5.5)²ccc 
[88] 
5.9 (4.1, 9.0)¹ 
5.9 (5.6, 6.4)²ddd 
[90] 
MTHFR 677 CC + 
SLC19A1 AA 
genotype 
5.2 (3.8, 6.4)¹  
5.0 (4.8, 5.3)²  
[60] 
4.7 (3.3, 5.8)¹ 
4.6 (4.3, 4.9)²aa 
[38] 
4.7 (3.4, 5.7)¹ 
4.5 (4.3, 4.8)²  
[53] 
4.9 (3.6, 7.1)¹ 
4.9 (4.6, 5.3)²ccc 
[52] 
5.8 (4.7, 7.9)¹ 
6.0 (5.6, 6.3)²ddd 
[52] 
MTHFR 677 CT + 
SLC19A1 GG 
genotype 
5.0 (3.9, 7.0)¹  
5.1 (4.9, 5.4)²  
[85] 
4.3 (3.2, 6.0)¹ 
4.4 (4.1, 4.6)²aaa 
[55] 
4.6 (3.4, 6.6)¹ 
4.7 (4.4, 4.9)²bb  
[76] 
5.2 (3.7, 7.9)¹ 
5.3 (5.0, 5.7)²ccc 
[75] 
6.1 (4.4, 8.9)¹ 
6.2 (5.9, 6.7)²ddd 
[70] 
MTHFR 677 CT + 
SLC19A1 GA 
genotype 
5.3 (4.0, 7.2)¹  
5.3 (5.1, 5.5)²  
[175] 
4.4 (3.4, 5.8)¹ 
4.4 (4.3, 4.6)²aaa 
[104] 
4.6 (3.4, 6.3)¹ 
4.5 (4.4, 4.7)²  
[155] 
5.1 (3.8, 6.8)¹ 
5.1 (4.9, 5.3)²ccc  
[143] 
6.0 (4.3, 8.0)¹ 
6.0 (5.7, 6.3)²ddd 
[149] 
MTHFR 677 CT + 
SLC19A1 AA 
genotype 
5.4 (3.9, 7.0)¹   
5.3 (5.0, 5.5)²   
[92] 
4.5 (3.5, 5.9)¹ 
4.5 (4.3, 4.8)²aaa 
[52] 
4.8 (3.5, 6.3)¹ 
4.7 (4.4, 5.0)²   
[75] 
5.3 (3.6, 7.1)¹ 
5.2 (4.9, 5.5)²ccc 
[78] 
6.0 (4.3, 9.5)¹ 
6.1 (5.7, 6.6)²ddd 
[68] 
MTHFR 677 TT + 
SLC19A1 GG 
genotype 
5.8 (4.5, 10.0)¹  
6.0 (5.5, 6.6)²*††ᶴ 
[35] 
5.2 (3.8, 7.0)¹ 
5.0 (4.6, 5.5)²aaa 
[25] 
5.3 (4.0, 8.2)¹ 
5.4 (4.9, 6.0)²^^**†≠≠ 
[31] 
5.8 (4.3, 9.9)¹ 
6.1 (5.5, 6.8)²†≠  
[32] 
6.9 (4.8, 14.2)¹ 
7.0 (6.0, 8.1)²d 
[29] 
MTHFR 677 TT + 
SLC19A1 GA 
genotype 
5.8 (4.4, 9.1)¹  
5.9 (5.5, 6.4)²§ɸ ɸ∞  
[46]  
4.7 (4.0, 6.0)¹ 
4.8 (4.4, 5.2)²aaa 
[31] 
4.9 (3.9, 6.9)¹ 
5.2 (4.8, 5.7)²£§}   
[42] 
5.6 (3.8, 7.9)¹ 
5.8 (5.2, 6.5)²  
[39] 
6.4 (4.8, 10.5)¹ 
6.9 (6.2, 7.7)²ddd 
[36] 
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Table 7. Maternal one carbon metabolism status according to maternal combination of both genotypes. 
 <12GW 15GW 24-27GW 34GW Labour 
MTHFR 677 TT + 
SLC19A1 AA 
genotype 
5.4 (3.7, 8.1)¹ 
5.5 (5.1, 6.0)²  
[42] 
4.9 (3.2, 6.2)¹ 
4.7 (4.2, 5.1)²aa 
[28] 
4.8 (3.0, 6.8)¹ 
4.6 (4.2, 5.2)²   
[36] 
5.3 (3.4, 7.4)¹ 
5.3 (4.8, 6.0)²  
[32] 
6.4 (4.0, 10.2)¹ 
6.4 (5.7, 7.3)²ddd 
[30] 
p value <0.001 0.069 0.002 0.006 0.050 
Abbreviations: GW, gestational week; MTHFR, methylenetetrahydrofolate reductase; SLC19A1, solute carrier family 19 member 1 (reduced folate 
carrier). 1Median (P10, P90). 2 Geometric mean (95% confidence interval).  Geometric means were compared between time points using ANOVA 
for repeated measures and between genotypes using ANOVA (post hoc Bonferroni p value are shown). *P<0.05, **p<0.01 TT/GG compared to 
CC/GA genotype. †p<0.05, ††p<0.01 TT/GG compared to CC/AA genotype. ʃ p<0.05 TT/GG compared to CT/GG genotype. ^^p<0.01 TT/GG compared 
to CC/GG. ≠p<0.05, ≠≠p<0.05 TT/GG compaed to CT/GA genotype.  §p<0.05 TT/GA compared to CC/GA genotype. ɸp<0.05, ɸɸp<0.01 TT/GA 
compared to CC/AA genotype. ∞P<0.05 TT/GA compared to CT/GG. £TT/GA compared to CC/GG genotype. }P<0.05 TT/GA compared to CT/GA 
genotype. $p<0.05, $$$p<0.001 CC/GG compared to CC/GA genotype. #p<0.05, ##p<0.01 CC/GG compared to CC/AA genotype. ap<0.05, aap<0.01, 
aaap<0.001 compared with <12 GW,  bp<0.05, bbp<0.01, bbbp <0.001 compared with 15GW,  cp <0.05,  ccp <0.01, cccp <0.001 compared with 24-
27GW,  dp <0.05,  ddp <0.01,  dddp <0.001 compared with 34GW. 
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There was a significant interaction between folic acid supplementation and plasma 
and red blood cell folate status according to MTHFR 677 C>T and SLC19A1 80G>A 
genotypes. People with the MTHFR 677 TT genotype had lower plasma folate 
concentrations than people with the CC and CT variants, even though they were 
taking folic acid supplements.  
Folate and tHcy status according to genotypes in fathers and cords are reported in 
Tables 8 and 9. Paternal tHcy was higher in the MTHFR 677 TT genotype compared 
to CC and CT genotypes. It did not differ among the SLC19A1 80 G>A genotypes. 
THcy was highest for the MTHFR 677 TT + SLC19A1 80 AA and MTHFR 677 TT + 
SLC19A1 80 GA genotype combinations (Table 8). Cord tHcy also differs among 
maternal MTHFR 677 C>T genotypes, with the highest concentration for the TT 
genotype (Table 9). 
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Table 8. Paternal one carbon metabolism status according to MTHFR 677C>T, SLC19A1 80 
G>A and the combination of both genotypes. 
Genotype Plasma 
folate 
(nmol/L) 
Erythrocyte folate 
(nmol/L) 
Plasma B12 
(pmol/L) 
Plasma 
homocysteine 
(µmol/L) 
MTHFR 677 C>T genotype 
      CC 9.2  
(4.5, 17.0)¹  
474.2  
(192.5, 806.1)¹   
371.2 
 (291.5, 519.4)¹   
9.3  
(7.3, 12.0)¹   
 8.9  
(8.2, 9.7)²  
[136] 
431.7  
(393.7, 473.5)²  
[128] 
379.9  
(362.2, 398.6)² 
[136] 
9.3  
(9.0, 9.7)²  
[136] 
      CT 8.9  
(4.8, 17.2)¹     
461.0  
(233.8, 804.9)¹     
374.5  
(273.2, 578.6)¹   
9.4  
(7.5, 12.7)¹   
 9.1  
(8.4, 9.7)² 
[189] 
439.8  
(409.9, 471.9)²  
[183] 
385.5  
(369.4, 402.2)² 
[188] 
9.7 
(9.4, 10.0)²  
[189] 
      TT 7.1  
(4.1, 18.1)¹   
396.9  
(146.0, 782.2)¹   
336.9 
 (248.2, 586.9)¹   
10.9  
(8.0, 19.4)¹   
 7.8  
(6.7, 9.1)²  
[53] 
343.5  
(290.0, 406.8)² *†† 
[50] 
356.9 
 (328.9, 387.3)² 
[53] 
12.3  
(10.8, 13.9)²*** ††† 
[53] 
p value  0.156 0.010 0.235 <0.001 
SLC19A1 80 G>A genotype 
      GG 8.7  
(4.7, 16.8)¹   
417.4  
(174.4, 714.4)¹      
378.5  
(268.2, 617.2)¹    
9.5  
(7.6, 12.7)¹   
 8.8 
 (8.0, 9.7)² 
[104] 
400.0  
(360.8, 443.4)² 
[99] 
394.9  
(369.3, 422.4)² 
[103] 
9.8  
(9.4, 10.2)² 
[104] 
      GA 9.0 
 (4.2, 16.5)¹        
481.3  
(213.9, 844.0)¹      
356.1  
(283.5, 526.4)¹   
9.4  
(7.4, 13.7)¹    
 8.7  
(8.1, 9.5)²  
[162] 
449.2  
(413.2, 488.3)² 
[154] 
368.9  
(354.4, 384.0)² 
[162] 
9.9  
(9.4, 10.3)² 
[162] 
      AA 8.9 
 (4.6, 18.6)¹   
455.9  
(185.5, 734.9)¹      
384.7 
 (261.4, 574.2)¹   
9.6  
(7.5, 15.4)¹ 
 9.0  
(8.2, 9.9)²  
[109] 
412.3  
(373.2, 455.4)² 
[105] 
381.8  
(362.1, 402.7)² 
[109] 
10.0  
(9.5, 10.7)² 
[109] 
p value 0.880 0.179 0.173 0.770 
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Table 8. Paternal one carbon metabolism status according to MTHFR 677 C>T, SLC19A1 80 
G>A and the combination of both genotypes. 
Genotype Plasma 
folate 
(nmol/L) 
Erythrocyte folate 
(nmol/L) 
Plasma B12 
(pmol/L) 
Plasma 
homocysteine 
(µmol/L) 
MTHFR 677 C>T   + SLC19A1 80 G>A genotype 
     CC-GG 8.6  
(4.4, 16.6)¹       
463.9  
(227.4, 843.0)¹  
349.0  
(291.5, 544.5)¹  
8.5  
(7.1, 12.4)¹  
 8.6  
(7.3, 10.2)² 
[37] 
431.1  
(362.2, 513.3)²  
[36] 
388.7 
 (346.6, 435.9)²  
[37] 
9.1 
 (8.4, 9.8)²  
[37] 
    CC-GA 9.1  
(4.2, 16.5)¹       
396.2  
(167.6, 745.1)¹  
378.7  
(296.5, 521.2)¹  
9.3 
 (7.4, 11.9)¹ 
 8.7  
(7.6, 9.9)²  
[65] 
415.8  
(358.5, 482.3)²  
[60] 
378.0  
(355.4, 402.0)²  
[65] 
9.5  
(8.9, 10.0)²  
[65] 
    CC-AA 9.6  
(4.9, 18.2)¹  
534.2  
(225.3, 748.4)¹ 
379.5  
(276.4, 580.9)¹  
9.6 
 (6.9, 12.4)¹      
 9.6  
(8.2, 11.2)² 
[35] 
469.1  
(400.2, 549.8)²  
[33] 
376.1  
(342.5, 412.9)²  
[35] 
9.4 
 (8.7, 10.1)²  
[35] 
    CT-GG 8.8  
(5.0, 18.6)¹   
377.7  
(183.4, 672.3)¹  
391.1  
(261.9, 650.8)¹  
9.9  
(8.1, 12.9)¹   
 9.0  
(7.8, 10.3)²  
[50] 
412.7  
(361.5, 471.2)²  
[49] 
405.7  
(367.3, 448.1)²  
[49]  
10.2 
 (9.7, 10.8)²  
[50] 
    CT-GA 9.5  
(4.3, 17.4)¹  
486.0  
(247.1, 848.9)¹  
342.6 
 (272.5, 572.9)¹  
9.4 
 (7.4, 13.4)¹  
 9.1  
(8.2, 10.2)²  
[83] 
480.8 
 (430.8, 536.6.5)²  
[80] 
363.9  
(342.6, 386.5)²  
[83] 
9.6  
(9.1, 10.1)² 
[83] 
    CT-AA 8.7  
(5.2, 17.4)¹   
464.4 
 (224.0, 728.9)¹   
401.6  
(309.8, 564.0)¹   
9.0  
(7.4, 13.0)¹   
 9.1  
(7.9, 10.5)²   
[54] 
427.1 
 (374.4, 487.4)²  
[52] 
406.1  
(378.5, 435.7)²  
[54] 
9.4  
(8.8, 10.0)² 
[54] 
    TT-GG 7.8  
(4.3, 19.2)¹  
307.6  
(134.2, 710.8)¹  
364.0  
(232.6, 634.2)¹  
9.3  
(6.9, 16.4)¹  
 8.5 
(6.4, 11.5)² 
[17] 
295.5  
(205.8, 424.4)²   
[14] 
378.3  
(316.0, 452.9)²  
[17] 
10.0  
(8.6, 11.7)²  
[17] 
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Table 8. Paternal one carbon metabolism status according to MTHFR 677 C>T, SLC19A1 80 
G>A and the combination of both genotypes. 
Genotype Plasma 
folate 
(nmol/L) 
Erythrocyte folate 
(nmol/L) 
Plasma B12 
(pmol/L) 
Plasma 
homocysteine 
(µmol/L) 
    TT-GA 6.5  
(3.7, 14.3)¹  
481.8  
(248.5, 849.5)¹  
389.0 
 (282.1, 502.9)¹  
11.3  
(9.2, 45.0)¹  
 7.1  
(5.6, 9.0)²  
[16] 
456.7  
(357.1, 584.1)²  
[16] 
367.3  
(329.7, 409.1)²  
[16] 
13.5 
 (10.3, 17.8)²  ɸɸɸ 
[16] 
    TT-AA 7.5 
 (2.9, 19.0)¹   
308.4  
(116.4, 784.1)¹   
311.3  
(248.2, 588.4)¹   
12.2  
(7.8, 30.0)¹   
 7.7  
(5.8, 10.4)²  
[20] 
303.8  
(228.1, 404.6)² §§ 
[20] 
332.0  
(287.3, 383.6)²  
[20] 
13.5  
(10.8, 16.8)² ᶴ ᶴ ᶴ    
[20] 
p value 0.647 0.006  0.142 <0.001 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; SLC19A1, solute carrier family 19 
member 1 (reduced folate carrier).1 Median (P10, P90). 2 Geometric mean (95% confidence interval) [n]. 
Geometric means were compared between genotypes using ANOVA, with post hoc Bonferroni 
correction for multiple comparisons. *P<0.05, ***p<0.001 TT compared to CC genotype. ††p<0.01 
†††p<0.001 TT compared to CT genotype. §§p<0.01 TT/AA compared to CT/GA genotype. ᶴ ᶴ ᶴp<0.001 
TT/AA compared to other genotypes except TT/GA. ɸɸɸp<0.001 TT/GA compared to other genotypes 
except TT/AA. 
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Table 9. Cord one carbon metabolism status according to MTHFR 677 C>T, SLC19A1 80 
G>A and the combination of both genotypes. 
Genotype Plasma folate 
(nmol/L) 
Plasma B12 
(pmol/L) 
Plasma 
homocysteine 
(µmol/L) 
MTHFR 677 C>T genotype 
CC 23.5 (11.3, 53.5)¹       322.4 (121.2, 677.7)¹          4.5 (3.1, 6.6)¹  
 24.2 (22.2, 26.3)² 
[186] 
314.6 (284.1, 348.3)²  
[180] 
4.5 (4.3, 4.7)²  
[186] 
CT 27.0 (13.1, 56.9)¹ 351.7 (138.9, 637.2)¹ 4.9 (3.3, 6.8)¹       
 26.6 (24.7, 28.5)² 
[238] 
326.9 (303.1, 352.5)² 
[231] 
4.8 (4.6, 5.0)²  
[238] 
TT 28.1 (11.9, 55.6)¹  336.1 (155.5, 640.8)¹             5.4 (3.6, 7.8)¹  
 26.9 (24.0, 30.1)² 
[97] 
311.3 (273.2, 354.8)² 
[93] 
5.3 (4.9, 5.6)²***  
[97] 
p value 0.168 0.754 0.001 
SLC19A1 80 G>A genotype 
GG 26.1 (12.7, 54.4)¹         348.6 (185.1, 660.7)¹       4.9 (3.3, 7.0)¹    
 25.7 (23.5, 28.1)² 
[134] 
329.1 (297.4, 364.3)² 
[132] 
4.9 (4.6, 5.2)² 
[134] 
GA 26.1 (12.2, 57.8)¹         356.5 (120.1, 621.5)¹        4.7 (3.4, 6.5)¹  
 26.0 (24.1, 28.1)² 
[241] 
320.6 (294.0, 349.7)² 
[232] 
4.8 (4.6, 4.9)² 
[241] 
AA 25.8 (11.7, 52.8)¹       337.1 (125.7, 679.9)¹      4.8 (3.0, 6.9)¹  
 25.4 (23.2, 27.8)² 
[142] 
315.1 (284.3, 349.3)² 
[136] 
4.7 (4.5, 5.0)² 
[142] 
p value 0.913 0.852 0.633 
MTHFR 677 C>T   + SLC19A1 80 G>A genotype 
CC-GG 27.0 (13.0, 58.5)¹ 334.4 (156.8, 660.3)¹ 4.8 (3.6, 6.6)¹ 
 27.0 (23.2, 31.5)² 
[54] 
321.3 (264.2, 390.9)² 
[53] 
4.8 (4.4, 5.1)²  
[54] 
CC-GA 23.2 (10.7, 47.3)¹  351.2 (161.6, 723.2)¹  4.4 (3.1, 6.6)¹  
 23.6 (20.8, 26.8)² 
[85] 
303.9 (258.1, 357.9)² 
[83] 
4.4 (4.1, 4.7)²  
[85] 
CC-AA 20.5 (10.5, 53.3)¹  351.2 (163.1, 731.7)¹  4.3 (3.1, 6.5)¹  
 22.0 (18.2, 26.6)² 
[46] 
335.2 (283.5, 396.2)² 
[43] 
4.4 (4.0, 4.9)²  
[46] 
CT-GG 24.7 (14.2, 46.1)¹  344.8 (177.2, 557.4)¹  5.1 (3.1, 7.4)¹  
 24.6 (21.8, 27.7)² 
[56] 
330.0 (290.8, 374.4)² 
[55] 
4.9 (4.5, 5.4)²  
[56] 
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Table 9. Cord one carbon metabolism status according to MTHFR 677 C>T, SLC19A1 80 
G>A and the combination of both genotypes. 
Genotype Plasma folate 
(nmol/L) 
Plasma B12 
(pmol/L) 
Plasma 
homocysteine 
(µmol/L) 
CT-GA 28.4 (12.6, 67.0)¹  382.8 (133.8, 641.4)¹  4.8 (3.6, 6.4)¹  
 28.3 (25.0, 32.0)² 
[107] 
337.0 (297.1, 382.3)² 
[103] 
4.8 (4.6, 5.1)²  
[107] 
CT-AA 27.7 (13.2, 50.4)¹   329.8 (123.4, 642.5)¹   4.8 (2.9, 6.9)¹   
 26.0 (23.3, 29.1)²  
[71] 
317.2 (276.2, 364.2)² 
[69] 
4.7 (4.4, 5.2)²  
[71] 
TT-GG 27.6 (8.9, 53.6)¹   338.4 (161.1, 711.6)¹  5.1 (3.7, 8.4)¹  
 25.5 (19.7, 33.1)² 
[24] 
345.0 (272.0, 437.5)² 
[24] 
5.1 (4.3, 6.0)²  
[24] 
TT-GA 25.2 (11.8, 48.7)¹   334.5 (134.7, 613.1)¹   5.3 (3.5, 7.8)¹   
 25.4 (21.6, 30.0)² 
[47] 
310.6 (259.9, 371.0)² † 
[44] 
5.3 (4.8, 5.8)²  
[47] 
TT-AA 30.2 (15.3, 65.7)¹   327.0 (55.0, 722.0)¹  5.7 (3.0, 8.1)¹  
 30.7 (24.8, 38.0)² 
[25] 
277.1 (198.7, 386.4)² 
[24] 
5.4 (4.7, 6.1)² 
[25] 
p value 0.180 0.917 0.025 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; SLC19A1, solute carrier family 19 
member 1.1 Median (P10, P90). 2 Geometric mean (95% confidence interval) [n]. Geometric means 
were compared between genotypes using ANOVA, with post hoc Bonferroni correction for multiple 
comparisons. ***p<0.001 TT compared to CC genotype. †p<0.05 TT/GA compared to CC/GA 
genotype.  
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The prevalences of the pregnancy outcomes investigated in the study are reported 
in Table 10. 
Table 10. Prevalences of the pregnancy outcomes included in the study.¹ 
Outcomes % N 
Pathological Doppler of 
uterine artery flow at 20GW² 
19.2 (16.3, 22.5) 117/609 
Gestational Hypertension³ 11.8 (9.5, 14.6) 75/635 
Intrauterine Growth 
Retardation4 
8.8 (6.9, 11.3) 56/726 
1 All data shown are percentages (95% confidence interval). 
2 Defined as the mean of pulsatility index of right and left uterine arteries ≥P95 or the 
presence of a bilateral notch in the uterine artery waveforms. 
3 Defined as systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 
mmHg. 
4 According to the Spanish Obstetrics and Gynaecology guidelines. 
 
In Table 11 the prevalence of pregnancy outcomes studied (pathological doppler, 
gestational hypertension and IUGR) according to maternal and paternal MTHFR 677 
C>T and SLC19A1 80 G>A genotypes and the combination of both are reported. 
Regarding the MTHFR 677 C>T genotype alone, there was no difference in 
prevalence of any of the adverse outcomes among the maternal or paternal 
genotypes. In the case of the SLC19A1 80 G>A genotype, intrauterine growth 
retardation was more prevalent in the paternal homozygote variant genotype (AA). 
No differences in prevalence in any of the outcomes was observed among the 
maternal genotypes and the combination of both paternal genotypes. 
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Table 11. Pregnancy outcomes prevalence according to maternal and paternal MTHFR 677 C>T, SLC19A1 80 G>A and the combination of 
both genotypes¹. 
 Pathological Doppler2 Gestational hypertension3  IUGR4 
 Maternal Paternal Maternal Paternal Maternal Paternal 
MTHFR 677 C>T genotype 
   CC 21.1 (16.0, 27.3) 
[42/199] 
15.2 (10.0, 22.2) 
[20/132] 
12.8 (8.9, 18.1) 
[26/203] 
8.9 (5.2, 14.9) 
[12/135] 
8.2 (5.3, 12.4)  
[19/233] 
8.6 (5.0, 14.5) 
[12/139] 
   CT 20.7 (16.3, 26.0) 
[56/270] 
18.8 (13.8, 25.1) 
[34/181] 
30.1 (22.1, 39.5) 
[31/308] 
12.8 (8.6, 18.6) 
[22/172] 
7.0 (4.8, 10.2) 
[24/342] 
5.2 (2.9, 9.4) 
[10/191] 
   TT 17.5 (11.3, 25.9) 
[18/103] 
24.5 (14.6, 38.1) 
[12/49] 
12.8 (7.5, 21.0) 
[12/94] 
12.0 (5.6, 23.8) 
[6/50] 
10.4 (6.1, 17.4) 
[12/115] 
9.3 (4.0, 19.9) 
[5/54] 
SLC19A1 80 G>A genotype 
   GG 20.1 (14.6, 27.2) 
[31/154] 
13.0 (7.8, 21.0) 
[13/100] 
11.8 (7.7, 17.7) 
[19/161] 
7.8 (4.0, 14.7) 
[8/102] 
8.1 (4.9, 12.9) 
[15/186] 
6.6 (3.2, 13.0) 
[7/106] 
   GA 19.6 (15.3, 24.8) 
[52/265] 
18.0 (12.7, 24.9) 
[27/150] 
10.1 (7.1, 14.1) 
[29/287] 
10.1 (6.2, 16.0) 
[15/148] 
7.9 (5.4, 11.4) 
[25/317] 
3.1 (1.3, 7.0) 
[5/163] 
   AA 21.2 (15.4, 28.4) 
[32/151] 
21.8 (15.1, 30.4) 
[24/110] 
13.5 (9.0, 19.7) 
[21/156] 
16.3 (10.5, 24.6) 
[17/104] 
8.2 (5.0, 13.0) 
[15/184] 
13.4 (8.3, 20.9)** 
[15/112] 
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 Pathological Doppler2 Gestational hypertension3 IUGR4 
 Maternal Paternal Maternal Paternal Maternal Paternal 
MTHFR 677 C>T   + SLC19A1 80 G>A genotype 
   CC-GG 13.1 (6.8, 23.8) 
[8/61] 
11.1 (4.4, 25.3) 
[4/36] 
10.6 (5.2, 20.3) 
[7/66] 
5.6 (1.5, 18.1) 
[2/36] 
5.5 (2.2, 13.3) 
[4/73] 
10.5 (4.2, 24.1)  
[4/38] 
   CC-GA 24.4 (16.7, 34.2) 
[22/90] 
17.7 (10.2, 29.0) 
[11/62] 
11.0 (6.1, 19.1) 
[10/91] 
9.2 (4.3, 18.7) 
[6/65] 
6.8 (3.3, 13.4) 
[7/103] 
4.5 (1.5, 12.4) 
[3/67] 
   CC-AA 25.0 (14.9, 38.8) 
[12/48] 
14.3 (6.3, 29.4) 
[5/35] 
19.6 (10.7, 33.2) 
[9/46] 
11.4 (4.5, 26.0) 
[4/35] 
14.0 (7.3, 25.3) 
[8/57] 
14.3 (6.3, 29.4) 
[5/35] 
   CT-GG 25.0 (16.0, 36.8) 
[16/64] 
16.3 (8.5, 29.0) 
[8/49] 
12.7 (6.8, 22.4) 
[9/71] 
10.4 (4.5, 22.2) 
[5/48] 
7.5 (3.5, 15.4) 
[6/80] 
4.0 (1.1, 13.5) 
[2/50] 
   CT-GA 19.1 (13.4, 26.5) 
[26/136] 
15.8 (9.3, 25.6) 
[12/76] 
8.3 (4.9, 13.7) 
[13/156] 
11.3 (5.8, 20.7) 
[8/71] 
8.2 (4.9, 13.3) 
[14/171] 
1.2 (0.2, 6.6) 
[1/82] 
   CT-AA 19.1 (11.5, 30.0) 
[13/68] 
21.8 (12.9, 34.4) 
[12/55] 
11.3 (6.0, 20.0) 
[9/80] 
17.6 (9.6, 30.3) 
[9/51] 
4.5 (1.8, 11.1) 
[4/88] 
12.3 (6.1, 23.2) 
[7/57] 
   TT-GG 24.1 (12.2, 42.1) 
[7/29] 
6.7 (1.2, 29.8) 
[1/15] 
12.5 (4.3, 31.0) 
[3/24] 
5.6 (1.0, 25.8) 
[1/18] 
15.2 (6.7, 30.9) 
[5/33] 
5.6 (1.0, 25.8) 
 [1/18] 
   TT-GA 10.3 (4.1, 23.6) 
[4/39] 
28.6 (11.7, 54.6) 
[4/14] 
15.0 (7.1, 29.1) 
[6/40] 
7.1 (1.3, 31.5) 
[1/14] 
9.3 (3.7, 21.6) 
[4/43] 
6.3 (1.1, 28.3) 
[1/16] 
   TT-AA 20.0 (10.0, 35.9) 
[7/35] 
35.0 (18.1, 56.7) 
[7/20] 
10.0 (3.5, 25.6) 
[3/30] 
22.2 (9.0, 45.2) 
[4/18] 
7.7 (2.7, 20.3) 
[3/39] 
15.0 (5.2, 36.0) 
[3/20] 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; SLC19A1, solute carrier family 19 member 1. 1All data shown are percentages (95% 
confidence interval). 2 Defined as the mean of pulsatility index of right and left uterine arteries ≥P95 or the presence of a bilateral notch. 3 Defined as 
systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg. 4 According to the Spanish Obstetrics and Gynaecology guidelines. 
Prevalence of the outcomes among the genotypes for each polymorphism were compared by the chi-square test. **P<0.01 TT compared to CC genotype. 
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4.2. One carbon metabolism and uterine artery pulsatility index 
 
Maternal MTHFR 677C>T genotype, uterine artery resistance (pulsatility 
index) and impaired placentation (pathological doppler measurements of 
uterine artery flow and waveforms). 
 
We investigated the association between maternal MTHFR 677C>T genotype and 
pulsatility index of the uterine arteries at 20 GW (dependent variable natural log 
transformed mean of the right and left uterine artery pulsatility index) using 
multiple linear regression analysis. The models included SLC19A1 80G>A genotype, 
and red blood cell folate and plasma cobalamin concentrations (at <12 GW and 15 
GW, in separate models). They were further adjusted for smoking habit during 
pregnancy, socioeconomic status, age, 1st trimester BMI, parity and gestational age 
in weeks and days at the time of the doppler measurement. None of the models 
were significant (data not shown). Impaired placentation is characterised as 
pathological when the mean uterine artery pulsatility index is elevated (≥P95) and/ 
or by the presence of bilateral notches in the uterine artery waveforms analysed by 
Doppler echography. Analysis of the association between maternal MTHFR 
genotype and pathological placentation using multiple logistic regression analysis in 
which the dependent variable was pathological Doppler outcome, and adjusting the 
models for the same confounding factors as described for uterine artery pulsatility 
index, also showed that there was no association.  
 
Maternal tHcy status and pulsatility index of uterine arteries 
 
We studied the association between early pregnancy tHcy at <12 and 15 GW, in 
separate models) and pulsatility index of uterine arteries using multiple linear 
regression analysis. The dependent variable was natural log transformed mean right 
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and left uterine artery pulsatility index. THcy was included in the models and they 
were adjusted for smoking during the first trimester only versus never, smoking 
throughout pregnancy versus never, mid and high versus low socioeconomic status, 
maternal age, 1st trimester BMI, parity (previous pregnancy <20 GW versus none) 
and gestational weeks at doppler measurement. The models were not significant. 
We repeated the analysis using the variable elevated tHcy status during early 
pregnancy (≥P90). While the model was not significant, the association between 
tHcy ≥P90 and pulsatility index was positive with a beta coefficient of 0.075 (P= 
0.059). We then investigated whether elevated early pregnancy tHcy was associated 
with impaired placentation (pathological measurement by Doppler echography at 
20 GW) using multiple logistic regression analysis. The categorical tHcy variable 
(≥P90 tHcy in early pregnancy versus <P90) replaced the genotypes, red blood cell 
folate and plasma cobalamin variables described in the models in the previous 
section at <12 and at 15 GW. The models were adjusted for smoking habit, 
socioeconomic status, BMI, age, parity and gestational age at doppler 
measurement. There was no association between elevated early pregnancy tHcy 
status and impaired placentation. 
 
Paternal genotype and uterine artery pulsatility index 
 
The association between paternal MTHFR 677C>T genotype and uterine artery 
pulsatility index was studied using multiple linear regression analysis. We performed 
the same maternal models, as at <12 and 15 GW, adding paternal MTHFR 677C>T, 
red blood cell folate concentration, age and smoking habit. The results are shown in 
Table 12. 
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Table 12. Predictors (Beta coefficients) of pulsatility index of uterine arteries according to 
paternal MTHFR 677 C>T genotype. 
  < 12 GW 15 GW 
Model 1  
(maternal, non adjusted) 
Model, R2, n 0.004, 
310 
-0.010, 186 
 Maternal MTHFR  
677TT genotype 
0.027 -0.102 
Model 2  
(maternal, adjusted)  
Model, R2, n 0.024, 
310# 
0.068, 186* 
 Maternal MTHFR  
677TT genotype 
0.011 -0.083 
 Maternal smoking throughout 
pregnancy vs never 
-0.088 -0.154* 
 Maternal BMI 0.005 0.207** 
Model 3  
(maternal adjusted 
and paternal factors) 
 
Model, R2, n 0.057, 
310** 
0.149, 186*** 
 Maternal MTHFR  
677TT genotype 
0.007 -0.088 
 Maternal smoking throughout 
pregnancy vs never 
-0.130* -0.168* 
 Maternal BMI -0.011 0.179* 
 Paternal MTHFR 677CT genotype 0.161** 0.205** 
 Paternal MTHFR 677TT genotype 0.131* 0.226** 
 Paternal age 0.126 0.084 
 Paternal smoking 0.109† 0.167* 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; BMI, body mass index; GW, 
gestational weeks. Excluded 2 outliers. Multiple linear regression analysis. Dependent variable, 
natural log transformed mean of the uterine artery pulsatility index of uterine arteries (PI). 
Independent variable for Model 1: maternal MTHFR 677 CT and TT versus MTHFR 677 CC genotype, 
maternal SLC19A1 80 GA and AA versus 80 GG genotype, low tertile red blood cell folate (<= 724.33 
nmol/L) and low tertile plasma cobalamin (<= 315.45 pmol/L) concentration at the corresponding 
time points of pregnancy for each model. Model 2: same variables as model 1 as well as smoking 
during the first trimester and throughout pregnancy versus never, mid and high versus low 
socioeconomic status, maternal age (y), 1st trimester BMI and parity (previous pregnancy versus 
none). Model 3 (paternal factors): same variables as model 2 as well as paternal MTHFR 677 CT and 
TT versus MTHFR 677CC genotype, red blood cell folate levels, age and smoking. *p<0.05, **p<0.01. 
#P= 0.086, †P= 0.067 
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The results show a positive association between paternal MTHFR 677 CT and TT vs 
CC genotypes and pulsatility index of uterine arteries in all models. Paternal smoking 
habit was also positively associated with uterine artery pulsatility index at 20 GW. 
As we observed before, maternal genotype was not associated. Maternal BMI was 
positively associated and smoking throughout pregnancy versus never was 
negatively associated with uterine artery pulsatility index. 
 
 
Paternal tHcy status and uterine artery pulsatility index  
 
The association between paternal tHcy and mean left and right uterine artery 
pulsatility index was investigated using multiple linear regression analysis. The 
dependent variable was the natural log transformed mean pulsatility index. We built 
on the maternal models by adding paternal tHcy concentrations, age and smoking 
habit. Paternal tHcy was positively associated with pulsatility index at <12 and 15 
GW. There was no association between maternal tHcy and pulsatility index.  
When we repeated the analysis including elevated tHcy (≥P90 versus <P90) at <12 
GW and elevated paternal tHcy , the model was also significant (n= 364, Adjusted R2 
=0.044, P= 0.005) and the results indicate a positive association between elevated 
paternal tHcy and increased uterine artery pulsatility index (paternal tHcy ≥P90 Beta 
coefficient= 0.151, P= 0.004). Paternal smoking compared to nonsmoking was also 
associated with increased uterine artery pulsatility index (Beta coefficient= 0.102, 
P= 0.060).  
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Paternal genotype and pathological Doppler measurement of uterine 
arteries at 20 GW 
 
We studied the association between paternal MTHFR 677C>T genotype and risk of 
pathological Doppler measurement of uterine arteries at 20 GW using multiple 
logistic regression analysis. We added the paternal factors MTHFR 677C>T 
genotype, age, smoking habit and red blood cell folate concentration to the same 
models used for the mothers, at <12 and 15 GW. The first model was not significant. 
Results from the model at 15 GW are shown.  
 
Table 13. Associations between paternal MTHFR 677C>T genotype and pathological 
Doppler measurement of the uterine arteries at 20 GW. 
 N R2 Maternal 
TT vs CC 
Paternal 
CT vs CC 
Paternal 
TT vs CC 
Paternal 
smoking 
Model 1  
(maternal, 
non adjusted) 
191 0.130* 0 - - - 
Model 2 
(maternal, 
adjusted) 
191 0.178# 0 - - - 
Model 3 
(maternal 
adjusted and 
paternal 
factors) 
192 0.358*** 0 4.0  
(1.3, 12.6) 
7.1 
(1.6, 32.8) 
3.2  
(1.3, 7.9) 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase. Multiple logistic regression 
analysis was used. Nagelkerke R2; OR (95% CI) for pathological Doppler measurement of the 
uterine arteries at 20 GW in mothers with MTHFR 677 CC vs CT and MTHFR 677 CC vs TT 
genotype are shown. Model 1: (basic model) comparing MTHFR 677 CC vs CT and MTHFR 677 
CC vs TT and SLC19A1 80GG vs GA and SLC19A1 80GG vs AA maternal genotypes. Model 2: 
Included the same variables as model 1 as well as lifestyle factors such as parity (previous 
pregnancy versus none), maternal age (y), 1st trimester BMI, smoking during pregnancy, mid 
and high versus low socioeconomic status, gestational age at doppler measurement, low 
tertile red blood cell folate (<= 724.33 nmol/L) and low tertile plasma cobalamin (<= 315.45 
pmol/L) concentration at 15 GW. Model 3: Included the same variables as model 2 as well as 
paternal MTHFR 677 CC vs CT and MTHFR 677 CC vs TT genotype, paternal red blood cell 
levels, age and paternal smoking habit. *p<0.05, **p<0.01. #P=0.051.  
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There is a clear association between paternal factors and increased risk of 
pathological Doppler assessment of the uterine arteries at 20 GW. Paternal MTHFR 
677 CT and TT were associated with four and seven times, respectively, more risk of 
pregnancy affected by impaired placentation compared to fathers with the MTHFR 
677 CC genotype. Paternal smoking also conveyed a threefold greater risk. Paternal 
red blood cell folate had a small but significant protective effect against impaired 
placentation OR (95% CI) 0.99 (0.99, 0.99). 
 
 
Paternal tHcy status and pathological Doppler measurement of the uterine 
arteries at 20 GW 
 
We investigated whether elevated paternal tHcy status is associated with risk of 
pathological Doppler measurement of the uterine arteries at 20 GW. The categorical 
maternal tHcy variable (≥P90 tHcy in early pregnancy versus <P90) replaced 
genotypes, red blood cell folate and plasma cobalamin variables in each model, 
described in the previous section for <12 and 15 GW. We included elevated paternal 
tHcy status (≥P90) and smoking habit in both models. The results are shown below 
in Table 14.  
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
144 
 
Table 14. Associations between paternal tHcy levels and pathological Doppler 
measurement of the uterine arteries at 20 GW. 
 N R2 Maternal 
tHcy ≥ P90 
Paternal 
tHcy ≥ P90 
Paternal 
smoking 
Model 1  
(maternal, non 
adjusted) 
370 0.001 1.3 (0.6, 2.9) - - 
Model 2 (maternal, 
adjusted) 
370 0.045 1.3 (0.5, 3.0) - - 
Model 3 
(maternal adjusted 
and paternal factors) 
370 0.089* 1.3 (0.5, 3.1) 2.7 (1.2, 6.0) 1.9 (1.0, 3.3) 
Abbreviations: tHcy, plasma total homocysteine. Multiple logistic regression analysis was used. 
Nagelkerke R2; OR (95% CI) for pathological Doppler measurement of the uterine arteries at 20 
GW in mothers with tHcy levels ≥ P90 at early pregnancy versus other percentiles. P90 tHcy cut 
offs (μmol/L) were <12GW 7.11, 15 GW 5.85, 34 GW 7.25, labour 8.52. Model 1: (basic model) 
comparing tHcy levels ≥P90 at early pregnancy versus other percentiles. Model 2: Included the 
same variables as model 1 as well as lifestyle factors such as parity (previous pregnancy versus 
none), maternal age (y), 1st trimester BMI, smoking during pregnancy, mid and high versus low 
socioeconomic status, and gestational age (w) at doppler measurement. Model 3: Included the 
same variables as model 2 as well as paternal tHcy levels ≥P90 (≥ 14.1 µmol/L). *p<0.05, 
**p<0.01. 
 
Elevated paternal homocysteine levels and smoking habit were associated with 
increased risk of pathological Doppler measurement of uterine arteries at 20 GW. 
Maternal tHcy was not associated. 
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4.3. One carbon metabolism and birthweight 
 
Association between maternal genotype and birthweight 
 
We investigated the association between maternal MTHFR 677C>T genotype and 
birthweight using multiple linear regression analysis. 3 models were designed to 
adjust for maternal folate and cobalamin status at different times of pregnancy (first 
trimester, mid-pregnancy, late pregnancy). We included the interaction term 
MTHFR 677C>T genotype * smoking habit during pregnancy in the model. This was 
significant in the 1st trimester (P=0.024). Therefore, we proceeded to carry out 
stratified analyses according to smoking habit (never smoking or smoking at some 
point of pregnancy). We excluded participants with gestational diabetes from these 
analyses. The results are shown in Table 15.  
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Table 15. Association between maternal genotype and birthweight, according to 
smoking habit during pregnancy (Beta coefficients). 
  1st trimester 34 GW Labour 
Non smokers     
Basic model Model, R2, n 0.001, 427 -0.005, 388 -0.002, 344 
 MTHFR 677TT 
genotype 
0.0004 0.042 0.017 
 SLC19A1 80GA 
genotype 
-0.051 0.005 -0.00003 
 Low tertile RBCF 0.095† -0.050 -0.028 
Complete model Model, R2, n 0.298,427*** 0.283, 388*** 0.271, 344*** 
 MTHFR 677TT 
genotype 
-0.018 0.025 0.026 
 SLC19A1 80GA 
genotype 
0.022 0.016 0.020 
 Low tertile RBCF 0.064 -0.081§ -0.069 
Smokers at some point of pregnancy 
Basic model Model, R2, n 0.060, 161* 0.010,146 -0.017,123 
 MTHFR 677TT 
genotype 
0.083 0.053 0.040 
 SLC19A1 80GA 
genotype 
0.169‡ 0.210* -0.053 
 Low tertile RBCF -0.229** -0.024 -0.020 
Complete model Model, R2, n 0.350, 161*** 0.261, 146*** 0.282, 123*** 
 MTHFR 677TT 
genotype 
0.186* 0.161¶ 0.076 
 SLC19A1 80GA 
genotype 
0.102 0.161¥ 0.003 
 Low tertile RBCF -0.175* 0.125 -0.069 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; SLC19A1, solute carrier family 19 
member 1; RBCF, red blood cell folate; GW, gestational weeks. Birth weight was the dependent 
variable in all models. Basic model: MTHFR 677CT versus 677CC genotype, MTHFR 677TT versus 
677CC genotype, SLC19A1 80GA versus 80GG genotype, SLC19A1 80AA versus 80GG genotype, 
low tertile RBCF: ≤708 nmol/L at <12 GW and ≤761 nmol/L at 34 GW, low tertile B12: ≤ 315 
pmol/L at <12 GW, ≤216 pmol/L at 34 GW and ≤199 pmol/L at labour concentrations versus the 
middle and high. Complete model: Smoking during the 1st trimester versus never, smoking 
throughout pregnancy versus never, maternal age (y), 1st trimester BMI, 3rd trimester 
haemoglobin <11 g/dL, parity (previous pregnancy versus none), gestational weeks at birth (w), 
foetal sex. †P=0.056, ‡P=0.080; §P=0.068; ¶P=0.054, ¥P=0.079. 
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The early pregnancy model showed that the MTHFR 677TT genotype was not 
associated with birth weight in non smokers but was positively associated with birth 
weight in smokers. A positive association between the SLC19A1 80GA genotype and 
birth weight was also observed in the basic model but weakened in the adjusted 
model. Low tertile red blood cell folate concentration was inversely associated with 
birthweight in smokers only. Both genotype – birth weight associations were 
confirmed in the mid-pregnancy model. 
Maternal red blood cell folate status and cord plasma folate status according to 
maternal smoking habit and genotype are shown in Table 16. Red blood cell folate 
status was lower in smokers at <12, 24-27 and 34 GW than in non smokers. Red 
blood cell folate status was lower in non-smoking mothers with the MTHFR 677TT 
genotype compared to those with the CC and CT genotype at <12, 24-27 and 34 GW. 
However, there was no difference in red blood cell folate status between genotypes 
in smoking mothers. Cord folate status did not differ among genotypes in any of the 
mothers or between smokers and non smokers. 
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Table 16. Maternal red blood cell folate and cord plasma folate status according to smoking habit and MTHFR 677 C>T genotype. 
 <12 GW 15 GW 24-27 GW 34 GW Cord 
Non smokers 981 (936, 1027) 
[546] 
1283 (1213, 1357) 
[313] 
1184 (1131, 1241) 
[475] 
1054 (960, 1158) 
[457] 
26.2 (24.7, 27.7) 
[428] 
CC 1047 (970, 1131) 
[167] 
1311 (1311, 1311) 
[96] 
1251 (1159, 1350) 
[150] 
1028 (957, 1103) 
[135] 
25.8 (25.7, 25.9) 
[133] 
CT 979 (979, 979) 
[257] 
1312 (1312, 1312) 
[155] 
1169 (1168, 1169) 
[224] 
1029 (1029, 1029) 
[220] 
24.7 (24.6, 24.8) 
[208] 
TT 880† (773, 1001) 
[85] 
1245 (1070, 1449) 
[59] 
1030† (905, 1173) 
[74] 
853† ᶴ (732, 995) 
[72] 
27.6 (27.5, 27.8) 
[69] 
Smokers 853** (788, 924) 
[191] 
1165 (1074, 1265) 
[133] 
1057** (981, 1141) 
[176] 
853*** (783, 929) 
[159] 
25.4 (23.3, 27.8) 
[149] 
CC 917 (916, 917) 
[67] 
1231 (1231, 1231) 
[50] 
1092 (1092, 1092) 
[62] 
873 (873, 873) 
[59] 
24.4 (24.2, 24.5) 
[58] 
CT 822 (822, 822) 
[85] 
1156 (1155, 1156) 
[59] 
1038.1 (1037.9, 1038.2) 
[77] 
864 (864, 864) 
[71] 
25.2 (25.1, 25.4) 
[65] 
TT 787 (787, 787) 
[34] 
1061 (1061, 1061) 
[24] 
994 (994, 994) 
[33] 
789 (788, 789) 
[29] 
28.0 (27.8, 28.1) 
[25] 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; GW, Gestational weeks. Geometric mean (95% confidence interval) [n]. Geometric 
means were compared between groups (non smokers versus smokers) and between genotypes using ANOVA, with post hoc Bonferroni correction 
for multiple comparisons. *P<0.05, **p<0.01 ***p<0.001 smokers compared to non smokers. †p<0.05, ††p<0.01 TT compared to CC genotype. 
ᶴp<0.05, TT compared to CT genotype. 
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Maternal tHcy levels predicting birthweight 
 
Applying the same stratification for smoking during pregnancy as in the 
MTHFR 677C>T models, we also studied the association between early and 
late pregnancy tHcy and birthweight, using multiple linear regression analysis. 
For early pregnancy we tested the association between maternal tHcy ≥P90 
(7.1 µmol/L at <12 GW or 5.9 µmol/L at 15 GW) versus <P90 with birthweight. 
In late pregnancy at (34 GW) and at labour we tested tHcy as a continuous 
variable. The tHcy variables replaced the genotypes and red blood cell folate 
and plasma cobalamin variables in each model. All the models were significant 
and the adjusted R2 ranged from 0.288 to 0.448. The results were confirmed 
when limited to the pregnancies in which the father participated in the study. 
These results are reported together with the fathers in the section on paternal 
tHcy and birth weight below (Table 18). In non-smokers, late pregnancy tHcy 
was positively associated with birthweight.  
 
 
Paternal genotype predicting birthweight 
 
We then investigated the association between paternal MTHFR 677C>T 
genotype and birthweight building on the same multiple linear regression 
model shown for the mothers by adding a final model including paternal 
MTHFR 677C>T genotype, plasma cobalamin and red blood cell folate 
concentrations. The results are shown in Table 17. 
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Table 17. Predictors, including paternal factors, of birth weight according to 
maternal smoking habit. 
  1st trimester 34 GW Labour 
Non smokers     
Adjusted model 
(maternal factors) 
Model, R2, n 0.230, 236*** 0.268, 214*** 0.237, 194*** 
 Maternal 
MTHFR 677TT 
genotype 
-0.011 0.061 -0.070 
 Maternal 
SLC19A1 80GA 
genotype 
-0.074 -0.028 -0.028 
 Maternal low 
tertile RBCF 
0.070 -0.080 -0.058 
 Maternal low 
tertile B12 
0.003 0.111‡ 0.109 
Complete model 
(paternal factors) 
Model, R2, n 0.238, 236*** 0.264, 214*** 0.228, 194*** 
 Maternal 
MTHFR 677TT 
genotype 
-0.023 0.059 -0.075 
 Maternal 
SLC19A1 80GA 
-0.079 -0.038 -0.036 
 Maternal low 
tertile RBCF 
0.080 -0.0075 -0.064 
 Maternal low 
tertile B12 
0.005 0.106 0.107 
 Paternal 
MTHFR 677TT 
genotype 
0.039 0.048 0.043 
 Paternal RBCF 0.114 0.050 0.004 
 Paternal 
plasma B12 
0.025† -0.012 -0.023 
Smokers      
Adjusted model 
(maternal factors) 
Model, R2, n 0.422, 66** 0.402, 60*** 0.429, 51** 
 Maternal 
MTHFR 677TT 
genotype 
0.185 0.163 0.118 
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Table 17. Predictors, including paternal factors, of birth weight according to 
maternal smoking habit. 
  1st trimester 34 GW Labour 
 Maternal 
SLC19A1 80GA 
genotype 
0.093 0.240 -0.019 
 Maternal low 
tertile RBCF 
-0.171 -0.004 -0.040 
 Maternal low 
tertile B12 
0.037 0.067 0.085 
Complete model 
(paternal factors) 
Model, R2, n 0.418, 66**  0.398, 60** 0.457, 51*** 
 Maternal 
MTHFR 677TT 
genotype 
0.213 0.221 0.201 
 Maternal 
SLC19A1 80GA 
0.083 0.252 0.002 
 Maternal low 
tertile RBCF 
-0.172 -0.012 -0.052 
 Maternal low 
tertile B12 
0.035 0.268 0.169 
 Paternal 
MTHFR 677TT 
genotype 
-0.059 0.0003 -0.083 
 Paternal RBCF 0.010 0.025 -0.069 
 Paternal 
plasma B12 
0.203† 0.241# 0.307* 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; SLC19A1, solute carrier family 
19 member 1; RBCF, red blood cell folate; GW, gestational weeks. Birth weight was the 
dependent variable in all models. Basic model: MTHFR 677CT versus 677CC genotype, MTHFR 
677TT versus 677CC genotype, SLC19A1 80GA versus 80GG genotype, SLC19A1 80AA versus 
80GG genotype, low tertile red blood cell folate (<= 724.33 nmol/L) and low tertile plasma 
cobalamin (<= 315.45 pmol/L) concentrations versus the middle and high tertiles at the 
corresponding time points of pregnancy for each model. Second model: Smoking during the 
1st trimester versus never, smoking throughout pregnancy versus never, maternal age (y), 1st 
trimester BMI, 3rd trimester haemoglobin <11 g/dL, parity (previous pregnancy versus none), 
gestational weeks at birth (w), foetal sex. Complete model (paternal factors): paternal MTHFR 
677CT versus 677CC genotype, MTHFR 677TT versus 677CC genotype, paternal cobalamin and 
red blood cell folate status. Beta coefficient values are shown. *p<0.05, **p>0.01, ***p<0.001. 
†p=0.073, ‡p=0.074, #p=0.063.  
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Paternal cobalamin status was positively associated with birth weight. 
Paternal MTHFR 677 C>T genotype and red blood cell folate concentration 
were not associated with birth weight.  
 
Paternal tHcy levels predicting birthweight 
 
Continuing with the same analysis that we performed with the mothers, we 
also studied the association between elevated paternal tHcy (≥P90, 14.1 
µmol/L, versus <P90) and birthweight using multiple linear regression analysis. 
We also applied the same stratification for smoking during pregnancy as in the 
MTHFR 677C>T models. The tHcy variable replaced the genotypes and red 
blood cell folate and plasma cobalamin variables in each model. Results are 
shown in Table 18.  
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Table 18. The associations between maternal and paternal tHcy and birth weight, 
according to maternal smoking habit. 
  1st trimester 34 GW Labour 
Non smokers     
Adjusted model 
(maternal 
factors) 
Model, R2, n 0.255, 289*** 0.295, 263*** 0.240, 274*** 
 Maternal tHcy -0.057 0.193*** 0.129* 
Complete model 
(paternal factors) 
Model, R2, n 0.254, 289*** 0.297, 263*** 0.271, 263*** 
 Maternal tHcy -0.054 0.193*** 0.129* 
 Paternal tHcy 0.043 0.067 -0.006 
Smokers  
Basic model 
(maternal 
factors) 
Model, R2, n 0.399, 75*** 0.367, 65*** 0.425, 67*** 
 Maternal tHcy -0.025 -0.040 -0.040 
Complete model 
(paternal factors) 
Model, R2, n 0.444, 75***  0.443, 69*** 0.450, 67*** 
 Maternal tHcy -0.047 -0.033 -0.039 
 Paternal tHcy -0.234* -0.295** 0.010 
Abbreviations: tHcy, plasma total homocysteine; GW, gestational weeks. Multiple linear 
regression analysis was performed with birth weight as the dependent variable in all models. 
Basic model: maternal tHcy at each corresponding time point of pregnancy (early pregnancy, 
P90: <12GW ≥ 7.11 µmol/L or 15 GW ≥ 5.85 µmol/L 34 GW and labour, direct tHcy 
concentrations). Second model: same as basic model + adjusting covariables including mid 
and high versus low socioeconomic status, maternal age (y), 1st trimester BMI, 3rd trimester 
haemoglobin <11 g/dL, parity (previous pregnancy versus none), gestational weeks at birth 
(w), foetal sex. Complete model (paternal factors): same as second model + paternal tHcy 
≥P90 (≥ 14.1 µmol/L). Beta coefficient values are shown. *p<0.05, **p>0.01, ***p<0.001. 
 
Paternal tHcy concentrations were inversely associated with birthweight in 
smoking mothers only, both in the early pregnancy and 34 GW models.  
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Maternal tHcy status during pregnancy and probability of 
intrauterine growth retardation 
 
We investigated tHcy status during pregnancy as a predictor of IUGR, using 
multiple logistic regression analyses. First, we tested the categorical tHcy 
variable (≥ P90 tHcy in early pregnancy versus < P90), as a potential biomarker 
for IUGR, in models adjusted for lifestyle factors such as parity, maternal age, 
BMI, smoking habit, socioeconomic status, anaemia and gestational diabetes. 
Because folic acid supplement use was highest during the first trimester, 
maternal tHcy category may have changed as pregnancy progressed. 
Therefore, we repeated the same analysis with two different variables to 
account for changes in tHcy category (≥P90 tHcy versus tHcy <P90 in early 
pregnancy or ≥P90 tHcy at some point of pregnancy versus tHcy always <P90). 
Results are shown in Table 19. 
Table 19. Associations between elevated maternal plasma homocysteine and intrauterine 
growth retardation. 
 N R2 Plasma tHcy BMI Smoking 
throughout 
pregnancy vs never 
tHcy ≥P90 vs tHcy <P90 in early pregnancy 
Model 1  
(non adjusted) 
590 0.003 0.6 (0.2, 2.1) - - 
Model 2 (adjusted) 590 0.091** 0.6 (0.2, 2.0) 0.9 (0.8, 0.9) 2.5 (1.2, 5.0) 
tHcy ≥P90 at some point of pregnancy versus low tHcy <P90 
Model 1  
(non adjusted) 
586 0.002 1.3 (0.6, 2.6) - - 
Model 2 (adjusted) 586 0.094** 1.2 (0.6, 2.5) 0.9 (0.8, 0.9) 2.5 (1.2, 5.0) 
Abbreviations: BMI, Body Mass Index; tHcy, plasma total homocysteine. Multiple logistic regression analysis was 
used. Nagelkerke R2; OR (95% CI) for IUGR. Mothers with high plasma homocysteine levels at early pregnancy 
and at some point of pregnancy versus low tHcy are shown. P90 tHcy cut offs (μmol/L) were <12 GW 7.11, 15 
GW 5.85, 34 GW 7.25, labour 8.52. Model 1: (basic model) comparing ≥P90 tHcy maternal levels at first 
extraction versus other percentiles or comparing ≥P90 tHcy maternal levels at some point of pregnancy vs 
always <P90 tHcy. Model 2: Included the same variables as model 1 as well as parity (previous pregnancy ≥ 20 
GW versus none), maternal age (y), 1st trimester BMI, smoking during pregnancy, mid and high versus low 
socioeconomic status, 3rd trimester haemoglobin <11 g/dL and gestational diabetes. *p<0.05, **p<0.01. 
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The results showed no association between plasma homocysteine and IUGR 
at early or at some other point of pregnancy. However, we observed a 
tendency, but not significant, for a higher probability of developing IUGR when 
tHcy is elevated at some point of pregnancy compared with always low (<P90). 
There was a clear association between smoking throughout pregnancy and 
increased risk of IUGR.   
We then assessed plasma folate and red blood cell folate status according to 
tHcy status divided in four categories at different pregnancy points; tHcy levels 
always <P90 (<7.1 μmol/L at <12 GW, <5.9 μmol/L at 15 GW, <7.2 μmol/L at 
34 GW, < 8.5μmol/L at labour) , tHcy levels low at 1st trimester (< 7.1 μmol/L), 
tHcy levels high at 1st trimester (≥ 7.11 μmol/L) and tHcy levels always high 
(≥P90 7.1 μmol/L, 7.2 μmol/L at 34 GW, 8.5 μmol/L at labour). The results are 
shown in Figure 10. 
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Figure 10. Mean Plasma folate throughout pregnancy and in the cord according to 
tHcy category. Blue: thcy always low (<12GW n=577, 15GW n=355, 24-27GW n=540, 
34GW n=507, labour n=489 and cord n=464). Orange: thcy low in beginning only 
(<12GW n=64, 15GW n=46, 24-27GW n=60, 34GW n=58, labour n=59 and cord n=55). 
Green: thcy high in beginning only (<12GW n=39, 15GW n=23, 24-27GW n=32, 34GW 
n=35, labour n=32 and cord n=31). Red: thcy always high (<12GW n=25, 15GW n=16, 
24-27GW n=24, 34GW n=23, labour n=21 and cord n=20). Means (dots) and 95% CI 
(bars) are reported. Student’s unpaired t-test comparing differences between tHcy 
categories: *p<0.05, **p<0.01, ***p<0.001 compared to tHcy always low (blue line); 
†p<0.05, ††p<0.01, †††p<0.001 compared to tHcy always high (red line).  
 
Plasma folate status according to pattern of tHcy change from early pregnancy 
< 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
157 
 
Figure 11. Mean Red blood cell folate throughout pregnancy according to tHcy 
category. Blue: thcy always low (<12GW n=565, 15GW n=354, 24-27GW n=429 and 
34GW n=495). Orange: thcy low in beginning only (<12GW n=63, 15GW n=46, 24-
27GW n=58 and 34GW n=57). Green: thcy high in beginning only (<12GW n=39, 15GW 
n=22, 24-27GW n=32 and 34GW n=35). Red: thcy always high (<12GW n=24, 15GW 
n=16, 24-27GW n=23 and 34GW n=20). Means (dots) and 95% CI (bars) are reported.  
Student’s unpaired t-test comparing differences between tHcy categories: *p<0.05, 
**p<0.01, ***p<0.001 compared to tHcy always low (blue line); †p<0.05, ††p<0.01, 
†††p<0.001 compared to tHcy always high (red line).  
 
Participants with low tHcy throughout pregnancy had the best plasma and red 
blood cell folate status throughout pregnancy and those with high tHcy 
throughout pregnancy always had the lowest plasma and red blood cell folate 
status (Figures 10 and 11).  In those that changed tHcy category as pregnancy 
progressed, folate status also changed. At <12 GW plasma folate status was 
similar between women with low tHcy in early pregnancy only and those with 
low tHcy throughout pregnancy. On the contrary, at <12 GW red blood cell 
folate levels are significantly higher in the group with low tHcy throughout 
pregnancy compared to those with low tHcy in the beginning only. At 15GW 
Red blood cell folate status according to pattern of tHcy change from early 
pregnancy 
< 
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plasma folate levels from participants with low tHcy in the beginning only are 
lower than those with always low tHcy concentrations. However, red blood 
cell folate levels do not differ between the groups (tHcy low in the beginning 
only versus tHcy levels always low) at 15 GW. From 24-27 GW throughout the 
rest of pregnancy, plasma folate status was consistently lower in the women 
that had started pregnancy with low tHcy status but then went on to belong 
to the high tHcy status group. From 24-27 GW to the end of pregnancy, 
participants with high tHcy levels at the beginning of pregnancy only, had 
higher red blood cell folate status than people with low tHcy levels in early 
pregnancy only. 
 
 
Paternal genotype and intrauterine growth retardation  
 
We also investigated the association between paternal MTHFR 677C>T 
genotype and probability of IUGR using multiple logistic regression analysis. 
We added the paternal MTHFR 677C>T genotype (reference CC genotype), 
plasma cobalamin and red blood cell folate concentrations to the complete 
maternal model with maternal MTHFR 677C>T genotype, red blood cell folate 
and plasma cobalamin at 1st and 3rd trimester, adjusted for lifestyle factors and 
complications such as anaemia and gestational diabetes. None of the models 
were significant and are not shown. Nevertheless, the relationship between 
the paternal MTHFR 677TT genotype compared to CC was as follows: in the 1st 
trimester model (n= 304) OR (95% CI) 1.1 (0.3, 4.1), in the 34 GW model (n= 
272) OR (95% CI) 1.8 (0.4, 7.5) and in the Labour model (n= 242) OR (95% CI) 
1.4 (0.4, 2.5).   
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Paternal tHcy status and intrauterine growth retardation 
 
We built on the multiple logistic regression models, previously described for 
the mothers, to investigate the association between elevate paternal tHcy 
(≥P90 versus the other percentiles) and probability of IUGR. We included the 
variable maternal tHcy ≥P90 at some point of pregnancy versus always <P90, 
I the model. The results are reported in Table 20.  
 
Table 20. Associations between elevated (≥P90 versus <P90) maternal and paternal tHcy 
and intrauterine growth retardation. 
 N R2 Maternal 
tHcy ≥P90 vs 
<P90 
BMI Smoking 
throughout 
pregnancy 
vs never 
Paternal 
tHcy ≥P90 vs 
<P90 
Model 1  
(maternal, non 
adjusted) 
390 0.008 1.7  
(0.7, 4.3) 
- - - 
Model 2 
(maternal 
adjusted) 
390 0.081 1.3  
(0.5, 3.4) 
0.9  
(0.8, 1.0) 
1.5  
(0.5, 4.7) 
- 
Model 3 
(maternal 
adjusted and 
paternal 
factors) 
390 0.123# 1.4  
(0.5, 3.9) 
0.9  
(0.7, 1.0) 
1.8  
(0.6, 5.7) 
4.5  
(1.7, 12.8) 
Abbreviations: BMI, Body Mass Index; tHcy, total plasma homocysteine. Multiple logistic regression 
analysis was used. Nagelkerke R2; OR (95% CI) for intrauterine growth retardation in babies born to 
mothers with high tHcy status (≥P901, 7.1 μmol/L at <12 GW, 5.85 at 15 GW, 7.25 at 34 GW, 8.52 
at labour) are shown. Model 1: (basic model) comparing ≥P90 tHcy maternal levels at some point 
of pregnancy vs <P90 tHcy throughout pregnancy. Model 2: Included the same variables as model 
1 as well as parity (previous pregnancy ≥20 GW versus none), maternal age (y), 1st trimester BMI, 
smoking during pregnancy, mid and high versus low socioeconomic status, 3rd trimester 
haemoglobin <11 g/dL and gestational diabetes. Model 3: Included the same variables as model 2 
as well as paternal tHcy (≥14.1 µmol/L, ≥P90 vs <P90). #P=0.06. 
 
Elevated paternal tHcy was associated with a greater probability of an IUGR-
affected pregnancy.  
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4.4. One carbon metabolism and gestational hypertension  
 
Maternal genotype and gestational hypertension 
 
We investigated the association between maternal MTHFR 677C>T genotype 
and risk of developing gestational hypertension using multiple logistic 
regression analysis. Pregnancies affected by gestational diabetes or 
intrauterine growth retardation were excluded from the analysis. Two models 
were designed: including SLC19A1 80G>A genotype and including red blood 
cell folate and plasma cobalamin concentrations at <12 or at 15 GW. We also 
adjusted the analysis for smoking habit, socioeconomic status, BMI, age and 
previous pregnancy. The adjusted R2 of the first complete model at <12 GW 
(n= 346) was 0.155 (p=0.019). There was no significant association between 
maternal genotype and gestational hypertension. BMI was a risk factor 
predicting gestational hypertension with an OR (95% CI) 1.2 (1.1, 1.2). Results 
from the second model, at 15 GW are shown in Table 21. 
Table 21. Associations between maternal MTHFR 677C>T genotype and 
gestational hypertension. 
 N R2 TT vs CC BMI 
Model 1  
(non adjusted) 
346 0.022 2.4 (0.9, 6.6) - 
Model 2 (adjusted) 346 0.155* 2.9 (1.0, 8.4) 1.2 (1.0, 1.3) 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; BMI, Body Mass Index. 
Multiple logistic regression analysis was used. Nagelkerke R2; OR (95% CI) for 
gestational Hypertension in mothers with MTHFR 677 CC vs CT and TT genotype are 
shown. Model 1: (basic model) comparing MTHFR 677 CC genotype vs TT or CT and 
SLC19A1 80 AA vs GA or GG genotypes. Model 2: Included the same variables as model 
1 as well as lifestyle factors such as previous pregnancies, age, BMI, smoking during 
pregnancy, low versus mid-high socioeconomic status, low tertile red blood cell folate 
(<= 724.33 nmol/L) and low tertile plasma cobalamin (<= 315.45 pmol/L) concentration 
at the corresponding time points of pregnancy for each model. **p<0.01, *p<0.05. 
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We observed an increased risk of developing gestational hypertension in 
mothers with the MTHFR 677 TT compared to CC genotype. BMI was also a 
predicting factor.  
 
Maternal tHcy status and gestational hypertension 
 
We also studied the association between early and late pregnancy tHcy and 
the risk of gestational hypertension, using multiple logistic regression analysis, 
again excluding pregnancies affected by intrauterine growth retardation and 
gestational diabetes. The categorical tHcy variable (≥P90 tHcy in early 
pregnancy versus < P90) replaced the genotypes and red blood cell folate and 
plasma cobalamin variables in each model, at <12 and 15 GW. Models were 
adjusted for smoking habit, socioeconomic status, BMI, age and parity. 
Elevated maternal tHcy levels in early pregnancy was not associated with 
increased risk of gestational hypertension. In the adjusted model, BMI was a 
risk factor for gestational hypertension with an OR (95% CI) 1.1 (1.1, 1.2) and 
having been pregnant previously was protective 0.56 (0.32, 0.96). 
 
Paternal genotype and gestational hypertension 
 
We investigated the association between paternal MTHFR 677C>T genotype 
and risk of developing gestational hypertension using multiple logistic 
regression analysis. To the same models used for the mothers, at <12 and 15 
GW, we added paternal MTHFR 677C>T genotype, smoking habit, age and red 
blood cell folate concentration. None of the models were significant.   
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
162 
 
Paternal tHcy status and gestational hypertension 
 
As we did with mothers, we also studied the association between paternal 
tHcy levels and the risk of gestational hypertension. The categorical tHcy 
variable (≥ P90 tHcy in early pregnancy versus < P90) replaced, genotypes, red 
blood cell folate and plasma cobalamin variables in each model, at <12 and 15 
GW. We included elevated paternal tHcy levels (≥P90), age and smoking habit 
as paternal factors in both models. The adjusted R2 of the model was 0.129 
(p=0.013). Neither elevated paternal tHcy or smoking were associated with 
risk of gestational hypertension. 
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5. Discussion 
 
5.1. General findings  
 
Our study population consists of a pregnancy cohort in which participants 
were recruited from their prenatal visits in the hospitals before 12GW. Most 
women reported planning their pregnancy. However, only 36% took folic acid 
supplements before conception. At their first prenatal visit, all women were 
routinely recommended to take folic acid supplements until the end of the 
first trimester. They adhered very well to this advice, and only 5.8% reported 
not taking any folic acid supplements during the first trimester. Their age 
ranged from 26 to 39 years, most had a mid-high socioeconomic status and 
25.7% of women smoked during pregnancy, 9.4% during the first trimester 
only and 16.3% throughout pregnancy. 19.2% of the mothers had impaired 
placentation indicated by pathological Doppler measurements of uterine 
artery flow at 20GW, 11.8% developed gestational hypertension and 8.8% 
intrauterine growth retardation. The percentage of pregnancies affected by 
these complications in other cohorts ranges between 2-17% for gestational 
hypertension (240) and 10-15% for IUGR (241).  
Paternal participation in the study was 66.1%. There were 3 main factors 
affecting paternal recruitment. Firstly, maternal consent was required to 
contact the fathers and 5.8% declined to provide the contact details. Secondly, 
we could not establish contact with 1% of the fathers. Thirdly 33.9% of the 
fathers allegated fear of needles, no interest or incompatible work schedule 
as the reason for declining the invitation. Only 6.8% of the fathers reported 
taking folic acid-containing supplements. Their age ranged between 29 to 41 
years, most had a mid-high socioeconomic status and 36.7% of the men 
smoked before and during pregnancy. 
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Folate status  
 
Median plasma folate during the first trimester of pregnancy was relatively 
high (28.9 nmol/L) and then declined as pregnancy progressed. On the other 
hand, median red blood cell folate status increased between the first trimester 
(936.4 nmol/L) and 15 GW (1266 nmol/L), before gradually declining into the 
3rd trimester. The decline in folate status occurred earlier in plasma folate 
compared to RBC folate because plasma folate reflects very recent intake 
(actual status) and is sensitive to folic acid supplementation, whereas RBC 
folate concentrations reflect both the long-term average of intake over the life 
span of RBC and folate stores in the liver (242). In addition, plasma folate as 
well as other nutrients circulating concentrations are affected by 
haemodilution due to the increase on plasma volume (243).  
50.1% of participants were close to plasma folate deficiency according to WHO 
criteria (≤ 10 nmol/L (8)) and 30.2% according to the old criteria (≤ 7 nmol/L 
(7)) at labour. The prevalence of folate deficiency depends on the cut off 
applied. We applied that of Chanarin et al (≤ 7 nmol/L (7)), in Figure 7 and 
Figure 8, because it is the one that was  used until the WHO in 2008 
recommended changing it to ≤ 10 nmol/L for folate deficiency (8). These 
recommendations in both cases are applicable outside of pregnancy. In the 
absence of an established cut off for pregnancy,  we consider it more precise 
to apply the previous (pre-mandatory fortification) cut off because our 
participants were not exposed to mandatory folic acid fortification and taking 
into the account that plasma micronutrient concentrations are lower due to 
haemodilution and increased glomerular filtration rate. Nevertheless, we 
highlight the need to establish a cut off for pregnant women.   
Globally, red blood cell folate status was not deficient. The advantage of 
measuring RBC folate during pregnancy is that it is not subject to the same 
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physiological changes as plasma folate concentration. Only 0.13% of the 
mothers started pregnancy with red blood cell folate deficiency ( <340 nmol/L 
(8)) and few cases were deficient by 34 GW (0.5%). Nevertheless, 51.8% did 
not meet the recommended red blood cell folate status of 906 nmol/L for 
NTDs prevention. We can expect participants to have good plasma folate 
status during the 1st trimester while they were taking folic acid supplements. 
The decline in plasma folate status started when folic acid supplement use was 
largely stopped, after 15 GW. Red blood cell folate concentrations also 
increased following the period of high folic acid supplement use. It did not fall 
until the 3rd trimester. There are other factors affecting also the drop in folate 
status during pregnancy when folate requirements are increased because of 
elevated folate utilization and catabolism (244). The preparation for the 
demands of rapid fetal growth that occur late in pregnancy may double 
nutrient requirement to protect fetal development (245). The increased 
demand on folate may lead to the mobilization of folate maternal reserves 
ending sometimes in the depletion of those reserves. Our group has previously 
shown that low folate status enhances the inverse association between 
betaine and tHcy in late pregnancy, reflecting increased betaine remethylation 
to homocysteine when folate availability becomes limited  (246). 
Haemodilution can be another factor involved in the decrease of folate 
concentrations. Maternal plasma volume expansion from 10 GW throughout 
pregnancy and serum albumin decrease, lead to a reduction in nutrient 
concentration in the circulation during the same period (243). In addition, 
changes in renal function during normal pregnancy due to increased 
glomerular filtration, increased kidney plasmatic flow and decreased kidney 
vascular resistance (247) may contribute to the excess of plasma folate 
elimination leading to a drop in folate status (248). 
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We observed that smoking affected maternal red blood cell folate status 
during pregnancy. It was lower in smokers than in non smokers. Comparing 
red blood cell folate status between these two groups allows us to see the 
long term effects of smoking on folate status, as well as a measurement of 
folate status unaffected by haemodilution. We did not have red blood cell 
folate determinations from the cord, but cord plasma folate concentration is 
unaffected by haemodilution. Despite the difference in folate status between 
the smoking and non-smoking mothers, plasma folate status in the cord did 
not differ. During pregnancy, folate transport to the foetus is enhanced by 
additional mechanisms for folate uptake and transport including folate 
receptor α expression by the placenta (249). If folate status is impaired in 
smoking mothers, there may be a compensatory effect to ensure the supply 
of folate to the fetus by increasing cellular folate uptake, as described in 
animal models. Hye Won Kim et al (2011) showed that folate receptor α 
expression in the placenta was higher (by 130%) in rats fed with a deficient 
folic acid diet compared to the folic acid supplemented group (250). 
The median of paternal plasma folate was close to folate deficiency (8.8 
nmol/L) and the median of red blood cell folate level was 456.8 nmol/L. 61% 
of the fathers had folate deficiency according to WHO criteria (plasma folate 
≤ 10 nmol/L (8)), and 35.6% according to the old criteria (7). This percentage 
is similar to that observed in the mothers at the end of pregnancy. The 
relatively high prevalence of folate deficiency in this population, compared to 
others like the population from the United States described by Bailey et al 
(251) with a low prevalence (< 1%) of folate deficiency (< 7 nmol/L), is likely 
due to poor dietary intake of folic acid in the form of fortified foods. There is 
no mandatory fortification of flour with food folic acid in Spain and, even 
though voluntarily fortified food products are available (breakfast cereals, 
cookies, milk, milkshakes, yogurts, canned juices, etc), consumption of these 
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is generally lower than in other countries. In addition, fathers no 
recommendations are in place to take folic acid supplements before 
conception.  
On the other hand, current trends are towards a dietary pattern increasingly 
further removed from the original Mediterranean diet in our general 
population, resulting in less vegetable and fruit intake (252). However, it is 
well known that dietary folate is relatively ineffective at increasing folate 
status compared with folic acid supplements and fortified food (44).  
We hypothesise that the lower folate status observed in the fathers compared 
to the mothers is due to the lack of targeted recommendations on folic acid 
supplementation in this group, to improve folate status. We previously 
reported, in a study of our adult population between 1998-2002, that in the 
absence of folic acid supplementation, 18.8% of women and men have folate 
deficiency. Furthermore, folate status is relatively low with geometric mean 
of plasma folate concentrations of 11.5 nmol/L and red blood cell folate of 810 
nmol/L (9). 
 
Homocysteine status  
 
The pattern of change in tHcy is similar to that which our group first described 
in 2002 (100). Folic acid supplementation influences tHcy, lowering its 
concentrations (99, 253). The extensive use of supplements by the mothers in 
our cohort may be one of the reasons why tHcy was low during the first 
trimester and fell by 15 GW and remained low at 27-27 GW. There was an 
increase in tHcy levels from 34 GW to the end of pregnancy. Independently of 
folate status, hormonal changes occurring during pregnancy and the 
physiologic role of homocysteine in the preparation of labour lead to a return 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
170 
 
towards nonpregnancy concentrations of tHcy in late pregnancy (35, 99). 
Previously, in a non supplemented cohort, our group observed higher tHcy 
levels in early pregnancy (geometric mean of 6.48 µmol/L) than those 
observed in the present population (100). The median tHcy in the fathers, of 
9.6 mol/L, is higher than the mothers, as expected due to the difference in 
tHcy between men and women (138, 254), the fact that tHcy was measured 
during pregnancy in women, and likely also because folic acid supplement use 
was prevalent in the women (99, 253). 
 
MTHFR 677 C>T and SLC19A1 80G>A genotype  
 
The homozygote variant genotypes of these two polymorphisms are quite 
prevalent in our pregnancy cohort, with 17.0% of the women with the MTHFR 
677 TT genotype and 27.2% with the SLC19A1 80AA genotype. The TT + AA 
genotype combination s was observed in 6.0% of the women. Among the 
fathers, 14.1% had the MTHFR 677 TT genotype, 28.9% the SLC19A1 80AA 
genotype and 5.3% the combination of TT + AA. Our group previously reported 
the MTHFR 677TT genotype to be present in 18.1% of adults in a 
representative sample of our local population (9) and 11.8% of newborns in 
Spain, data from hospitals of the National Health Service (15), lower than the 
prevalence in our cohort. This prevalence is also higher than in other countries 
such as Italy, France or The Netherlands (15). 
The maternal MTHFR 677TT genotype does not affect plasma folate 
concentrations during pregnancy in our population. In contrast, red blood cell 
folate concentrations were lower in the MTHFR 677TT compared to CC 
genotypes in early, mid and late pregnancy and also compared to CT 
genotypes in late pregnancy. However, the stratified analysis according to 
smoking habit during pregnancy showed no differences in red blood cell folate 
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levels between CC and CT compared to TT genotypes in smokers. There were 
no differences in cord plasma folate among the genotypes in either group. This 
might be explained by a compensatory effect in smoking mothers, commented 
before, necessary to ensure adequate supply of folate to the foetus. Despite 
the lack of difference in folate status, higher tHcy levels in the mothers with 
the TT genotype were observed compared to CC or CT genotypes from 15 GW 
to the end of pregnancy. This suggests that folate status is still in fact impaired 
in the TT mothers during pregnancy. It is possible that any compensation in 
maternal folate status in these mothers, is prioritised for the foetus before the 
mother. Regarding the SLC19A1 80G>A polymorphism, plasma folate, red 
blood cell folate and tHcy concentration did not differ between genotypes. In 
a previous study our group reported that compared with the CC and GG 
genotypes for MTHFR 677 and SLC19A1 80 genotypes respectively, people 
with the TT or AA alleles had lower plasma folate and RBCF plasma levels (9). 
We may not have observed the effect of these polymorphisms on folate status 
due to extensive folic acid supplement use. Nevertheless, the effects of the 
polymorphism on folate reserves (red blood cell folate) and the functional 
folate status biomarker (tHcy) were evident. Also, plasma variables are 
affected by the physiological effects of pregnancy including haemodilution 
(243), increased glomerular filtration rate (247) and foetal growth 
requirements (244). Determinations of folate status in clinical laboratories are 
largely based on plasma folate concentrations and these may not accurately 
reflect true underlying status due to these reasons.  
Fathers with the MTHFR 677TT genotype had lower red blood cell folate 
concentrations and higher tHcy compared to the other genotypes. Some 
studies have previously reported the relation between the MTHFR 677TT 
polymorphism and the increase in total plasma homocysteine (40, 255). Our 
group have recently shown that the MTHFR 677TT genotype was the most 
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important determinant of tHcy in men and that the association was stronger 
in smokers (139). Plasma folate concentrations also tended to be lower in 
fathers with the TT genotype. In the case of the SLC19A1 80G>A 
polymorphism, no significant differences in one carbon metabolism status 
between genotypes were observed.  
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5.2. One Carbon Metabolism and uterine artery pulsatility index 
and impaired placentation 
 
Relation between genetics and uterine artery pulsatility index and 
impaired placentation 
 
We explored whether the MTHFR 677 C>T polymorphism influences 
placentation, assessed by uterine artery pulsatility index and Doppler wave 
forms at 20 GW. We did not find any association between the maternal 
genotype and placentation. Abnormal uterine artery Doppler measurement is 
commonly used in the screening of pregnant women to detect increased 
resistance to flow in the uterine arteries due to impaired placentation. Poor 
perfusion indicated by increased uterine artery resistance is associated with 
adverse pregnancy outcomes (167). The homozygote variant MTHFR 677TT 
genotype has been associated with elevated tHcy and decreased serum folate 
concentrations (14) and is considered a genetic risk factor for some obstetric 
complications such as IUGR (256) and preeclampsia (257). Out of pregnancy, 
MTHFR 677TT genotype has been also related with increased risk of venous 
thrombosis (258), due to the alterations in arterial structure and function 
caused by elevated homocysteine concentrations. In that way, this 
polymorphism may affect uterine artery resistance also, and increase the risk 
of developing pregnancy outcomes.  
Stonek et al (2008) obtained the same results as ours in a prospective study 
where they measured the uterine artery pulsatility index values and unilateral 
or bilateral diastolic notches at 12 and at 22 GW of 1995 singleton pregnant 
women. No statistical differences between mean uterine artery Doppler 
values and bilateral or unilateral notch in any MTHFR genotype were found, 
showing that the MTHFR C677T polymorphism does not influence Doppler 
flow measurements (259). In the same line, Driul et al (2005) in a case control 
study with 103 preeclamptic women found no association between the 
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polymorphism and uterine artery flow. The frequency of homozygosity for the 
MTHFR mutation in the group of women with abnormal Doppler 
measurement and preeclampsia was 21.7% while it was 10.3% in the group 
with normal pregnancies with no significant differences (260). 
Contrarily, more recently Akdemir et al (2018) among 71 patients with 
recurrent pregnancy loss, observed that the uterine artery impedance was 
higher in the group with multiple thrombophilic mutations (MTHFR C677T 
among them) compared with the group who had a single thrombophilic 
mutation (261). Even though their study group are not comparable with our 
population, because they include complicated pregnancies, and they 
measured the combination of some polymorphisms, this result may suggest 
that the implication of MTHFR C677T alone is not strong enough to lead to an 
adverse pregnancy outcomes As Stoneak et al have proposed, may be it is not 
reasonable to speculate that MTHFR genotype influences Doppler flow 
measurements, because in their results none of the three MTHFR genotypes 
showed a significant association with Doppler measurement (259). However, 
it is important to consider that environmental factors such as folate status and 
smoking can modify the effect of the MTHFR 677TT polymorphism (289, 290). 
We have studied those factors in detail, especially RBC folate status in the 
context of smoking. We have observed no differences between MTHFR 677 
C>T genotypes among smoking mothers, and cord folate status did not differ 
among genotypes in any of the mothers or between smokers and nonsmokers. 
The high prevalence of folic acid supplement use during the first trimester 
(more than 90% of our mothers) leading to good folate status, may hide the 
effect of the MTHFR 677TT polymorphism. May be for those reasons in the 
studies commented before, as well as in our study, we do not observe an 
association between maternal genotype and uterine artery pulsatility index 
and impaired placentation. Or may be further investigation is needed to have 
strong evidence.  
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On the other hand, paternal MTHFR 677 CT and TT genotypes were associated 
with impaired placentation compared with the CC genotype. This was 
confirmed by their association with increased resistance in the uterine arteries 
and increased probability of pathological Doppler assessment of the uterine 
arteries at 20 GW.  
Uterine artery perfusion during pregnancy involves the maternal-placental-
foetal unit. Trophoblast invasion of the uterine arteries is the basis for 
successful placentation and during placentation for establishing the maternal-
placental-foetal unit (259). As commented in the introduction, trophoblast 
invasion of the uterine arteries converts them from their spiral, high 
resistance, non-pregnant form to their tubular, low-resistance pregnant form. 
If this conversion is incomplete, placentation is impaired and placental 
perfusion is reduced leading to increased risk of severe pregnancy outcomes. 
Doppler sonography of the uterine arteries is an established screening method 
to detect impaired uterine artery flow.  
There is a strong paternal genetic component in trophoblast formation and 
function. If we consider that certain combinations of maternal and fetal 
genotypes may impede proper placentation and trophoblast invasion (264), 
paternal genes can also affect placentation, but is rarely considered. With the 
results obtained, we propose that paternal genotype is crucial for a successful 
trophoblast invasion. To the best of our knowledge, this is the first study to 
report this and further investigation should replicate this association as well 
as exploring other genotypes.  
 
We found that paternal smoking was a predictive factor of uterine artery 
pulsatility index and tripled the risk of impaired placentation. Paternal 
smoking is a common factor studied in the investigation of the possible 
implication of the father in pregnancy complications. In 1994, Martinez  
showed that the number of cigarettes smoked by the father was associated 
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with lower birthweight in children with non-smoking mothers (265). Three 
years later, Horta et al (1997) confirmed that women whose partner smoked 
were at higher risk of having a child with IUGR [OR 95%CI 1.3 (1.1, 1.7)] (266). 
It has been hypothesized that mutations in the paternal germ line caused by 
the tobacco, can later cause mutations in the offspring and impact directly on 
the health of the newborn (267). Further support of this hypothesis is provided 
by in vitro evidence that cigarette smoking increases oxidative DNA damage in 
human sperm cells and causes mutations in germ cells (268). However, the 
results are still unclear and further investigation is needed to clarify the 
correlation between paternal smoking habit and perinatal outcomes.  
 
Relation between tHcy and uterine artery pulsatility index and 
impaired placentation 
 
Maternal tHcy status was not associated with placentation (either pulsatility 
index or pathological Doppler measurement of uterine arteries at 20 GW). 
Poor placentation, measured by Doppler uterine flow, is an underlying cause 
of preeclampsia (269) and other complications related with abnormal 
trophoblastic invasion. Some of the hypothesized factors leading to abnormal 
trophoblast invasion are disruptions of endothelial junctional proteins (270), 
subendothelial changes in uterine arteries (271) and generalized vascular 
complications. Elevated total homocysteine levels have been shown to have a 
deleterious effect on the vascular endothelium (272) and have been linked 
with various pregnancy complications (273).  
If tHcy is elevated the risk of some pregnancy complications caused by 
endothelial dysfunction leading to modulation of the arterial resistance to 
flow, we would expect to find an association between elevated tHcy and 
Doppler parameters. However, homocysteine plasma determinations are 
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affected by folic acid supplementation and that might mask any association 
between tHcy and impaired placentation. In our cohort, maternal tHcy was 
normal during the first trimester when they are being supplemented and their 
levels rise when supplementation stops.  
Few studies have investigated this. Yu C et al (2004) in a multicentre study with 
683 healthy pregnant women investigated the association between maternal 
plasma homocysteine concentrations (mid-trimester) and preeclampsia, in 
women with abnormal uterine artery Doppler outcome (22-24 GW). 
Differences in maternal tHcy concentrations were not significant between 
women with abnormal uterine artery Doppler and controls. Furthermore, they 
did not report any difference in maternal tHcy levels in those with an adverse 
pregnancy outcome compared to those with uncomplicated pregnancies 
(190). This finding is in the same line as ours, even though their samples were 
collected at mid trimester and were nonfasting. More recently, Maged et al 
(2017) evaluated the role of maternal tHcy concentrations (15-19 GW) and 
uterine artery Doppler (18-22 GW) as a possible predictor of pregnancy 
complications related to poor placentation in 453 women. They observed that 
tHcy levels and uterine artery resistance index were significantly higher in 
preeclampsia, IUGR and other complications groups when compared to the 
uncomplicated group. Also, the percentages of participants with uterine artery 
notch (unilateral or bilateral) were significantly higher in the group with 
complications compared with the control one (274).  
Many other studies have investigated tHcy levels and uterine artery doppler 
separately, as possible predictors for pregnancy complications. In addition, the 
use of both parameters has been proposed to improve the sensitivity of 
prediction of pregnancy complications relative to the use of each one alone 
(274). The lack of association between maternal homocysteine plasma 
concentrations and pathological Doppler measurement of uterine arteries in 
our study may be because our cut off point for P90 levels of homocysteine was 
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not high enough to cause endothelial disfunction. Low levels of homocysteine 
in the highest percentile may be due to folic acid supplementation in our 
participants. As mentioned previously, women that temporarily took folic acid 
supplements in the first trimester may only have had transitory “low” tHcy and 
in that sense were misclassified as belonging to the low tHcy group. We do not 
know if their tHcy was high during the early stages of placentation and before 
they started to take the supplements. It would be unethical to test this in 
humans because the recommendation is for women to take folic acid 
supplements before and during early pregnancy, but it might be interesting to 
test in animal studies. Mingda HAN et al (2012) demonstrated in a mouse 
model that exposure to elevated serum homocysteine levels (by injection) 
during embryonic day 6.75 have a moderate effect on altered embryonic 
blood flow and placental anomalies including IUGR. They observed a mis 
expressed NMM-IIs, a cytoskeletal protein family associated with cell 
migration, in mouse placentas (275). Xu X et al (2016) also studied the effect 
of elevated homocysteine concentrations (injections of 50mg/g/day on 
embryonic day 7.5) in pregnant mice. Those animals showed preeclampsia like 
symptoms such as higher systolic blood pressure and proteinuria in late 
pregnancy and decreased expression levels of vascular endothelial growth 
factor in the placenta compared with control mice (276). 
 
On the other hand, elevated paternal tHcy was positively associated with 
uterine artery pulsatility index and showed a threefold increase in risk of 
developing pathological Doppler measurement of uterine arteries at 20 GW. 
This association confirmed what we might have expected to observe in 
mothers in the absence of folic acid supplementation. Paternal tHcy was not 
affected by folic acid supplementation because few of them took supplements 
before conception. In general, paternal folate status was lower than in the 
mothers and low, as previously reported by our group in a population study 
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(9) in the absence of mandatory folic acid fortification. In this context, maybe 
the potential effect of tHcy increasing uterine artery flow resistance is 
detectable. It is possible that tHcy is related with pathological Doppler via 
endothelial dysfunction, as previous non-pregnant animal and human studies 
have described  (272). We also hypothesise that in cases where the mother 
develops pregnancy complications, but with no apparent underlying risk 
factors, paternal factors can be the precursors of these complications. Is has 
been shown that fathers born from a complicated pregnancy have more risk 
of fathering a pregnancy with adverse outcomes (17). As we observe in our 
results, while maternal factors seem to have no apparent relation with 
pathological doppler measurement, paternal homocysteine levels were 
associated with it. More investigation will be necessary to answer this 
question, especially focused on paternal factors which have been scarcely 
considered to date.   
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5.3. One Carbon Metabolism and birthweight and intrauterine 
growth retardation 
 
Relation between genetics and birthweight and intrauterine growth 
retardation 
 
There was an interaction between the MTHFR 677 C>T genotype and smoking 
in their association with birth weight. In the stratified analysis by smoking 
pattern, the MTHFR 677TT genotype was only associated with birthweight in 
smoking mothers. Compared to the CC reference genotype, the TT genotype 
was associated with increased birth weight. We would expect to see a 
negative effect of smoking, a long established risk factor for low birth weight 
(277) in all genotypes. This unexpected result might be explained by the 
increase of placental folate receptors in situations of impaired folate status as 
commented before (250). The only evidence we have of this is the fact that 
cord plasma folate status was unaffected by either maternal smoking habit or 
MTHFR 677C>T genotype, despite the fact that maternal folate status was 
affected by each of these factors. Thamar Ayo Yila et al (2012) observed the 
effect that we were expecting. In their study with 1784 native Japanese 
mother-child pairs, the MTHFR 677 T allele was associated with lower birth 
weight in the offspring of active smokers. Contrary to our results, they also 
found a protective effect of the CT genotype against low birth weight only in 
the absence of smoke (278). A limitation of stratified analysis is the reduced 
sample size in the sub-groups. However, it is unlikely that the unexpected 
effect that we observed is due to low sample size in the TT genotype group 
because it was confirmed in early and mid-pregnancy and despite lack of 
significance in late pregnancy, the positive association was maintained. Our 
study did not set out to investigate the effect of smoking on birth weight, but 
rather to control for it as an established confounding factor. We do not 
interpret the TT genotype in smoking mothers as a protective factor for birth 
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weight in the offspring but hypothesise that the observed association is 
related with a potential compensatory mechanism in mothers with two 
factors adversely affecting birth weight. Low early pregnancy red blood cell 
folate status was inversely associated with birth weight in smokers only. This 
early pregnancy measurement of red blood cell folate was a true reflection of 
folate status, before first trimester supplement use affected red blood cell 
folate status. In countries with mandatory folic acid fortification or high intake 
of voluntarily fortified foods and higher prevalence of folic acid supplement 
use, it is possible that the negative association between low early pregnancy 
maternal folate status and birth weight might be missed. 
In several studies the MTHFR 677TT genotype in the mother has been 
associated with low birth weight in the offspring. In a metanalysis published 
in 2017, including 25 studies, Han Wu et al concluded that the maternal 
MTHFR 677TT genotype was associated with increased probability of low 
birthweight, OR (95%CI) 2.3 (1.4, 3.5). They proposed that the identification of 
the maternal MTHFR 677TT genotype may play a key role for primary 
prevention of low birth weight (12). Lee et al (2013) in a Mendelian 
randomization analysis to investigate the causal relation between maternal 
tHcy levels, as represented by MTHFR C677T genotype, with birth weight of 
the offspring, found that birthweight was significantly lower in mothers with 
the TT genotype compared to the CC and CT genotypes. They also observed a 
dose-response association with homocysteine concentrations for each 
additional T allele, and birth weight decreased as maternal tHcy at 24-28 GW 
increased (p=0.06) (279). Those results may explain the association between 
this polymorphism and birthweight of the newborn. Reduced enzyme activity 
due to the MTHFR C677T polymorphism, increases plasma homocysteine 
levels (13). This in turn may lead to oxidative stress, endothelial damage and 
placental thrombosis (280). All these conditions might be associated with 
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impaired flow of uterine arteries, inadequate trophoblast invasion and poor 
pregnancy outcomes (281). On the other hand, other reports observed no 
association between MTHFR 677C>T genotype and risk of IUGR. Infante-
Rivarde et al, reported twice the absence of association between 
thrombophilic polymorphisms and intrauterine grow restriction. In 2002 in a 
case-control study including 493 newborns with IUGR, they reported no 
increased risk of IUGR among mothers with the MTHFR 677TT genotype (282). 
With a subgroup of the same cohort, in 2005 they conducted a family study 
including 250 case trios (affected newborn, mother and father). They tested 
whether there was excess transmission of the MTHFR C677T and A1298C 
haplotypes (CA, TA, CC, TC) to affected offspring and they observe that 
transmission and haplotype frequencies were not different between case and 
controls groups (283). Their results are in line with ours, however, their study 
was in the presence of mandatory folic acid fortification and paternal 
genotype was performed from buccal swabs. Giovanni Larciprete et al (2007) 
reported similar findings in a case control study with 284 pregnant women in 
Rome. Even though MTHFR C677T genotypes were more prevalent than other 
thrombophilia mutations included in the study, they did not observe an 
increased incidence of adverse pregnancy outcomes in subjects with the 
MTHFR TT genotype (284). Interestingly, they did not have cases with MTHFR 
mutations combined with hyperhomocysteinemia. Folate supplementation of 
their population may mask a potential association between the polymorphism 
and IUGR or other adverse pregnancy outcomes. It has been proposed that 
variations in the relative contribution of disease alleles in different 
populations might explain the discrepant results of previous studies on MTHFR 
and pregnancy complications (284). This could be another reason for the 
absence of association between the MTHFR 677 C>T polymorphism and IUGR 
in our study. In addition, an increase of IUGR cases in our population would 
increase our statistical power and possibility of observing the association. 
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Also, an increase in paternal participation would improve sample size for 
observing an association between the paternal polymorphism and IUGR. 
Regarding a paternal effect, we found few studies investigating paternal 
thrombophilic mutations as a possible risk factor for IUGR. Several are focused 
on other paternal factors such as age, ethnicity, weight and height and other 
polymorphisms.  
 
Low red blood cell folate status was inversely associated with birth weight in 
the mothers that smoked at some point of pregnancy. Low folate status has 
previously been reported to be related with adverse pregnancy outcomes, 
including birth weight (285). Exposure to tobacco smoke during pregnancy is 
a well-known risk factor for adverse perinatal outcomes as many studies have 
previously described (286). The first correlation between smoking and fetal 
adverse outcomes was proposed in 1957 by Simpson (287) who pointed out 
how the neonates of smoking mothers weighed 200g less on average than 
neonates of non-smoking mothers. Furthermore, smoking has also been 
shown to be associated with low RBC folate (288). We saw the inverse 
association between low RBCF levels and birth weight in smoking mothers but 
not in non smoking mothers. This may be because smoking mothers also had 
lower RBC folate status. Or maybe because smoking has  a direct negative 
effect on birthweight mediated by hypoxia, as smoking reduces the oxygen 
binding capacity and oxygen supply is essential for placental and fetal growth 
(289). Another possible explanation is that nicotine may lead to 
vasoconstriction in the maternal circulation with subsequent reduced blood 
flow to the placenta and the fetus (290).  
We also observed that paternal cobalamin status was positively associated 
with birthweight. Maternal inadequate or deficient vitamin B12 status has 
been previously associated with higher risk of low birthweight (264, 270). 
Despite not finding previous studies focused on paternal B12 status, there are 
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studies suggesting that maternal and paternal micronutrient intake, including 
B vitamins involved in one carbon metabolism, which are essential for DNA 
methylation, can influence the programming of the offspring’s epigenome 
influencing neonatal outcomes (228). Following this evidence, we hypothesize 
that paternal B12 status can influence the programming of genes involved in 
fetal growth and subsequent offspring’s birthweight.  
 
Relation between tHcy and birthweight and intrauterine growth 
retardation 
 
Previously our group reported that elevated tHcy at 8 GW is associated with 
increased probability of birth weight percentile <P25 in the offspring (35). That 
study was carried out between 1992-1996, before prenatal supplementation 
with folic acid was routinely recommended in Spain. In this study what we 
have observed is a positive association between late pregnancy tHcy (34 GW 
and at labour) and birthweight only in non-smoking mothers. In normal 
pregnancy, tHcy increases at the end of pregnancy (292). Homocysteine can 
be methylated to form methionine required for cell proliferation and gene 
expression essential for fetal growth (293). In addition, in vitro studies show 
that homocysteine enhances spontaneous contractions of myometrium 
derived from pregnant women (294). The increase in tHcy late in 
uncomplicated pregnancies may suggest a physiologic role for homocysteine 
in the preparation for labour.  
The Reus- Tarragona Birth Cohort study set out to investigate whether 
elevated first trimester tHcy is an early pregnancy biomarker for IUGR in the 
foetus. There was no association between elevated tHcy (≥P90) in the first 
trimester and increased risk of IUGR.  The early pregnancy blood sample was 
collected later in the RTBC study (up until 12 GW) compared to the previous 
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one (at 8 GW). Geometric mean tHcy (6.48 µmol/L) was higher in the previous 
study than in the RTBC study (5.3 µmol/L). Later blood sample collection as 
well as folic acid supplement use in the RTBC are two factors associated with 
lower tHcy, compared to the previous study.  
What we observe in this thesis is a possible masking of elevated plasma 
homocysteine levels due to the transitory effect of folic acid supplementation. 
In a non-fortified country like Spain, women are recommended to take folic 
acid supplementation 3 months before pregnancy. As we mentioned before, 
93.8% of the women in the RTBC reported use of folic acid supplements but 
the timing and dose was variable. In the majority of cases this 
supplementation was during the first trimester only. When participants 
stopped the oral supplement use, their folate status fell. tHcy is sensitive to 
folic acid supplement use so the first trimester measurement may be more 
indicative of recent folic acid supplement use, rather than long term 1CM 
status. This is contrary to the previous study in our group where tHcy at 8 GW 
was likely to reflect true underlying 1CM metabolic status.  
McNulty et al (2013) showed in a randomized controlled trial that continued 
folic acid supplementation during the second and third trimester prevented 
the elevation in homocysteine concentrations by 36 GW that otherwise occur 
with the progression of pregnancy (295). More recently, Shazia H Chaudhry et 
al (2019) reported that one of the factors significantly associated with lower 
homocysteine concentration was folic acid supplementation in the Ottawa 
and Kingston Birth Cohort (296). Maybe for this reason we cannot see the 
negative effect of elevated tHcy levels as previously observed by our group 
when the folic acid supplementation was not extensive as it is now. However, 
it has been proven that when women stop folic acid supplement use during 
pregnancy their tHcy levels increase again. In a trial performed with German 
women, 500μg of folic acid were administered for 8 weeks, and when they 
stopped the supplementation homocysteine and folate returned to baseline 
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levels (297). Our group have previously described that continued supplement 
use beyond the first trimester was associated with lower tHcy from 24 to 27 
GW compared with non use (92). In the RTBC women, supplementation in 
early pregnancy may mask the real status of tHcy in women with apparently 
normal levels but that return to their true tHcy status when they stop folic acid 
supplementation. In those cases, they return to their original status and 
became part of the group with increased risk. The true normal tHcy mothers 
would be those with tHcy consistently <P90 throughout pregnancy. Therefore, 
in a setting where mandatory folic acid fortification is absent and folate status 
is only temporarily enhanced for the duration of folic acid supplement use, 
first trimester tHcy appears not to be a useful biomarker of IUGR for all women 
and consequently the possible risk of developing IUGR may not be reflected. 
We did observe in the RTBC study that women with early pregnancy tHcy <P90 
but with tHcy ≥P90 later in pregnancy, had a tendency for higher risk of IUGR. 
Another difference between the RTBC study and the previous one by our 
group is in the endpoint. Previously it was birth weight <P25 whereas in the 
RTBC study it was IUGR (≤P10). Other studies have demonstrated the 
association between elevated homocysteine levels and IUGR. The Generation 
R cohort in The Netherlands (2012), based on early pregnancy (13 GW) with a 
higher sample size (n=5805), reported that the risk of delivering an SGA infant 
was higher in women with homocysteine concentrations in the highest 
quintile (≥8.3 µmol/L) compared with women in the reference group (adjusted 
OR 1.68; p=0.006) (298). In India, the Pune Maternal Nutrition Study form 
Yajnik et al reported that mothers with higher plasma homocysteine 
concentrations delivered earlier and had lighter babies (36). They have a 
cohort of 526 women who took folic supplements from 18 GW. Some studies 
report no association between tHcy status and IUGR. Rosario d’Anna et al 
(2004) failed to demonstrate any difference in serum homocysteine levels at 
early pregnancy (16 GW) among women who later developed IUGR (299). The 
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population studied had no mandatory folic acid food fortification policy, like 
ours (Italy), and they only included non-smoking participants. Another study 
performed in Canada during early pregnancy (<20 GW) observed that high 
tHcy was not significantly associated with having an SGA infant (273). Those 
results were similar to ours but in the presence of mandatory folic acid food 
fortification and a larger cohort of 2016 women. Hogg et al (2000) in a study 
with prenatal zinc treatment, did not report differences between the zinc and 
placebo groups in the mean plasma homocysteine level in late pregnancy (26-
37GW), and also no difference in tHcy levels between pregnancies 
complicated by IUGR and those that resulted in normal foetal growth (300). 
Although the study was performed with a non-comparable population, they 
were African American women, the results were in line with ours.  
 
Elevated paternal tHcy was inversely associated with birth weight in the babies 
born to mothers that smoked during pregnancy and increased the probability 
of IUGR. We did not stratify the IUGR models by maternal smoking status 
because this would have reduced our statistical power due to the low number 
of IUGR cases. However, we did adjust for maternal smoking and the negative 
association between elevated paternal tHcy and foetal growth was confirmed 
in these models. Elevated paternal tHcy has been previously associated with 
higher risk of NTDs (207) and recurrent pregnancy loss (109). But, as far as we 
know, no research has been focused on paternal homocysteine 
concentrations and the pregnancy complications studied in this thesis. We 
hypothesise that the link between homocysteine, other micronutrients and 
metabolites from the 1C metabolic network and DNA methylation could be 
involved. Coppedè et al (2019) described an inverse correlation between 
plasma homocysteine and DNA methyltransferase 1 methylation levels. 
DNMT1 is responsible for the maintenance of DNA methylation patterns 
during cell division. The folate metabolic pathway may be relevant in the 
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development of disorders characterized by altered DNA methylation (301). 
Alterations in paternal germ cells or spermatozoids DNA methylation may 
transfer disease predisposition to the second generation according to the 
intergenerational inheritance effect (302). 
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5.4. One Carbon Metabolism and Gestational Hypertension 
 
Relation between genetics and Gestational hypertension 
 
We found that women with MTHFR 677 TT versus CC genotype had almost 3 
times more risk of developing gestational hypertension. Our findings were 
largely in line with other studies and metanalysis confirming the relationship 
between the variants of that polymorphism and gestational hypertension. The 
MTHFR 677 C>T polymorphism has been previously associated with 
hypertension and stroke outside of pregnancy (303). Our group recently 
reported that the TT genotype is associated with increased risk of 
hypertension in adults under 50 years of age (139). There are also several 
studies that have investigated the association between the polymorphism and 
gestational hypertension.  
Hernández-Díaz et al (2005) studied U.S. and Canadian white women with 
nonmalformed infants and found that the T allele was present int 69% of 
women with gestational hypertension versus 57% of control women. 
Compared with 677CC homozygotes, the OR (95% CI) of gestational 
hypertension for women who were 677 TT/CT was 1.9 (0.9, 4.0) (304). 
Stronger associations were found in two metanalysis. Kosmas et al (2004) 
across 23 comparisons (3169 hypertensive women and 3044 controls) found 
that having the T allele (TT or CT) increased the OR (95% CI) of gestational 
hypertension by 1.2 (1.0, 1.4) in patients with diastolic hypertension > 
110mmHg. No association was seen in patients with less severe diastolic 
hypertension. They conclude that the C677T polymorphism increased the risk 
of severe hypertension but not the risk for milder hypertension (305). More 
recently, Yang et al (2014) confirmed also that the C677T polymorphism was 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
 
190 
 
significantly associated with gestational hypertension with an OR (95% CI) 1.2 
(1.1, 1.3) (306).  
However, some results are controversial. An underestimated effect of the 
polymorphism may come from the variance of the polymorphism according to 
ethnicity. When Yang et al stratified the analysis by ethnicity they observed 
significant association among East Asian and Caucasian, but not among 
Latinos, Black Africans and Indians (306). The use of folic acid supplementation 
during pregnancy can also mask the effect. Hernández-Díaz et al suggest that 
the association between MTHFR C677T polymorphism and gestational 
hypertension disappeared when they restrict the analyses to women 
supplemented with folic acid during the first five months of gestation (304). In 
the case of our study, we did not observe an association between the 
genotype and gestational hypertension when we adjusted for folate status 
when it was highest during pregnancy, during the peak of folic acid 
supplement use during the first trimester. We were strict in excluding 
pregnancies affected by gestational diabetes and intrauterine growth 
retardation from our analysis. While these pregnancy complications and 
underlying conditions can occur simultaneously, with gestational 
hypertension, in an initial analysis, exploring potential mechanisms, we 
excluded them. On the other hand, an inconsistent definition of gestational 
hypertension or prenatal control of the same can also be bias for the results. 
We strictly adhered to the definition of gestational hypertension, so that we 
did not misclassify participants with underlying hypertension as having 
hypertension induced by pregnancy. We only included pregnancies that had 
complete prenatal control of blood pressure (consisting of a measurement 
before and after 20 GW), in our analysis.  
On the contrary, paternal genotype was not associated with increased risk of 
gestational hypertension. We did not find in our literature search, any other 
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study of the association between paternal MTHFR 677 C>T genotype and 
gestational hypertension. Nonetheless, Hernández-Díaz et al (2005) suggest a 
possible effect of the offspring genotype in the risk of gestational 
hypertension because they found an association between fetal 677TT/CT 
genotype and maternal risk of gestational hypertension [0R (95%CI) 2.4 (1.1, 
5.0)] (304). As foetal genotype is determined 50% from father’s genotype, we 
propose that paternal genotype can influence maternal risk of developing 
gestational hypertension. Other studies have suggested that paternal 
imprinted genes in the fetus contribute to increase pregnant woman’s risk to 
develop preeclampsia (307). It makes sense if we consider that preeclampsia 
results from dysfunctional placentation and the placenta has the same 
genotype as the fetus.  
 
We found that maternal BMI was also a risk factor for gestational 
hypertension. We expected this because BMI is a well known risk factor for 
hypertension and gestational hypertension. Previous studies have also 
reported the same association (308, 309, 310). In addition, is well known that 
have had previous pregnancies reduces the risk to develop gestational 
hypertension compared to nulliparous women (311).  
 
 
Relation between tHcy and Gestational hypertension 
 
We found no association between maternal and paternal tHcy levels and the 
risk of gestational hypertension. Some studies showed that elevated tHcy is a 
risk factor of developing hypertension outside of pregnancy (312, 313). Our 
group recently reported that elevated tHcy was only associated with increased 
risk of hypertension in adults older than 50 years (139) and it is unclear that 
homocysteine is causally involved. Furthermore, a potential association is 
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harder to see between tHcy and gestational hypertension because tHcy 
concentration is greatly affected during pregnancy by physiological and 
endocrinological processes (100). There have been few studies of such an 
association. Studies examining maternal tHcy levels at early pregnancy, like 
ours, have demonstrated a relationship between elevated tHcy and 
preeclampsia but they did not find the same association with gestational 
hypertension. In addition, we did not find studies examining the contribution 
of paternal homocysteine levels to the risk of gestational hypertension. 
In a prospective cohort study, Dodds et al reported that there was no 
significant association between tHcy concentration before 20 GW and the risk 
of developing gestational hypertension (273). Sun et al (2017) in a 
retrospective cohort study with 147 confirmed cases of gestational 
hypertension failed to find a significant difference between tHcy 
concentrations in the gestational hypertension and control groups (240). They 
only found a significant association in the group of severe preeclampsia 
compared to controls with an OR (95% CI) of 1.1 (1.1, 1.2). Cotter et al (2003) 
studied 71 cases of non-severe preeclampsia and 142 controls in Dublin, taking 
blood samples at early pregnancy. Participants with plasma homocysteine 
values >7.8 µmol/L (upper third) had significantly increased risk of developing 
preeclampsia [OR 95%CI 4.1 (1.4, 12.6)] (85). 
Prenatal tHcy may not be a good biomarker for gestational hypertension, but 
it is relevant for detecting preeclampsia. Normally, elevated tHcy 
concentrations are related with severe disease status leading to a higher 
damage of the structure of blood vessels. It has been suggested that low 
concentrations of tHcy may even affect the endothelium slightly and play a 
subtle role in occurrence of lowest disease stages (240) like gestational 
hypertension, making this relationship almost undetectable. In our study 
population, mothers are mostly folic acid supplemented at early pregnancy. 
This could be a reason why our tHcy ≥P90 group have tHcy levels too low to 
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cause the endothelial dysfunction and the following rise of blood pressure. 
Lastly, another possibility lies in the difference between the pathological 
processes involved in gestational hypertension and preeclampsia, justified by 
the higher increase on tHcy concentrations in preeclampsia than in gestational 
hypertension (240). 
Further investigation is needed to establish whether there is an association 
between paternal factors related to one carbon metabolism and gestational 
hypertension or preeclampsia. This knowledge would inform preventive 
preconception policies including fathers.  
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5.5. General discussion  
 
Pregnancy complications derived from impaired placentation, including 
gestational hypertension and IUGR are the main causes of perinatal morbidity 
and mortality and a risk for different diseases in the newborn (314). Even 
though there are some established genetic and environmental factors that 
contribute to these adverse outcomes, they can appear in women who were 
healthy before pregnancy, without a history of complications themselves or in 
their family (315). The risk factors are usually studied in the context of the 
maternal-foetal-placental unit, without considering paternal factors (19). 
However, maternal risk factors alone may not explain the cause of the 
complication in many cases. In this thesis, we have proposed some paternal 
factors as contributors to the development of pregnancy complications. As 
important adverse pregnancy outcomes can trace their origin to the placenta, 
paternal factors affecting placentation may influence the risk of adverse 
pregnancy outcome. The results of the Reus Tarragona Birth Cohort reported 
in this thesis show that paternal MTHFR C677T genotype and elevated tHcy 
levels are associated with impaired placentation and lower birthweight. In 
addition, we observed that in some cases maternal factors were not 
associated as a risk factor for those adverse outcomes. Nevertheless, this 
applied to elevated tHcy during early pregnancy and the MTHFR 677TT 
genotype and it is possible that their underlying associations with adverse 
outcomes were not detected due to the protective effect of folic acid 
supplementation during the first trimester of pregnancy in 94.2% of the 
mothers, and from preconception in about a 36% of them. Previous studies 
have also focused on the important role of paternal genetic and nutritional 
status on the success of placenta and fetal development. In a study with male 
rats exposed to a high-fat diet and females on a control diet, Sheau-Fang et al 
(2010) have shown that the offspring had early onset of impaired insulin 
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secretion and glucose tolerance, as well as altered gene expression in 
pancreatic islets (316). Bielawski et al (2002) in a study performed also in rats, 
observed that paternal chronic alcohol intake decreased messenger RNA 
expression of cytosine methyltransferase in sperm, which could result in 
hypomethylated DNA which is then passed on to the offspring (21). In the 
same line, Lundi et al (2017) have observed that mice exposed to both a folate 
deficient diet and a high dose of folic acid supplementation have male 
descendants (F1) with lower sperm counts which leads to increased postnatal 
death in the offspring (F2) (189). Therefore, it is also important to consider 
that paternal lifestyle, apart from genetics, can play a role in pregnancy 
complications and fetal programming. We consider that it will be important to 
include paternal factors in the focus of interest to learn more about their 
implication in complications developed during pregnancy that we cannot 
explain only with maternal factors. In a context without mandatory folic acid 
fortification like Spain, where 61% of the men adult have folic acid deficiency, 
it would be interesting to establish a protocol of folic acid supplementation in 
fertile man planning to have a baby to avoid pregnancy complications if 
scientific evidences support it.  
 
Strengths and Limitations  
 
The principal strength of our study is the time on data collection. The 
prospective design from early pregnancy allows as to have clinical, obstetric 
and lifestyle data from the first trimester of pregnancy and a blood sample 
before 12 GW with a confirmed viable foetus. It’s very difficult to obtain first 
trimester data because it depends on the timely initiation of prenatal care by 
the mother. Most studies have data from the mid or final trimesters of 
pregnancy. We also have the participation of the fathers, which is difficult to 
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obtain because they are not visited as part of prenatal care and they have to 
agree to come voluntarily and especially for the interview and blood sample. 
Many are uninterested for work reasons or don’t want to come to the hospital 
to give a blood sample. In the fathers, the absence of folic acid food 
fortification in Spain and the very low use of folic acid supplementation use, 
allowed us to study the effect of the MTHFR C677T polymorphism in 1C 
metabolism and pregnancy complications without the masking effect of folic 
acid.  
One of the limitations of this thesis is that observational studies do not allow 
to assume causality effect in the associations studied. However, we adjusted 
for potential confounding factors. Over 60% of the fathers participated, but it 
is possible that these were more motivated for research and possibly 
healthier. However, this did prevent us from testing our hypothesis as shown 
by the novel associations we observed.  Another limitation is our participant 
recruitment. We could not access participants having the prenatal check-up 
outside the hospital, before 12 GW. Participants visiting the hospital for the 
prenatal care were mostly people with more risk of developing pregnancy 
complications and some hospital / university staff.   
 
Future perspectives 
 
Further investigation will be useful to replicate the results regarding paternal 
involvement in pregnancy adverse outcomes. Our study reports ground 
breaking results about paternal MTHFR C677T genotype and 1C metabolism 
influence on pregnancy complications. More studies focused on this topic 
would inform future recommendations or protocols. If the father is associated 
with pregnancy complications that we cannot explain by maternal risk factors 
and thus not covered by primary and secondary prevention measures, the 
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associated complications likely emerge when it is too late. We could focus on 
recommendations for the father at preconception. Recommendations on diet 
and healthy lifestyle or folic acid supplement use in the father might 
contribute to reducing the incidence of pregnancy complications. In addition, 
further investigation will be useful to know the mechanisms by which paternal 
factors are affecting those adverse outcomes. Epigenetic factors have been 
proposed as a possible mechanism (206). Micronutrients involved in one 
carbon metabolism can contribute to DNA methylation and affect foetal 
programming (228). 
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6. Conclusions 
 
Main objective 
 
To investigate the association between genetic, nutritional and metabolic 
components of the maternal and paternal 1C metabolic network and the 
probability of impaired placentation, intrauterine growth retardation and 
gestational hypertension. 
 
Specific objectives 
 
- To compare the likelihood of impaired placentation, intrauterine 
growth retardation or gestational hypertension between the maternal 
or paternal MTHFR 677C>T (TT versus CC, CT versus CC) and SLC19A1 
80 G>A (AA versus GG, AG versus GG) genotypes. 
Maternal MTHFR 677 C>T genotype was not associated with impaired 
placentation. 
Fathers with MTHFR 677 CT and TT genotypes have fourfold and 
sevenfold, respectively, more probability of impaired placentation 
compared to the CC genotype.  
Maternal MTHFR 677 TT genotype was positively associated with 
birthweight only in smokers. 
Maternal and paternal genotypes were not associated with increased 
risk of IUGR. 
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Mothers with the MTHFR TT genotype were threefold more likely to 
develop gestational hypertension compared to mothers with the CC 
genotype.  
Paternal genotypes were not associated with increased risk of 
gestational hypertension. 
Maternal and paternal SLC19A1 80 G>A genotypes were not 
associated with increased risk of any of the three pathologies. 
 
- To investigate the association between elevated early pregnancy 
maternal tHcy, elevated paternal tHcy and the probability of impaired 
placentation diagnosed by pathological Doppler of uterine arteries at 
20 gestational weeks, intrauterine growth retardation or gestational 
hypertension.  
Elevated first trimester maternal tHcy was not associated with 
impaired placentation.  
Pregnancies from fathers with elevated tHcy have threefold increased 
risk of impaired placentation compared to fathers with normal tHcy.  
Elevated maternal tHcy at late pregnancy was positively associated 
with birthweight in non smokers. 
Elevated first trimester maternal tHcy, as a standalone measurement, 
was not associated with increased risk of intrauterine growth 
retardation. 
Elevated paternal tHcy was associated with a nearly fivefold greater 
probability of an IUGR-affected pregnancy.  
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No association between maternal and paternal tHcy concentrations 
and the probability of gestational hypertension were found.  
 
- To explore whether the associations between the genotypes and the 
three pathologies is modulated by the status in the 1C metabolism 
nutrients. 
Maternal red blood cell folate status is affected by the MTHFR 677 C>T 
genotype. Mothers with the TT genotype have lower RBC folate 
compared with the CC and CT genotype at 12, 24-27 and 34 GW. 
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Scientific and academic contributions and other merits 
 
Articles 
 
Cavallé-Busquets P, Inglès-Puig M, Fernandez-Ballart JD, Haro-Barceló J, Rojas-
Gómez A, Ramos-Rodriguez C, Ballesteros M, Meyer K, Ueland PM, Murphy 
MM. Moderately elevated first trimester fasting plasma total homocysteine is 
associated with increased probability of miscarriage. The Reus-Tarragona 
Birth Cohort Study. Biochimie. 2020;173:62-67. 
doi:10.1016/j.biochi.2020.01.008 
Haro-Barceló J, Cavallé-Busquets P, Fernandez-Ballart J, Ramos-Rodriguez C, 
Rojas-Gomez A, Roigé J, Ballesteros M, Ueland PM, Murphy MM. The 
contribution of paternal folate metabolism to placentation and fetal size. In 
preparation to be published in the American Journal of Obstetrics and 
Gynecology.  
Haro-Barceló J, Rodriguez-Ramos C, Rojas A, Murphy MM, Fernandez-Ballar J. 
The contribution of paternal factors to pregnancy complications of placental 
origin: systematic review. In preparation. Registred in PROPSPERO ID: 148864.       
 
International conference contributions 
 
Conference: 11th International Conference on One Carbon Metabolism, B 
Vitamins and Homocysteine. Arhus (Denmark), 2017. 
Authors: Ornosa-Martin G, Solé-Navais P, Cavallé-Busquets P, Fernandez-
Ballart JD, Haro-Barceló J, Ballesteros M, Ueland PM, Meyer K, Murphy MM. 
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Title: Early pregnancy folate and cobalamin status and overweight and obesity 
in children at 7.5 years. 
Format: Poster. 
 
Conference: Federation of American Societies for Experimental Biology 
(FASEB). Nova Scotia (Canada), 2018. 
Authors: Júlia Haro-Barceló, Alejandra Rojas-Gomez, Gemma Ornosa-Martin, 
Pol Sole-Navais, Monica Ballesteros, Montserrat Ingles-Puig, Per M. Ueland, 
Klaus Meyer, Joan D. Fernandez-Ballart, Pere Cavallé-Busquets, Michelle M. 
Murphy.  
Title: Associations between maternal and paternal 1C metabolism and mid-
childhood growth and health in the Reus-Tarragona Birth Cohort Study. 
Format: Poster. 
 
Conference: Federation of American Societies for Experimental Biology 
(FASEB). Nova Scotia (Canada), 2018. 
Authors: Alejandra Rojas-Gomez, Júlia Haro-Barceló, Gemma Ornosa-Martin, 
Pol Sole-Navais, Monica Ballesteros, Montserrat Ingles-Puig, Per M. Ueland, 
Klaus Meyer, Joan D. Fernandez-Ballart, Pere Cavallé-Busquets, Michelle M. 
Murphy.  
Title: Associations between prenatal 1C metabolism and mid-childhood 
metabolic profile in the Reus-Tarragona Birth Cohort Study. 
Format: Poster. 
 
Conference: 12th International Conference on One Carbon Metabolism, B 
Vitamins and Homocysteine. Montbrió del Camp (Spain), 2019. 
Authors: Júlia Haro-Barceló, Alejandra Rojas-Gomez, Carla Ramos-Rodríguez, 
Gemma Ornosa-Martin, Pol Sole-Navais, Monica Ballesteros, Montserrat 
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Ingles-Puig, Per M. Ueland, Luis Masana, Mercedes Heras, Joan D. Fernandez-
Ballart, Pere Cavallé-Busquets, Michelle M. Murphy. 
Title: Genetic and metabolic alterations in paternal one carbon metabolism 
and development of pregnancy complications of placental origin. 
Format: Poster. 
 
Conference: 12th International Conference on One Carbon Metabolism, B 
Vitamins and Homocysteine. Montbrió del Camp (Spain), 2019. 
Authors: Alejandra Rojas-Gomez, Júlia Haro-Barceló, Carla Ramos-Rodríguez, 
Gemma Ornosa-Martin, Pol Sole-Navais, Monica Ballesteros, Montserrat 
Ingles-Puig, Per M. Ueland, Luis Masana, Mercedes Heras, Joan D. Fernandez-
Ballart, Pere Cavallé-Busquets, Michelle M. Murphy. 
Title: Associations between prenatal plasma homocysteine and metabolic 
score at mid-childhood. 
Format: Poster. 
 
Conference: 12th International Conference on One Carbon Metabolism, B 
Vitamins and Homocysteine. Montbrió del Camp (Spain), 2019. 
Authors: Montserrat Inglès-Puig, Joan Fernandez-Ballart, Pere Cavallé-
Busquets, Júlia Haro-Barceló, Mónica Ballesteros, Alejandra Rojas-Gómez, 
Carla Ramos-Rodriguez, Per M Ueland, Klaus Meyer, Michelle M Murphy. 
Title: Moderately elevated 1st trimester fasting plasma total homocysteine is 
associated with increased probability of miscarriage. A prospective cohort 
study. 
Format: Poster. 
 
Conference: Virtual FASEB. The Folic Acid, Vitamin B12 and One-Carbon 
Metabolism Conference. 2020 
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Authors: Michelle M. Murphy, Júlia Haro-Barceló, Luis Adolfo Santos, 
Alejandra Rojas-Gomez, Carla Ramos-Rodríguez, Joan D. Fernandez-Ballart, 
Marta Herrero, Pol Solé-Navais, Monica Ballesteros, Pere Cavallé-Busquets.  
Title: Preconception and first trimester folic acid supplement use and folate 
status. The Reus Tarragona Birth Cohort. 
Format: Poster. 
 
Teaching and academic activities  
 
Medicine Grade in the Faculty of Medicine and Health Sciences of Universitat 
Rovira i Virgili (approximately 60 hours/ year; 2016-2019)  
- Research and Documentation Bases (70%)  
- General Epidemiology (30%)  
 
Other contributions  
 
- Active role in the fieldwork of the pregnancy and follow-up phases of the 
Reus-Tarragona Birth Cohort.  
 
Involvement in scientific projects  
 
Title: Genetic and metabolic alternations in maternal and paternal one carbon 
metabolism related with pregnancy complications of placental origin. 
Principal Investigator: Michelle Murphy.  
Duration: 3 years.  
REF: 16/00506 
Funding source: Instituto de Salud Carlos III/ Fondo FEDER. 
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Nom......................................................................         Data .... ..... .... 
 
QÜESTIONARI DE FREQÜÈNCIA DE CONSUM ALIMENTARI 
 
INSTRUCCIONS PER OMPLIR-LO 
 
Procuri contestar tranquil·lament aquest qüestionari. Prengui’s el temps que consideri 
necessari. En el cas de tenir algun dubte contacti amb nosaltres per correu electrònic: 
silvia.fernandez@urv.cat o per telèfon: 977 759379 (Equip NUTCIR). Aquest qüestionari 
pregunta per la freqüència en la que consumia, de forma habitual, determinats aliments, 
durant els 6 mesos previs a l’embaràs de la seva parella.  
 
La freqüència de consum s’ha d’especificar als quadres de la dreta del llistat d'aliments 
d’aquest qüestionari. Per a cada aliment del llistat ha d’apuntar el número de vegades que 
el consumia. Per exemple : 
 
 Si el consumia tots els dies de la setmana, posi un 7 a la columna “A LA 
SETMANA”.  
 Si el consumia alguna vegada a la setmana, posi les vegades: 1-2-3-4-5 o 6 a la 
columna “A LA SETMANA”. Pensi sempre en sumar el consum de totes les 
menjades del dia (esmorzar, dinar, berenar, sopar o altres).  Per exemple, si prenia 
llet per esmorzar cada dia i per sopar alguna vegada a la setmana: 7 + 4 = 11 
vegades a la setmana. 
 Si consumia l’aliment alguna vegada al mes, posi les vegades: 1 ó 2 ó 3 etc. en la 
columna “AL MES”. 
 Si no el consumia mai o gairebé mai, deixi la casella en blanc, sense posar res.  
  
Exemple: Un home esmorzava habitualment un got de llet (7 vegades) amb magdalenes (7 
vegades), per sopar a vegades prenia llet (4 vegades) i a vegades prenia iogurt de postres 
(3 vegades). A més, menjava peix algunes vegades a la setmana per dinar (2 vegades) i 
altres vegades per sopar (4 vegades). De llegums en consumia alguna vegada al mes 
(aproximadament 3 vegades). I no menjava mai formatge de règim.  
 
El consum l’apuntaria de la següent manera: 
 
LLISTAT D’ALIMENTS QUANTES VEGADES MENJAVA...? 
 A LA SETMANA AL MES 
Llet 11  
Iogurt 3  
Coc ràpid, magdalenes.. 7  
...   
Peix 6  
...   
Llegum  3 
   
Formatge de règim   
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QÜESTIONARI DE FREQÜÈNCIA DE CONSUM ALIMENTARI 
 
 
LLISTAT D’ALIMENTS QUANTES VEGADES MENJAVA...? 
 A LA SETMANA AL MES 
Llet   
Iogurt   
Xocolata: bombons, “Kit-Kat” “Mars”...   
Cereals inflats d’esmorzar (“Corn-Flakes”  “Kellog’s”)   
Galetes tipus “maria”   
Galetes amb xocolata, crema...   
Magdalenes, coc ràpid,...   
Ensaïmada, Donut, croissant...   
 
 
 A LA SETMANA AL MES 
Amanida: Enciam, tomàquet, escarola...    
Mongetes verdes, bledes, o espinacs   
Verdures de guarnició: albergínia, carbassó, 
xampinyons... 
  
Patates al forn, fregides o bullides   
Llegums: llenties, cigrons, fesols ...   
Arròs blanc, paella   
Pasta: fideus, macarrons, espaguetis...   
Sopes i cremes   
 
 
 A LA SETMANA AL MES 
Ous   
Pollastre o gall d’indi   
Vedella, porc, xai (bistec, empanada...)   
Carn picada: llonganissa, hamburguesa   
Peix blanc: lluç, mero...   
Peix blau: sardines, tonyina, salmó...   
Marisc: musclos, gambes, llagostins, pop, calamars...   
Croquetes, empanadilles, pizza   
Pa (en entrepans, a les menjades...)   
 
 
 A LA SETMANA AL MES 
Pernil salat, dolç, embotits   
Formatge fresc  (Burgos,...) o baix en calories   
Formatges: curats o semicurats, cremosos   
 
 
 A LA SETMANA AL MES 
Fruites cítriques: Taronja, mandarina   
Altres fruites: Poma, pera, préssec, albercoc, plàtan   
Fruites en conserva (en almívar...)   
Sucs de fruita natural   
Sucs de fruita comercial    
Fruits secs: cacauets, avellanes, ametlles   
Postres làctics: natilles, flam, mató   
Pastissos de crema o xocolata   
Bosses d’aperitiu (“chips”, “chetos”, “fritos”...)   
Llaminadures: gominoles, caramels...    
Gelats   
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LLISTAT D’ALIMENTS QUANTES VEGADES MENJAVA...? 
 A LA SETMANA AL MES 
Begudes ensucrades (“coca-cola”, “Fanta”...)   
Begudes baixes en calories (coca-cola light...)   
Vi, sangria    
Cervesa   
Cervesa sense alcohol   
Begudes destil·lades: (Whisky, ginebra, conyac,...)   
 
 
Indiqui  amb una X la resposta que vulgui assenyalar: 
 
1.- Han canviat els seus hàbits alimentaris des dels 6 mesos previs a l’embaràs de la seva 
parella fins ara?  
 
Sí__       No__       
 
En cas que la resposta sigui afirmativa, esculli el tipus de dieta que fa actualment: 
 
฀ Dieta baixa en calories (reducció de pes) 
฀ Dieta hipercalòrica 
฀ Dieta hiperproteica 
฀ Dieta per a hipercolesterolèmia 
฀ Dieta per a diabètics 
฀ Dieta baixa en sal 
฀ Altres ______________________________________________________ 
 
     
2.- A taula, s'afegia sal a les menjades?  
 
Mai__       Alguna vegada__          Freqüentment __           Gairebé sempre __ 
 
 
3.- Com definiria la seva gana d’aquells 6 mesos?  
 
     Molta __             Força __              Normal __              Poca __                Gens__                    
 
 
4.- Quin tipus de llet prenia habitualment?:  
   
     Sencera __            Semidescremada __                 Descremada __ 
 
 
5.- Quin tipus de iogurt consumia habitualment? 
 
a) Natural ___ b) Natural descremat ___ 
c) De sabors ___ d) De sabors descremat ___ 
e) Amb trossets de fruita__ ___ f) Amb trossets de truites descremat ___ 
 
 
6.- Quin tipus de pa  menjava habitualment?:       Blanc __       Integral __ 
 
 
7.- Es posava tomàquet i oli als entrepans?:  
 
 
     Sempre__       Habitualment__    Alguna vegada__      Gairebé mai__ 
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 Nom..........................................................................    Data .... ..... .... 
 
 
ENQUESTA  SOBRE HÀBITS I ESTIL DE VIDA 
 
 
Per diferents motius, els hàbits nutricionals i l’estil de vida del pare poden tenir una 
clara incidència en el procés de la reproducció. Si us plau, contesti sincerament 
aquestes preguntes per ajudar-nos a valorar la influència que podien haver tingut 
en el desenvolupament de l’embaràs de la seva parella.  
 
Completi aquesta informació (pensant en els 6 mesos previs a l’embaràs de la 
seva parella): 
Data de naixement:  _____  
Pes:   ______ kg 
Alçada: _______ cm 
Antecedents mèdics:  _________________________________________________ 
 
__________________________________________________________________ 
Grups ABO i Rh: _______ 
 
1. Ús de suplements vitamínics 
 
Va prendre suplements vitamínics durant els 6 mesos anteriors a l’embaràs de la 
seva parella?      ฀ Sí     ฀ No              
 
Només en cas que sí: 
 -  Quin? ___________________________________ 
 
 -  Quantes vegades a la setmana el prenia? 
฀ Cada dia 
฀ Alguns dies (1-3 vegades) 
฀ La majoria dels dies (4-6 vegades) 
 
 
 -  Quantes pastilles/sobres/ampolles prenia cada dia? ____________ 
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2. Esmorzar 
 
3. Tabac :   
 
Era fumador passiu (exposat al fum de tabac habitualment, a casa o a la feina)? 
฀ Sí     ฀ No     
 
Era fumador actiu abans que la seva parella es quedés embarassada? 
฀ Sí     ฀ No              
          
 0 cigs/dia 1-5 cigs/dia 6-10 cigs/dia > 10 cigs/dia 
Quants cigarrets fumava els 6 mesos 
abans de l’embaràs de la seva parella? 
    
 
Si era fumador actiu: 
฀ Va mantenir el seu hàbit durant tot l’embaràs       
฀ Va abandonar totalment el seu hàbit durant tot l’embaràs       
฀ Va reduir el seu consum de tabac durant l’embaràs  
 
4. Alcohol: 
 Mai 
/Ocasionalment 
< 3 cops 
/setmana 
Cada dia com aperitiu 
i/o amb els àpats 
> 7 copes  
/setmana 
Als 6 mesos anteriors a l’embaràs 
de la seva parella, amb quina 
freqüència bevia alcohol ?  
    
 
Ha pres algun tipus de substància tòxica en els 5 anys anteriors a l’embaràs de la 
seva parella (marihuana, cocaïna, heroïna, etc...)?     
฀ Sí     ฀ No              
En el cas que sí,  especifiqui quines: ____________________________________ 
 
 Mai Ocasionalment Regularment 
Als 6 mesos anteriors a l’embaràs de la 
seva parella, amb quina freqüència prenia 
substàncies tòxiques ?  
   
 
 Sí No 
Tenia el costum d’esmorzar?   
Esmorzava cereals inflats habitualment (ex. Kelloggs / Nestlé etc)?    
Prenia cafè amb cafeïna?   
Prenia cafè descafeïnat?   
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
5. Activitat física: 
a ) De què treballava? ___________________________________________ 
 
b ) Com definiria el treball d’aquell moment? 
- Bàsicament d’estar assegut i caminar poc (estudiant, docent, conductor de 
vehicles, dependent, administratiu, ...)  
 
 
- Caminar força però sense fer esforç vigorós (pagès, fàbrica, carter...)  
 
 
- Bàsicament de molta activitat física (esportista) 
 
 
 
c ) Quina activitat feia en el seu temps lliure? 
- Lectura, televisió i activitats que no requereixin activitat física important. 
 
 
- Caminar, anar amb bicicleta, jardineria (no s’inclou el transport d’anar i tornar 
del treball). 
 
 
- Córrer, esquiar, gimnàstica, jocs amb pilota o esports vigorosos regularment. 
 
 
- Entrenament esportiu regular per competició.  
 
 
 
Quants cops per setmana realitzava les activitats de la pregunta anterior? _____ 
 
 
6. Ingressos anuals nets totals a la llar, en aquell moment: 
 
 
- Nombre de persones que formaven la unitat familiar: _______  
 
- Ingressos totals: 
 
Exemple, si la dona tenia un sou de 20000 €, l’home un de 18000€ i hi havia un avi que 
vivia amb la família i rebia una pensió de 6000 € 
 
< 9000 € >9000 € - 19000 € >19000 € - 25000 € >25000 € - 35000 € > 35000 € 
    ■ 
 
 
≤ 9000 € >9000 € - 19000 € >19000 € - 25000 € >25000 € - 35000 € > 35000 € 
     
 
 
Anoti qualsevol dubte o aclariment relacionat amb aquesta enquesta: 
 
 
 
 
Moltes gràcies per la teva participació. 
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
Research paper
Moderately elevated first trimester fasting plasma total homocysteine
is associated with increased probability of miscarriage. The Reus-
Tarragona Birth Cohort Study
Pere Cavalle-Busquets a, b, c, Montserrat Ingles-Puig a, d, Joan D. Fernandez-Ballart b, c, e,
Júlia Haro-Barcelo c, e, Alejandra Rojas-Gomez c, e, Carla Ramos-Rodriguez c, e,
Monica Ballesteros d, Klaus Meyer f, Per M. Ueland f, Michelle M. Murphy b, c, e, *
a Hospital Universitari Sant Joan de Reus, Spain
b IISPV, Spain
c CIBEROBN, Spain
d Hospital Universitari Joan XXIII de Tarragona, Spain
e Unitat de Medicina Preventiva i Salut Pública, Facultat de Medicina i Ciencies de La Salut, Universitat Rovira i Virgili, Reus, Spain
f BeVital AS, Bergen, Norway
a r t i c l e i n f o
Article history:
Received 30 November 2019
Accepted 15 January 2020
Available online 18 January 2020
Keywords:
Early pregnancy
Homocysteine
Red blood cell folate
Miscarriage
Reus-Tarragona birth cohort
a b s t r a c t
The association between elevated early pregnancy fasting plasma total homocysteine (tHcy) and
miscarriage risk was investigated prospectively in participants (n ¼ 544) from the Reus-Tarragona Birth
Cohort study. Pregnancy was confirmed before 12 gestational weeks (GW) by ultrasound scan and a
fasting blood sample collected. Pregnancies with complications other than miscarriages were excluded.
Miscarriages were diagnosed by ultrasound scan and gestational age at the time of miscarriage estimated
by embryo size, where possible. Cases in which blood samples were collected more than a week after the
miscarriage, or the miscarriage was of known cause, were excluded.
Fasting plasma folate, vitamin B12, tHcy, cotinine (biomarker of smoking), red blood cell (RBC) folate,
MTHFR 677C > T (rs1801133) and SLC19A1 80G>A (rs1051266) genotypes were determined.
The exposed group consisted of participants with first trimester tHcy  P90 (7.1 mmol/L) (n ¼ 57) and
unexposed of those with tHcy < P90 (n ¼ 487). Adherence to folic acid supplement recommendations,
plasma folate, plasma vitamin B12, RBC folate and prevalence of optimal RBC folate status ( 906 mmol/L)
were lower in the exposed compared to unexposed group. The prevalences of the MTHFR 677 TT ge-
notype and miscarriage were higher in the exposed group. The relative risks (95% CI) of pregnancy
ending in miscarriage were 2.5 (1.1, 5.7) and 2.1 (1.0, 4.5) for participants in the high tHcy and suboptimal
RBC folate groups (compared to the reference groups) respectively. Adherence to folic acid supplement
recommendations was positively associated, while the MTHFR 677 TT versus CC genotype and smoking
versus non-smoking were negatively associated, with RBC folate status.
© 2020 Published by Elsevier B.V.
1. Introduction
1.1. Background
Moderately elevated fasting plasma total homocysteine (tHcy)
has been associated with various pregnancy complications or
adverse outcomes such as neural tube defects [1], preeclampsia [2]
or low birth weight [3,4], among others [5]. Homocysteine meta-
bolism is regulated by gene-nutrient interactions and depends on
dietary B-group vitamins: folate, vitamin B12, pyridoxine, and
riboflavin as well as choline and betaine. The MTHFR 677C > T
(rs1801133) and SLC19A1 180G > A (rs1051266) polymorphisms
affect the role of folate in homocysteine metabolism and folate
transport, respectively. They have negative effects on folate status
and are associated with elevated tHcy [6].* Corresponding author. Unitat de Medicina Preventiva i Salut Pública, Facultat de
Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, 43201, Reus, Spain.
E-mail address: michelle.murphy@urv.cat (M.M. Murphy).
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1.2. Evidence to date regarding tHcy and miscarriage/pregnancy
loss
Numerous studies have investigated the association between
tHcy and recurrent pregnancy loss or miscarriage. However, early
pregnancy tHcy determinations from the index pregnancy inwhich
miscarriage is clinically diagnosed are difficult to obtain. Most
studies compared tHcy, measured after the affected pregnancies
have ended, between women with a history of recurrent miscar-
riage versus normal pregnancy. Some of these studies reported
higher tHcy in women with a history of miscarriage compared to
normal pregnancy [7e10] and that the probability of history of
miscarriage was increased with increasing tHcy concentration [7].
However, in this latter study, vitamin B12 deficiency prevalence
was high among the miscarriage cases but low in the controls.
Other studies did not observe any differences in tHcy between
women with history of pregnancy loss compared to normal preg-
nancies [11e14]. The disparity in results between the aforemen-
tioned studies may be due to various reasons. None of them
measured tHcy before the clinical diagnosis of miscarriage in the
affected pregnancy. tHcy levels decrease during pregnancy [15] so
nonpregnant measurements may not accurately reflect even early
pregnancy concentrations. Furthermore, following the pregnancy
loss women were taking folic acid supplements in many studies in
preparation for the next pregnancy, thus affecting their tHcy.
Studies with a reliable measurement of the exposure of interest
prior to the miscarriage are lacking. In addition to the limitations
regarding the exposure measurements, endpoints based on a
clinical diagnosis of miscarriage are also scarce. This is relevant
because efforts to differentiate between miscarriages likely
resulting from other factors unrelated to tHcy, such as foetal
chromosomal abnormalities ormaternal infection, arewarranted. A
prospective study from preconception throughout pregnancy in
which conception and pregnancy loss were monitored by urinary
hCG concentrations, concluded that elevated tHcy at preconception
(12.4 mmol/L) did not increase the relative risk of early pregnancy
loss [16]. Miscarriage causes are not assessed in this study of
pregnancy loss before 6 GW. Another prospective study, from the
first prenatal visit, of 100 pregnancies measured tHcy in blood
samples collected between 4 and 16 GW. No difference in tHcy was
observed between the women that went on to miscarry and those
that had a normal pregnancy outcome [17]. It is not clear whether
the statistical power was sufficient (there were only 12 mis-
carriages), the timing of sample collection covered a range of 12
weeks which affects tHcy and no information was provided
regarding the timing, cause or type of miscarriage. Impaired
vitamin B12 status was associated with a higher probability of
miscarriage in that same study. A large French study reported
higher tHcy in samples collected following hospitalization for
miscarriage in the index pregnancy compared to elective preg-
nancy termination controls of similar gestational age [18]. The
blood samples in cases and controls were collected soon after the
events and detailed information regarding miscarriage diagnosis
and exclusion of cases due to known causes is provided.
1.3. Hypothesis and aims
We hypothesised that moderately elevated early pregnancy
tHcy is a potential biomarker of idiopathic first trimester miscar-
riage risk.
The aim of this study was to investigate, prospectively, the as-
sociation between moderately elevated early pregnancy tHcy and
the risk of first trimester miscarriage in the Reus-Tarragona Birth
Cohort.
2. Materials and methods
2.1. Study participants
Women attending their first prenatal clinic at the University
hospitals Sant Joan Reus and Joan XXIII Tarragona between 2005
and 2016, with confirmed pregnancy of less than 12 GW, were
invited to participate in the Reus Tarragona Birth Cohort (RTBC)
study. The study was approved by the Hospitals’ Research and
ethical committees and signed informed consent following the
guidelines of the Declaration of Helsinki was obtained from all
participants.
2.2. Blood sample collection
Fasting blood samples were collected at < 12 GW, 15 GW,
24e27 GW, 34 GW and nonfasting samples at labour. For the pur-
poses of the present report, only the first blood sample will be
considered. Participants that developed pregnancy complications
other than miscarriage (preeclampsia, intrauterine growth retar-
dation, gestational hypertension, among others) were excluded
(n¼ 75) from this report. A total of 544 pregnancies were included.
Samples were stored at 80 C in the Pere Virgili Health Research
Institute (IISPV) biobank until analysis. Clinical, nutritional and
lifestyle data were recorded and plasma folate and RBC folate
(microbiological assay with Lactobacillus casei) [19], plasma vitamin
B12 (microbiological assay with Lactobacillus leichmannii) [20] and
homocysteine (tHcy) and cotinine concentrations were determined
by liquid-tandem mass spectrometry [21]. The MTHFR 677C>T
(rs1801133) and SLC19A1 180G>A (rs1051266) genotypes were
determined by matrix-assisted laser desorption/ionization/time-
of-flight MS [22]. (Bevital; www.bevital.no). Data regarding smok-
ing habits was collected from three different sources including
interrogation by the investigating team (questionnaire), plasma
cotinine determinations and from the prenatal history (recorded by
the clinicians).
2.3. Pregnancy confirmation and miscarriage diagnosis
Between 11 and 13 þ 6 GW, pregnancy was confirmed by ul-
trasound scan. The majority of the miscarriages were first trimester
spontaneous “missed” abortions diagnosed on detection of no
foetal heartbeat by ultrasound scan at 12 GW. The remaining mis-
carriages were in course and diagnosed on referral from the
emergency room when the clinical symptoms were manifested.
Ultrasound scans revealing absence of foetal heartbeat or empty
yolk sac were diagnosed as miscarriage. Gestational age at the time
of miscarriage was estimated, where possible, from the crown-
rump length or biparietal diameter of the embryo. Cases of mis-
carriages occurring more than 7 days before blood sample collec-
tion, were excluded from the study.
2.4. Statistical analysis
Participants were classified as exposed to moderately elevated
first trimester tHcy ( P90: 7.1 mmol/L), n¼ 57, or unexposed (< P90),
n ¼ 487. Smokers were identified based on plasma cotinine con-
centration  10 ng/ml and/or confirmation of smoking habit by
questionnaire or on interrogation by the clinicians during the
prenatal check-ups. Quantitative variables with non-normal dis-
tributions were natural log transformed for the application of
parametric statistical tests. Means between groups were compared
using ANOVA and proportions using the Chi-square test. We fitted a
Cox regression model to calculate the relative risk (RR) of miscar-
riage associated with moderately elevated tHcy. The model was
P. Cavalle-Busquets et al. / Biochimie 173 (2020) 62e67 63
UNIVERSITAT ROVIRA I VIRGILI 
GENETIC AND METABOLIC ALTERATIONS IN MATERNAL AND PATERNAL ONE CARBON METABOLISM 
AND DEVELOPMENT OF PREGNANCY COMPLICATIONS OF PLACENTAL ORIGIN 
Júlia Haro Barceló 
 
adjusted for maternal age and smoking habit (active smoking
versus non-smoking during pregnancy). Similarly, another Cox
regression model was fitted to determine the RR of miscarriage
associated with suboptimal RBC folate status during the first
trimester of pregnancy. Predictors of tHcy and RBC folate status
were assessed using multiple linear regression analysis and mul-
tiple logistics regression analysis respectively. IBM-SPSS software
was used for all statistical tests. Significance level was set at
p < 0.05.
3. Results
3.1. Cases included
Of the miscarriage cases, nine were excluded for the following
reasons: chorioamnionitis (n ¼ 3), antiphospholipid syndrome
(n ¼ 1), myoma (n ¼ 1), trisomy 18 (n ¼ 1), late miscarriage, >
18 GW (n ¼ 2), missing information (n ¼ 1). The 32 miscarriages
occurring before 18 GWand of unknown causewere included in the
analysis.
3.2. Participant characteristics according to first trimester tHcy
category
Participant characteristics are described in Table 1. SLC19A1
80G>A genotypes, smoking habits, parity, maternal age and body
mass index did not differ between the exposed and unexposed
groups. Adherence to folic acid supplement recommendations of
400 mg/d was high in both groups but higher in the group with
tHcy < P90. Plasma vitamin B12 status, plasma and RBC folate status
were lower and the MTHFR 677 TT genotype prevalence higher in
the exposed versus unexposed to moderately elevated tHcy group.
The WHO recommends a RBC folate status of 906 nmoL/L or more
to prevent neural tube defects [23]. A higher proportion of partic-
ipants in the high tHcy group had RBC folate concentrations below
this recommendation and the proportion of early pregnancy
miscarriage was higher in the exposed (high tHcy) than the unex-
posed group.
3.3. Exposure to first trimester tHcy and risk of miscarriage
The association between first trimester tHcy status and risk of
miscarriage is reported in Table 2. Participants with tHcy at or
above the 90th percentile (7.1 mmol/L) had over twice the risk of
having a miscarriage. Risk of miscarriage also increased with
increasing maternal age. We assessed whether RBC folate status
below 906 nmoL/L affects the risk of miscarriage (Table 2). Women
with RBC cell folate status< 906 nmol/L were twice as likely to have
a miscarriage compared to women with red blood cell folate 
906 nmol/L, after adjusting for maternal age, parity and smoking.
3.4. Participant characteristics according to pregnancy outcome
The participant characteristics according to outcome (miscar-
riage or normal pregnancy) are reported in Table 3. Women with
pregnancies that ended in miscarriage were older, adhered less to
the recommendation to take 400 mg/d of folic acid in the form of
supplements and more of them had suboptimal folate reserves
(indicated by RBC folate concentration, showing folate reserves
entering pregnancy) compared to women that went on to have
normal pregnancy outcomes.
3.5. Factors predicting first trimester tHcy
The predictors of first trimester tHcy were assessed using
multiple lineal regression analysis (Table 4). The strongest predictor
was MTHFR 677 TT genotype, followed by plasma creatinine, parity
and plasma folate. In a separate model in which first trimester
plasma folate was replaced with RBC folate, the strongest predictor
was RBC folate, followed by plasma creatinine, MTHFR 677 TT ge-
notype and parity.
3.6. Factors influencing first trimester RBC folate status
The factors influencing the probability of having optimal RBC folate
status in the first trimester of pregnancywere assessed usingmultiple
logistic regression analysis (Table 5). Regular use of folic acid sup-
plements at or above the recommended dose of 400 mg/d strongly
Table 1
Participant characteristics according to exposure to first trimester fasting plasma total homocysteine category.
First trimester fasting plasma total homocysteine group
 P90
1
< P90 Total
MTHFR 677 C > T genotype, %
CC 23.6 [13/55]2 35.2 [170/483] 34.0 [183/538]
CT 43.6 [24/55] 49.3 [238/483] 48.7 [262/538]
TT 32.7 [18/55] 15.5 [75/483]** 17.3 [93/538]
SLC19A1 80 G > A genotype, %
GG 38.2 [21/55] 26.7 [128/480] 27.9 [149/535]
GA 38.2 [21/55] 46.5 [223/480] 45.6 [244/535]
AA 23.6 [13/55] 26.9 [129/480] 26.5 [142/535]
First trimester smoking, % 31.6 [18/57] 26.9 [131/487] 27.4 [149/544]
First trimester folic acid use, %3 89.1 [49/55] 94.5 [446/487]*** 93.9 [495/527]
Multiparity, % 47.4 [27/57] 54.2 [264/487] 54.4 [296/544]
Age (years), mean (95% CI) 32.4 (30.9, 33.9) [57] 32.1 (31.7, 32.5) [486] 32.2 (31.8, 32.5) [543]
BMI (kg/m2), mean (95% CI) 24.6 (23.2, 26.0) [55] 23.8 (23.4, 24.3) [464] 23.9 (23.5, 24.2) [516]
Plasma folate (nmol/L), geometric mean (95% CI) 14.4 (11.2, 18.4) [57] 26.7 (25.2, 28.4) [487]*** 25.1 (23.6, 26.6) [544]
Plasma vitamin B12 (pmol/L), geometric mean (95% CI) 283 (261, 343) [57] 369 (358, 381) [487]** 363 (352, 373) [544]
tHcy (mmol/L),
geometric mean (95% CI)
8.4 (8.0, 8.7) [57] 5.1 (5.0, 5.2) [487]*** 5.3 (5.2, 5.4) [544]
RBC folate (nmol/L), geometric mean (95% CI) 556 (477, 647) [57] 954 (910, 1001) [474]*** 901 (859, 945) [531]
RBC folate < 906 nmol/L, % 78.9 [45/57] 46.4 [220/474]*** 49.9 [265/531]
Miscarriage, % 14.0 [8/57] 4.9 [24/487]* 5.9 [32/544]
Gestational week at miscarriage, mean (95% CI) 9.3 (7.8, 10.8) [7] 10.4 (9.1, 11.8) [16] 10.1 (9.1, 11.1) [23]
Abbreviations: tHcy: fasting plasma total homocysteine, RBC: red blood cell. 17.1 mmol/L, 2[n], 3 400 mg/d. Statistical comparison between 2 groups, Chi square for proportions
and ANOVA for quantitative variables: *p < 0.05, **p < 0.01, ***p < 0.001.
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Table 2
Assessment of Relative risks of pregnancy ending in miscarriage according to early pregnancy fasting plasma total homocysteine (tHcy) and RBC folate status using Cox
regression analysis. Abbreviations: tHcy: fasting plasma total homocysteine, RBC: red blood cell. 1Relative risk; 2measured at< 12 gestational weeks; 3P90: 7.1 mmol/L;
4adjusted
for parity (multiparous versus nulliparous) and for smoking versus nonsmoking during pregnancy.**p < 0.01.
RR1 (95% CI) Deviance likelihood ratio, chi square n, df
Unadjusted tHcy2 model 17.2 544, 1**
tHcy  P90 versus < P90
3 2.85 (1.28, 6.34)
Adjusted tHcy2 model 17.5 543, 4**
tHcy  P90 vs < P90 2.52 (1.12, 5.68)
Maternal age (y) 1.13 (1.04, 1.22)
Unadjusted RBC folate2 model4 2.6 531, 1
RBC folate
<906 versus  906 nmol/L
1.83 (0.87, 3.81)
Adjusted RBC folate2 model4 15.0 530, 4**
RBC folate
<906 versus  906 nmol/L
2.11 (1.00, 4.45)
Maternal age (y) 1.15 (1.06, 1.24)
Table 3
Participant characteristics according to pregnancy outcome.1 [n], Abbreviations: tHcy: fasting plasma total homocysteine, RBC: red blood cell. Statistical com-
parison between 2 groups, Chi square for proportions and ANOVA for quantitative variables: *p < 0.05,**p < 0.01,***p < 0.001, #p ¼ 0.067.
Miscarriage Normal pregnancy
n ¼ 32 n ¼ 512
MTHFR 677 C > T genotype, %
CC 36.7 [11/30]1 33.8 [173/508]
CT 40.0 [12/30] 49.4 [253/508]
TT 23.3 [7/30] 16.8 [86/508]
SLC19A1 80 G > A genotype, %
GG 30.0 [9/30] 27.7 [140/505]
GA 33.3 [10/30] 46.2 [234/505]
AA 36.7 [11/30] 25.9 [131/505]
First trimester smoking, % 21.9 [7/32] 28.0 [145/512]
First trimester folic acid supplement use, % 68.0 [17/25] 95.2 [478/502]***
Multiparity, % 50.0 [16/32] 53.7 [280/512]
Age (years), mean (95% CI) 34.6 (32.9, 36.3) [32] 32.0 (31.6, 32.4) [511]**
BMI (kg/m2), mean (95% CI) 23.5 (21.7, 25.3) [15] 23.9 (23.5, 24.3) [501]
Plasma folate (nmol/L), geometric mean (95% CI) 20.4 (14.7, 28.2) [32] 25.4 (23.9, 27.0) [512]*
Plasma vitamin B12 (pmol/L), geometric mean (95% CI) 359 (316, 408) [32] 363 (352, 374) [512]
tHcy (mmol/L), geometric mean (95% CI) 6.0 (5.4, 6.7) [32] 5.3 (5.2, 5.4) [512]**
RBC folate (nmol/L), geometric mean (95% CI) 837 (679, 1030) [31] 905 (861, 950) [500]
RBC folate < 906 nmol/L, % 64.5 [20/31] 49.0 [245/500]#
Table 4
Predictors of first trimester tHcy using multiple lineal regression analysis.
Beta coefficient Adjusted R square n, df
Model 1 0.090*** 504, 10
MTHFR 677 TT versus CC genotype 0.220***
Plasma creatinine (mmol/L) 0.180***
Parity (multiparous versus nulliparous) 0.126**
Plasma folate (nmol/L) 0.109*
Model 2 0.148*** 491, 10
RBC folate (nmol/L) 0.273***
Plasma creatinine (mmol/L) 0.192***
MTHFR 677 TT versus CC genotype 0.185***
Parity (multiparous versus nulliparous) 0.119*
Abbreviations: RBC: red blood cell. The dependent variable in both models is ln tHcy. Both models were adjusted for maternal age, plasma B12, smoking, MTHFR 677 CT
versus CC genotype SLC19A1 80 AA vs GG and SLC19A1 80 GA vs GG genotypes. *p < 0.05, **p < 0.01, ***p < 0.001.
Table 5
Assessment of predictors of probability of optimal red blood cell folate status ( 906 mmol/L) usingmultiple logistic regression analysis. Model adjusted for maternal age,
previous pregnancy, MTHFR 677 CT versus CC, SLC19A1 80 AA vs GG and SLC19A1 80 GA vs GG genotypes.***p < 0.001.
OR (95% CI) Nagelkerke R2 n, df
Model 0.123*** 505, 9
First trimester folic acid use (400 mg/d) 15.1 (3.5, 64.9)
Smoking vs nonsmoking 0.53 (0.31, 0.91)
MTHFR 677 TT vs CC genotype 0.56 (0.33, 0.94)
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increased the probability of having optimal RBC folate status. On the
other hand, smoking versus nonsmoking and theMTHFR TT versus CC
genotype were associated with 44% and 47% reductions, respectively,
in the probability of having optimal RBC folate status.
4. Discussion
4.1. Principal findings
Elevated early pregnancy tHcy was associated with more than
double the risk of having a miscarriage. First trimester RBC folate
concentration < 906 nmol/L, indicative of suboptimal folate re-
serves entering pregnancy, was also associated with increased risk
of miscarriage. Smoking had a negative effect on RBC folate status
while folic acid supplement use at or above the recommended
400 mg/d had a protective effect.
4.2. Comparison with previous studies
Most previous studies determined tHcy after the miscarriage
had occurred. A study that did collect blood samples between 4 and
12 GW reported no difference in tHcy between miscarriage cases
and controls [16]. There were two important differences between
that study and ours. Firstly, it only had 12 miscarriage cases. It is
unclear whether it was sufficiently powered to detect a difference
in tHcy between cases and controls, if it existed. Furthermore, RBC
folate status in general was higher in that study than in ours. Sec-
ondly, no details regarding timing, types or potential causes of
miscarriage were provided. To the best of our knowledge, the other
study with tHcy measurements nearest to the miscarriage was in
patients being treated for the miscarriage [17]. That study by Gris
et al., was large and had blood samples and ultrasound confirma-
tion of the miscarriage close to the time of the event. Miscarriages
occurring late in pregnancy or due to chromosomal abnormalities
or maternal infection were also excluded from that study. Our
findings confirm their findings that miscarriage risk was increased
with increasing tHcy concentrations. They reported a twofold in-
crease in risk for tHcy  9.9 mmol/L. This effect size is similar to our
observation regarding tHcy  7.1 mmol/L.
4.3. Interpretation
The mechanism for the association between tHcy and miscar-
riage warrants investigation. It is possible that elevated tHcy in our
study is marking impaired folate status. The most important pre-
dictors of first trimester tHcy were RBC folate, followed by the
MTHFR 677 TT genotype. We previously reported in a population
study from the same region that adults with the MTHFR 677 TT
genotype had lower folate status (both plasma and RBC folate) as
well as higher tHcy than their CC or CT genotype counterparts [6].
We also observed in that same study that 18.8% of the participants
had folate deficiency. In contrast to widespread folic acid use in the
Reus Tarragona Birth Cohort, the population study did not include
folic acid users. Nevertheless, there is no mandatory fortification
with folic acid in Spain and most participants in the Reus Tarragona
Birth Cohort did not initiate folic acid supplementation until they
were pregnant [24]. Use of the recommended dose of folic acid
supplements and plasma folate status were lower in cases than in
controls and the percentage of cases with RBC folate below the
threshold recommended by theWHO to prevent neural tube defect
affected pregnancies, was higher in cases than in controls.
Impaired one carbon metabolism due to low folate status, the
MTHFR 677C>T polymorphism or other polymorphisms affecting
the role of folate or other nutrients in the one carbon metabolic
network have been associated with adverse outcomes stemming
from anomalies in early pregnancy [5]. It is possible that the physio
pathological mechanism leading to embryo developmental abnor-
malities, impaired placentation and foetal growth is shared, at least
in part, in pregnancies affected by suboptimal one carbon meta-
bolism. Impaired chorionic vascularisation in spontaneous
miscarriage tissue from women with history of recurrent preg-
nancy loss and with tHcy >18.3 mmol/L was reported in a study by
Nelen et al. [25]. It is also possible that anomalies in DNA methyl-
ation and other epigenetic processes arising from impaired one
carbon metabolism are involved. However, further research in this
field is required to explore and establish the associations between
early pregnancy folate status and tissue-specific outcomes, their
impact and replication between studies.
4.4. Strengths and limitations
Strengths of this study were that pregnancy was confirmed by
ultrasound scan and tHcy was determined before the miscarriage
occurred. Few previously reported studies have achieved these
measurements due to the difficulty in obtaining them. Late
miscarriage cases (caused by infections or foetal developmental
abnormalities) as well as miscarriages due to known causes such as
chromosomal abnormalities were also excluded. Strictly, fasting
blood samples and confirmation of pregnancy by ultrasound scan
before 12 GW were required for eligibility to be included in the
study. The study was designed to measure first trimester tHcy as a
potential biomarker of adverse pregnancy outcome and blood
samples were processed in strict adherence to protocol to prevent
homocysteine release from blood cells [26].
Furthermore, RBC folate concentration was determined and is
indicative of folate reserves during preconception and the start of
pregnancy. It is spared the effects of haemodilution and the initial
effects of folic acid supplement use (unlike plasma folate concen-
tration and tHcy, which are sensitive to folic acid supplement use at
the time of the blood draw).
Estimation of time of miscarriage in “missed” spontaneous
abortions based on changes in transvaginal ultrasound measure-
ments of crown-rump length or parietal circumference of the em-
bryo are susceptible to error depending on time elapsed between
cessation of foetal heartbeat and the performance of the scan.
Gestational age based on reported date of the last menstrual period
by the participants is also subject to error. However, we were able
to minimise these errors due to the prospective nature of the study
and recording of the timing of the blood samples and ultrasound
scans. We stipulated that any miscarriage suspected to have
occurred more than 7 days before the blood samples would be
excluded.
4.5. Implications
This study shows that in the absence of mandatory fortification
with folic acid, women not adhering to the recommended intake of
400 mg/d from folic acid supplements, are more likely not to meet
the threshold RBC folate status proposed to offer protection against
folate sensitive neural tube defects. This study shows that RBC
folate status below this threshold also increases the risk of
miscarriage. Smoking was negatively associated with RBC folate
status. These results indicate that the message regarding the
importance of periconception folic acid in the prevention of
adverse pregnancy outcome needs to be reinforced, and especially
in smokers.
5. Conclusions
Moderately elevated early pregnancy tHcy is associated with 2.5
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times more risk of early miscarriage, of unknown cause. The results
provide evidence to support the consideration of early pregnancy
tHcy as a potential biomarker of adverse pregnancy outcome.
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